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SUMMARY
Haemostasis is the physiological response to blood loss following vascular injury. The 
process produces a fibrin-platelet clot which seals the damaged blood vessel. Fibrinogen is 
polymerised to fibrin by thrombin which is produced by the coagulation pathways. Plasma 
fibrinogen has been related in several studies to the development of ischaemic heart disease 
and stroke, but the relationship with peripheral arterial disease is less well established. 
Another haemostatic factor, fibrin D-dimer, is the terminal breakdown product of cross-linked 
fibrin, and is thought to reflect the degree of active fibrin formation and subsequent activation 
of fibrinolysis. Fibrin D-dimer has not been widely investigated in terms of cardiovascular 
risk, and little information is available on its relationship to peripheral arterial disease.
This thesis is composed of two studies. The principal aim of the first study, the Sites of 
Atheroma Study, was to deteimine whether plasma fibrinogen, fibrin D-dimer and other 
haemostatic factors (von Willebrand Factor and plasminogen activator inhibitor - type I ) were 
related to the angiographic site and severity of atherosclerosis in the arteries of the lower limb. 
The principal aim of the second study, the Prognostic Study of Intermittent Claudication, was 
to determine whether plasma fibrinogen, fibrin D-dimer and other haemostatic factors (von 
Willebrand Factor and tissue plasminogen activator), were related to the future incidence of 
atherothrombotic events, and deterioration of peripheral arterial disease in subjects with 
intermittent claudication.
The study samples in both studies consisted of men and women with ischaemic symptoms in 
the lower limb referred to the Peripheral Vascular Clinic, Royal Infirmary of Edinburgh. In
the Sites of Atheroma Study, 192 patients referred for angiography were categorised by site 
and severity of peripheral atherosclerosis using the Bollinger angiographic scoring system. 
A clinical examination was conducted on each patient including the administration of a 
questionnaire and taking of a blood sample for the measurement of haemostatic factors. In the 
Prognostic Study, 607 patients with inteimittent claudication who had had a comprehensive 
examination at baseline, including measurement of haemostatic factors, were followed up over 
six years to deteimine the incidence of fatal and non-fatal ischaemic heart disease and stroke 
and deterioration of peripheral arterial disease. Follow-up data were obtained from hospital 
records, general practitioners, self-administered questionnaires, the Information and Statistics 
division of the Common Services Agency and the Scottish National Health Service Central 
Registry.
Results from the Sites of Atheroma Study indicated that 34 (17.7%) patients had 
predominantly aorto-iliac disease, 85 (44.3%) had femoro-popliteal disease and 73 (38.0%) 
had dual-site disease. There were no significant differences in the mean levels of the 
haemostatic factors between patients with disease affecting different sites. An independent 
relationship was found between nephelometric fibrinogen and between fibrin D-dimer and 
disease severity only in the femoro-popliteal arteries. On multiple regression, fibrinogen 
remained independently associated with disease severity in the femoro-popliteal arteries, when 
life-time smoking or current smoking were taken into account. There was no influence of 
current smoking on the association between fibrin D-dimer and disease severity but, on 
inclusion of life-time smoking, the association became non-significant.
In the Prognostic Study of Intermittent Claudication, a total of 210 (34.6%) patients died
during the six year follow-up period. Of these 90 (42.9%) died from ischaemic heart disease, 
29 (13.8%) from stroke and 27 (12.9%) from other vascular causes, including cardiac 
arrhythmias and raptured aneurysm. Ninety three (15.3%) patients had a non-fatal myocardial 
infarction and 79 (13.0%) had a fatal or non-fatal stroke. Forty five (7.4%) patients undeiwent 
investigations for peripheral arterial disease and 64 (10.5%) patients progressed to severe 
chronic leg ischaemia. A total of 203 (33.4%) patients did not have a vascular event or show 
any deterioration of limb ischaemia.
Baseline median levels of plasma fibrinogen, fibrin D-dimer and von Willebrand Factor were 
significantly higher in patients who died from ischaemic heart disease compared to those who 
had no vascular events. Tissue plasminogen activator antigen levels were significantly 
elevated in patients who suffered a stroke. All the relationships between the haemostatic 
factors and vascular events became weaker and statistically non-significant in analysis 
adjusting for cardiovascular risk factors and baseline ischaemic heart disease.
von Willebrand Factor levels were significantly raised in claudicants who developed severe 
chronic leg ischaemia (rest pain, ulceration and gangrene). In multivariate analyses adjusting 
for life-time smoking, fibrinogen became significantly associated with the risk of vascular 
intervention, and von Willebrand Factor was associated with the risk of severe chronic leg 
ischaemia.
In conclusion, these results indicate that there may be a stronger relationship between chronic 
smoking and increased fibrin turnover than coagulation in symptomatic peripheral arterial 
disease. Increased coagulation and fibrinolytic activity may also contribute to thrombosis or
progression of atherosclerosis in the coronary and cerebral arteries in claudicants. The effect 
that fibrinogen, fibrin D-dimer and other haemostatic factors may have on the progression of 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW
1.1 Peripheral Arterial Disease
1.1.1 Histopathology of lesions
Atherosclerosis in the lower limb may cause stenosis or occlusion of the distal aorta, iliac, 
femoral, popliteal or tibio-peroneal arteries. Lesions in these arteries tend to be segmental 
although, overall, the distribution of disease may be highly diffuse and affect multiple sites 
within the lower limb arteries. The histopathology of peripheral atherosclerosis is, however, 
similar to atherosclerosis occurring at other sites within the arterial tree. There are four main 
types of lesions : early lesions, fatty streaks, advanced and complicated lesions (Badimon et 
al 1993).
Atherogenesis is thought to be initiated by the dismption of endothelial cell function caused 
by factors such as cigarette smoking, hypercholesterolaemia, immuno-complexes and infection 
(Ross 1993). Early lesions form within the intima, the innemiost layer of the arterial wall, and 
are characterised by accumulation of lipid-laden macrophages (foam cells). Progression of the 
disease to a fatty streak is dependent on further accumulation of lipid and smooth muscle cells 
within the intima. Fatty streaks can be either flat or raised. Most children will have these 
lesions occurring in the aorta between the ages of two and 15 years of age.
When the structure of the intima becomes disrupted and a lipid core has developed, the lesion 
is classified as advanced and is common in young adults from about the age of 20 years 
onwards. Although it may not cause a reduction in blood flow, this type of lesion can be 
clinically significant because it is prone to rupture or fissuring due to thinning of the fibrous 
cap overlying the lipid core. Progression of disease is also related to increases in fibrous tissue 
within the intimai, medial and adventitial layers of the artery. This can result in projection of 
the lesion into the lumen and blood flow may be reduced. Mural thrombi also can become 
incorporated within the vessel wall and contribute to narrowing of the lumen.
Finally, when the lesion undergoes degenerative changes, such as ulceration, fissuring or 
haemorrhage, it is classified as a complicated lesion. Such changes can cause thrombosis and 
occlusion of the arteiy so that symptoms of ischaemia may occur. Inflammation, the cytotoxic 
products released from macrophages, shear stress and vasospasm have been implicated as 
causal factors in intimai disruption. Levels of systemic risk factors and the degree of 
disruption may also determine the size and persistence of the thrombus and the severity of the 
resulting clinical event (Badimon et al 1993).
1.1.2 Definition of peripheral arterial disease
The term ’peripheral arterial disease', which is synonymous with 'peripheral vascular disease', 
is used primarily to describe atherosclerotic disease of the arteries of the upper limb and of 
the lower limb distal to the aortic bifurcation. Disease in the upper limb arteries is 
comparatively rare, however, and therefore the term is generally used to denote atherosclerotic 
disease in the arteries supplying the lower limb.
An individual cannot be classified as simply 'diseased' or 'non-diseased' because the 
pathological process begins early in life and by the age of 40 years, most adults will have 
lesions in the peripheral arteries (Mitchell and Schwartz 1965). However, ischaemic 
symptoms do not appear until the disease is relatively advanced. For the purpose of initial 
clinical evaluation and for use in epidemiological surveys, peripheral arterial disease is usually 
diagnosed by the presence of symptoms, such as intermittent claudication, and by non-invasive 
tests to detect the degree or effects of arterial narrowing. Traditionally, angiography is 
considered the best objective method of quantifying atherosclerotic disease and is used as the 
reference point against which non-invasive techniques are validated.
1.13 Measurement of peripheral arterial disease
The WHO Intermittent Claudication Questionnaire, which was developed in the early 1960's 
(Rose 1962), has been until recently the most widely used method of detecting symptomatic 
peripheral arterial disease in the general population. However, new questionnaires have 
recently been developed in an attempt to improve the validity of the WHO questionnaire, 
which has a particularly poor sensitivity in comparison to diagnosis made by a doctor. For 
example, the Edinburgh Claudication Questionnaire demonstrated a sensitivity of 85% 
compared to 65% for the WHO questionnaire when evaluated in community and hospital 
surveys (Leng and Fowkes 1992), although the specificity was over 95% for both 
questionnaires. Consequently, the Edinburgh Claudication Questionnaire is now being used 
in an increasing number of epidemiological studies investigating the prevalence of peripheral 
arterial disease.
A variety of non-invasive techniques have been used to assess both symptomatic and 
asymptomatic disease in epidemiological studies. These include palpation of peripheral 
pulses, segmental pressure measurements, pulse waveforms detected by oscillography, the 
ankle brachial pressure index (ABPI), exercise and reactive hyperaemia tests.
Measurement of the ankle brachial pressure index (ABPI) is perhaps the most common non- 
invasive method of assessing the severity of lower limb atherosclerosis and is used extensively 
both in clinical practice and in population surveys. In selected hospital patients, an ABPI of 
<0.9 has been shown to be approximately 95% sensitive and 100% specific in identifying 
angiogram positive disease in the lower limb (Bernstein and Fronek 1982; Laing and 
Greenhalgh 1983). However, this cut-off point may be less valid in confirming the presence 
of asymptomatic disease in individual cases within the community. In the Edinburgh Artery 
Study, for example, the distribution of the ABPI was normal, but with a slight negative skew, 
and with no obvious level differentiating abnormally low levels. About 18% of the population 
had an ABPI <0.9 (Fowkes et al 1991).
In subjects who have a raised central aortic pressure, or a condition such as diabetes mellitus, 
where arteries can be relatively rigid due to medial calcification, the ABPI can be normal at 
rest in spite of considerable atherosclerotic disease. A stress test, such as an exercise or 
reactive hyperaemia test, can identify the presence of haemodynamically significant lesions 
and hence improve diagnostic sensitivity in such cases. In subjects with peripheral arterial 
disease, systolic ankle pressures are reduced and pressure recovery time is increased after 
exercise, or after occluding blood flow in the leg during the reactive hyperaemia test (Laing 
and Greenhalgh 1983). However, the exercise test may not be appropriate for claudicants or
those with concomitant coronary disease, who may be unable to complete the test.
The reactive hyperaemia test, although uncomfortable, is probably more suitable for use in 
epidemiological suiveys than a treadmill test, since it is conducted at rest and uses simple 
equipment. A 20% change in ankle systolic pressure from the resting to the hyperaemic state 
is usually considered valid in identifying cases of peripheral arterial disease. The accuracy of 
this test has recently been assessed. The cut-off point of 20% was shown to have a sensitivity 
of only 52% in identifying tme cases of peripheral arterial disease (Leng et al 1993). Overall, 
the findings suggest that a combination of non-invasive tests should be used to investigate the 
wide spectrum of disease which may occur in the general population.
Duplex ultrasonography is a more sophisticated non-invasive technique which is being 
increasingly used in vascular units and has recently been employed in two large scale 
epidemiological surveys, the Atherosclerosis Risk in Communities (ARIC) Study in the United 
States and the Edinburgh Artery Study (Howard et al 1993; Mowbray et al 1997). Duplex 
ultrasound detects arterial disease by a combination of high resolution ultrasound imaging and 
assessment of blood flow within the vessel using the Doppler effect, which describes the effect 
on a waveform when there are differences between transmitter and receiver frequencies, due 
to movement between them.
Arteries pioduce characteristic waveforms on Doppler which are altered by the presence of 
atherosclerotic disease. Criteria have been developed which relate the changes in waveform 
to the extent and severity of disease. The criteria for the peripheral arteries are based on 
alterations in peak systolic velocity and spectral broadening which occur at sites of disease.
One of the major advantages of duplex ultrasound is its ability to directly visualise the severity 
and location of atherosclerosis within arteries. On the other hand, it is also recognised as being 
relatively expensive, complex and time consuming (Allan 1991). Studies comparing 
ultrasound to angiography in the diagnosis of stenoses > 5 0 %  diameter in the aorta, iliac, 
femoral and popliteal vessels in symptomatic patients have reported good sensitivity (82%- 
87%) and specificity (92%-96%) (Kohler et al 1987; Cossman et al 1989). The validity and 
reproducibility of results using this technique have yet to be established in epidemiological 
surveys in the community, however.
Angiography (or arteriography) is considered the best objective method of quantifying 
atherosclerotic disease in living subjects and is used as the reference against which non- 
invasive measurement techniques of existing arterial disease are validated. The visualisation 
of the lower limb arterial system was first reported by Brooks in 1924 and the technique was 
improved by the development of organic contrast media in 1929 (Swick 1929). The use of a 
percutaneous catheter technique to cannulate the peripheral arteries has further refined the 
technique. Modern radiological practices have also greatly improved diagnostic accuracy, and 
have reduced the risk of patients developing significant complications and also the level of 
discomfort which can occur during the procedure.
Angiography was developed to directly visualise arterial segments since the disease process 
changes the geometiy of the affected artery by narrowing the vessel lumen. Therefore, it is 
primarily used to illustrate the location and extent of atherosclerosis. It is less accurate, 
however, at predicting the haemodynamic effects of a stenosis, or progression of disease and 
is unable to detect the morphological changes of a complicated plaque which can lead to
thrombosis, such as haemorrhage, ulceration and necrosis.
Disease severity is expressed as 'percentage stenosis ', or the percentage reduction in the lumen. 
In the lower limb arteries, developing lesions tend to develop eccentrically, affecting the 
posterior wall more severely, and atheroma occurs more commonly at bifurcations and origin 
of vessels. Therefore, the extent of atherosclerosis can be under-estimated unless projections 
in more than one plane are assessed.
1.1,4 Prevalence of peripheral arterial disease
The first large scale survey to determine the prevalence of intermittent claudication in the 
general population was conducted in Framingham, USA, in 1949 (Kannel and Shurtleff 1973). 
Since then, major epidemiological studies assessing the prevalence of both symptomatic and 
asymptomatic peripheral arterial disease have been carried out in many other countries, 
including Switzerland, Finland, Israel and Scotland (Leng and Fowkes 1993).
Most of these surveys have used the WHO questionnaire (Rose 1962) to determine the 
prevalence of intermittent claudication. The prevalence has varied widely, ranging from 0.3% 
in one survey in the East coast of America to 7.7% in a Finnish survey (Leng and Fowkes
1993). These differences reflect not only possible population differences, but also the different 
age and sex stmctures of the population samples, possible healthy worker effects and varying 
quality of measurement. Also, discrepancies in translation of the questionnaire may have 
contributed to differences in the reported prevalences internationally. Overall, however, it can 
be concluded that the prevalence of intermittent claudication increases with age and occurs
more frequently in men than in women (Leng and Fowkes 1993).
The prevalence of asymptomatic disease in the general population has been less widely 
studied, but appears to be much higher than that of claudication. In surveys which have used 
only an ABPI < 0.9 as an indicator of disease, prevalence has varied from 4% in two studies 
from Belguim and Israel (De Backer et al 1979; Gofin et al 1987) to as high as 17% in the 
Edinburgh Artery Study (Fowkes et al 1991). However, the study population in the latter 
survey was considerably older (between 55 and 74 years) which may have partly accounted 
for the difference in disease prevalence. In another study, which used a combination of non- 
invasive tests, including a reactive hyperaemia test, the prevalence of asymptomatic disease 
in large peripheral arteries increased from 3% in subjects less than 60 years of age to over 20% 
in subjects of 75 years and older, although the inclusion of hyperlipidaemic subjects may have 
affected the prevalence rates (Criqui et al 1985),
1.1.5 Incidence of peripheral arterial disease
The incidence of peripheral arterial disease has been reported in only four large scale 
epidemiological studies at present. After 26 years follow-up in the Framingham Study, the 
incidence of claudication in men aged 40-49 years was estimated to be 0.2% a year and 
showed a progressive increase to 1.2% in men aged 60-69 years (Kannel and McGee 1985). 
Among chemical workers in the Basle Study, five year incidence rates, although not directly 
comparable, were similar, and ranged between 1% in men aged 35-44 years to 6% in those 
aged 65 years and above (Widmer et al 1985). The estimates from the Speedwell prospective 
Study were also comparable. Symptoms of claudication developed in 0.3 % of men aged 45-49
years and 0.5% of men aged 60-63 years (Bainton et al 1994). The most recent survey, the 
Edinburgh Artery Study reported the highest incidence of 9% overall, but included "probable" 
claudicants, a term defined by Criqui et al (1985) to improve the sensitivity of the WHO 
questionnaire (Leng et al 1996). All four studies were in agreement that the trend for 
incidence increased with age, and was higher in men than women, although the gap between 
men and women closed with increasing age and particularly after the menopause.
1.1.6 Aetiology of peripheral arterial disease
Risk factors associated with the development of peripheral arterial disease have been identified 
in an increasing number of epidemiological suiweys, although most are of cross-sectional or 
case-control design (Leng and Fowkes 1993). The strength of the observed relationships has 
varied greatly from study to study; this probably reflects not only differing methods of 
diagnosis, but also the age and sex of the population studied and methods used to deteimine 
levels of risk factors. Although risk factors are thought to act synergistically, the role of the 
main risk factors in peripheral arterial disease is described individually below.
Cigarette smoking
Cigarette smoking is a major risk factor for peripheral arterial disease, both in the onset and 
progression of disease (Murabito et al 1997). It also appears to be a comparatively more 
important risk factor for this disease than for ischaemic heart disease (Fowkes et al 1992). 
Cross-sectional suiveys have shown that the relative risk of developing peripheral arterial 
disease in smokers ranges between 1.4 to 10.0 (Leng and Fowkes 1993), It is probable,
however, that self-reported smoking in population-based surveys is inaccurate, and this may 
explain the wide range of risk estimates.
In one prospective study, the Framingham Study, 78% of incident cases of intemiittent 
claudication were attributed to smoking (Kannel and Shurleff 1973). Furthermore, a strong 
dose-dependent effect of smoking on the risk and severity of peripheral arterial disease has 
been observed (Criqui et ai 1985; Fowkes et al 1992). In more severe disease, approximately 
90% of patients attending vascular clinics are cigarette smokers (Hughson et al 1978a). 
Moreover, the clinical prognosis in patients is worse in those who continue to smoke. For 
example, the rate of amputation and re-occlusion of grafts is far higher in smokers than those 
who stop smoking (Juergens et al 1960).
Blood pressure
Elevated blood pressure is considered a relatively weak risk factor for intermittent 
claudication. Systolic blood pressure is on the whole, however, thought to be more closely 
related to peripheral arterial disease than diastolic pressure (Schroll and Munck 1981; Gofin 
et al 1987). After 26 years of follow-up, the Framingham Study reported a three times higher 
risk of claudication for men with hypertension, systolic pressure being more strongly 
associated with the level of risk than diastolic pressure (Kannel and McGhee 1985). In 
contrast, the Basle Study found that there was no effect of either diastolic or systolic pressure 
on development of disease (Da Silva et al 1979). Flowever, since blood pressure may rise as 
a consequence of peripheral arterial disease through increases in peripheral resistance or 
because of a decrease in aortic compliance (Levenson et al 1982), it may be difficult to
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establish whether blood pressure has a truly independent effect on risk of disease.
Diabetes mellitus
Peripheral arterial disease is a major complication of diabetes mellitus. Diabetes has long been 
recognised as associated with vascular disease in the distal arteries, and with a poor prognosis 
in terms of development of severe chronic leg ischaemia, graft failure and amputation, 
although peripheral neuropathy may also contribute (Jarrett 1991). It is not surprising 
therefore, that population studies have consistently found the incidence of intermittent 
claudication to be significantly higher in diabetics compared to non-diabetics, although most 
of those affected are non-insulin dependent (Herman et al 1977; Slitonen et al 1986; Kannel 
and McGhee 1985).
The relationship between non-diabetic glucose intolerance and peripheral arterial disease is 
not so well defined, however. Community sui^veys have shown inconsistent associations 
between prevalent or incident claudication and either elevated fasting glucose or blood glucose 
after an 'oral glucose load' (Leng and Fowkes 1993). This lack of effect could be related to 
small numbers, particularly when cases are further subdivided by gender. Only the 
Framingham Study has reported an unequivocal independent relationship between impaired 
glucose tolerance and risk of disease (Kannel and McGhee 1985). On balance, therefore, 
glucose intolerance cannot be confirmed as a risk factor for peripheral arterial disease.
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Blood lipids
Serum total cholesterol is an important risk factor for ischaemic heart disease, but evidence 
suggests that, overall, it may be a weaker risk factor for peripheral arterial disease. Patients 
with peripheral arterial disease have demonstrated raised levels of semm cholesterol and also 
lower levels of HDL cholesterol in most hospital-based case-control studies (Jacobsen et al 
1984; Rühling et al 1989; Cardia et al 1990), but not all (Dormandy et al 1973a; Bradby et al 
1990). Conflicting results have also been found cross-sectionally (Fowkes 1988).
In longitudinal studies, the association between total cholesterol and development of 
intermittent claudication, or disease estimated by the ABPI is weak, but statistically significant 
on multivariate analysis (Schroll and Munck 1981; Kannel and McGhee 1985). These 
estimates could have under-estimated the true risk, however; firstly because they are based 
only on one measurement of cholesterol which tends to fluctuate over time and secondly, 
because levels are associated with LDL cholesterol, which demonstrates an imperfect 
correlation with total cholesterol levels. Correction of these types of bias led to a substantial 
increase in the degree of risk associated with total cholesterol in one prospective study 
investigating ischaemic heart disease (Law et al 1994), and this effect may also be applicable 
to lower limb disease.
The relationship between triglycerides and peripheral arterial disease is inconclusive. 
Triglyceride levels are often raised in hospital patients with claudication, but in population 
studies, an independent effect is usually not maintained after adjusting for other lipids. In the 
Edinburgh Artery Study, however, there appeared to be a significant independent relationship
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between triglycerides and more severe lower limb disease, but further confirmation is required 
(Fowkes et al 1992). It has been suggested that lipoprotein subfractions may, in fact, be better 
discriminators of peripheral arterial disease than lipid levels (Pilger et al 1988).
Hvpercoagulabilitv
Fibrinogen has been investigated more than any other haemostatic factor in studies relating 
hypercoagulability to the occurrence of peripheral arterial disease. In case-control studies of 
subjects with established and also asymptomatic disease, plasma fibrinogen levels are 
consistently elevated compared to controls (Dormandy et al 1973a; Christe et al 1984; Smith 
et al 1993) and have also been associated with severity of angiographic lower limb 
atherosclerosis (Lassila et al 1993). From the limited prospective data available, it appears that 
fibrinogen may also be related to the future clinical onset of peripheral arterial disease (Kannel 
et al 1992). The presence of both symptomatic and asymptomatic peripheral arterial disease 
has been associated with elevated plasma levels of other haemostatic factors, including tissue 
plasminogen activator (Smith et al 1994), von Wiilebrand Factor (Blann and McCollum 1992; 
Folsom et al 1993), plasminogen activator inhibitor and fibrin D-dimer (Cortellaro et al 1993; 
Lassila et al 1993). In particular, the importance of fibrin D-dimer as a risk factor for 
peripheral arterial disease, both in primary and secondary prediction is becoming increasingly 
apparent (Al-Zahrani et al 1992; Fowkes et al 1993; Woodburn et al 1995),
1.2 Overview of Haemostasis
This section provides an overview of haemostasis as background to a more detailed literature
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review of the roles of fibrinogen and fibrin D-dimer in this process.
Haemostasis is the physiological response to blood loss following vascular injury. The 
process produces a fibrin-platelet clot which effectively seals the damaged blood vessel. 
Generation of the clot and subsequent clot lysis involves complex interactions between 
vascular endothelium, blood platelets, coagulation factors and components of the fibrinolytic 
system which are finely regulated to localise the clot to the area of damage.
1,2.1 Primary haemostasis
Following injury to the vessel, vasoconstriction mediated by serotonin and thromboxane A 2  
precedes platelet adhesion, aggregation and foimation of a platelet plug. This process is 
teimed primary haemostasis and in small blood vessels, such as arterioles and capillaries, is 
usually adequate to control bleeding. Platelet adhesion is stimulated by vessel wall damage 
and exposure of blood to collagen from the subendothelial matrix. Platelet-collagen binding 
is mediated by a specific platelet membrane receptor, glycoprotein la/IIa. However, binding 
to von Wiilebrand Factor (vWF), a multimeric protein expressed by endothelial cells, is 
essential for noimal platelet adhesion via the platelet receptor, glycoprotein Ib (Sixma 1987).
These interactions result in a monolayer of platelets spreading across the vessel endothelium. 
Further recruitment of platelets occurs only after platelet activation which is stimulated by 
agonists, such as thrombin, adenosine diphosphate (ADP) and thromboxane A2 . This 
autocatalytic process involves morphological changes in the platelet shape, the expression of 
the glycoprotein receptor Ilb/IIIa for binding of fibrinogen and exposure of negatively charged
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phospholipid molecules on the platelet surface for the binding of coagulation factors. In 
addition, platelet micro-particles are formed which have strong pro-coagulant activity.
During activation, platelets release the contents of four types of intra-cellular granules: a- 
granules, dense bodies, lysosomes and peroxisomes. High concentrations of thrombin or 
collagen stimulate a-granule release of proteins which mediate coagulation, including 
fibrinogen, vWF, factor V, platelet-derived growth factor, platelet factor 4, beta- 
thromboglobulin (6-TG), plasminogen, and plasminogen activator inhibitor (PAI). Dense 
bodies secrete serotonin, adenosine, nucleotides and inorganic phosphates, in response to 
stimulation by ADP, adrenaline and relatively lower concentrations of thrombin and collagen. 
Lysosomes contain proteolytic enzymes and peroxisomes contain catalases and other proteins.
Expression of the platelet glycoprotein receptor Ilb/IIIa for fibrinogen leads to platelet 
aggregation by calcium-dependent inter-platelet bridging. Under high shear conditions, e.g. 
at arterial stenoses, binding of vWF to this receptor is necessaiy for platelet aggregation.
1.2.2 Coagulation pathways
The function of the blood coagulation system is to produce fibrin in order to stabilise and 
strengthen the platelet plug formed as a result of endothelial damage. Blood coagulation is 
described as a cascade of reactions which involves the formation of enzyme-cofactor 
complexes and substrates (Mann 1988). Inactive factors (zymogens) are converted 
sequentially to the active protease enzymes which bind to regulatory factors (co-factors) and 
calcium ions to generate thrombin which polymerises the substrate, fibrinogen to fibrin. In
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vivo assembly of these complexes takes place on negatively charged phospholipid surfaces of 
activated platelets or endothelial cells which amplifies the activation rate of the coagulation 
factors and also localises the clot to a particular site. It is generally accepted that there are two 
distinct systems in fibrin generation, the intrinsic and extrinsic pathways. However, this 
division is arbitrary since the pathways are integrated physiologically. These pathways are 
shown in Figure 1.
Intrinsic coagulation pathwav
This pathway is described as 'intrinsic' because all the components are present in blood in an 
inactive precursor form. It can be initiated experimentally by the absorption of factor XII and 
a complex of three proteins, high molecular weight kininogen, prekallikrein and factor XI, 
onto a negatively charged surface, and is teimed the 'contact phase'. The conversion of factor 
XII to activated factor XII (XIIJ is followed sequentially by activation of factors XI, IX, X and 
prothrombin. A co-factor, factor VIII, is required for factor IX  ^to convert factor X to X  ^in 
conjunction with ionised calcium, phospholipid and factor IX  ^on cell surfaces. The function 
of factor VIII is to orientate factor IX  ^and its co-factor VIII^ on the phospholipid surface for 
optimal catalysis. The phospholipid surfaces of platelets can further promote coagulation 
pathways by the expression of binding sites for factors V  ^and VIIL.
Although the activation of factor XII is involved in other physiological processes, e.g. 
fibrinolysis, inflammation and the complement system (Colman 1993), the relevance of factor 
XII to coagulation in vivo is not clear. Patients with a deficiency of factor XII do not exhibit 
abnormal haemostasis, whereas a lack of factor XI can cause a severe bleeding disorder. Thus,
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an alternative mechanism may exist to produce factor XI  ^which does not require factor XII. 
It has been proposed that thrombin produced by the extrinsic pathway directly activates factor 
XI, which in turn generates additional factor XI  ^through autoactivation, although this has not 
been demonstrated in vivo (Gailani and Broze 1991).
Extrinsic coagulation pathwav
It is generally accepted that in vivo coagulation is initiated when tissue factor (TF), the high 
affinity glycoprotein receptor for factor VII, is expressed on activated cells. Although TF is 
present on many extravascular cells such as subendothelial collagen and adventitial cells, 
intravascular expression of TF on endothelial cells and monocytes occurs through stimulation 
by thrombin and the cytokines, interleukin-1, endotoxin and tumour necrosis factor, agonists 
which are also involved in the inflammatory response and infection (Gladal 1984).
Subsequent exposure of TF to blood due to injury results in the rapid formation of a 1:1 
complex with factor VII and activation of factor IX to IX^. Approximately 1% of factor VII 
circulates in plasma in the active form. Factor X  ^can also be directly generated by the TF- 
factor Vila complex (although this is rapidly inactivated by tissue factor pathway inhibitor 
when a trace of factor Xa is produced) and by the factor IXg-factor Villa complex. The rate of 
factor X activation by the factor IXg-VIHa complex is much greater than the rate of generation 
catalysed by the TF-factor VII^ complex (Mann et al 1990), and may be the main mechanism 
of factor Xg formation in vivo. Finally, a third complex, the prothrombinase complex, is 
formed between factor (generated by either of the two coagulation pathways) and its co­
factor Va on the phospholipid surface of activated platelets or endothelial cells.
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The production of thrombin from prothrombin is described as the final common pathway of 
coagulation. Factors and prothrombin from the prothrombinase complex bind to the cell 
membranes by gamma carboxyglutamic residues and calcium ion bridging. Prothrombin 
undergoes three catalytic cleavages regulated by factor to produce a two-chain thrombin 
molecule linked by disulphide bonds which is released from the cell surface (Krishnaswamy 
et al 1987).
Formation of the fibrin clot
Thrombin catalyses the polymerisation of fibrinogen by the initial release of fibrinopeptide A 
by peptide bond cleavage at the amino terminal end of the A a chain, and then release of 
fibrinopeptide B from the Bp chain. This allows the resulting fibrin monomers to interact in 
a half-overlap and side-to-side manner to form protofibrils which grow into linear networks, 
called fibrin gel. The structure of the gel is influenced by the rate of fibrinogen activation by 
thrombin, the formation of which is dependent on the fibrinogen concentration (Blomback
1994). At high fibrinogen concentrations, the gel becomes rigid and tight and occupies a 
greater volume than gel formed at lower fibrinogen concentrations (Blomback et al 1994). 
The stability of the fibrin clot or gel is increased by cross-linkage of fibrin polymers catalysed 
by factor XIII, activated by thrombin in the presence of ionised calcium. Gamma chains of 
adjacent protofibrils are rapidly linked to foim dimers by covalent isopeptide bonding, 
followed by slower Aa chain linkage. This cross-linking increases the elasticity, tensile 
strength and resistance to plasmin degradation of the fibrin clot. Factor XIII also interacts with 
the adhesive platelet protein, fibronectin to promote binding of platelets and the fibrin clot to 
the vessel wall, thus effectively sealing the damaged endothelium.
18
FIGURE 1 THE C O A G UL ATION SYSTEM
INTRINSIC S Y S T E M EXTRINSIC S Y S T E M
T I S S U E  D A M A G E
CONTACT A C(Ê>t T I S S U E  F A C T O R
P L A T E L E T
^ O S P H O L I P lb :
C O M M O N  PATHWAV
THROMBIN
F I B R I N O G E N
X J[IÏ
S O L U B L E  F I B R I NM O N O M E R  — ^  •F I B R I N  P O L Y M E R I S A T I O N
F I B R I N  CLOT 
-► i
C R O S S -L IN K E D  F IB R IN
19
Regulation of blood coagulation
There are a number of mechanisms which prevent coagulation from becoming generalised. 
Central to this control is the ability of the endothelium to modify its function in response to 
pro-coagulant stimuli by expressing anti-coagulant activity. Antithrombin-III (AT-III) can 
inactivate circulating thrombin. In addition, AT-III is able to neutralise the activity of factors 
Xlla, XIa, IXa, and X  ^ (Clause and Comp 1986) and the tissue factor-Vllg complex (Lawson 
et al 1993). The formation of these complexes is accelerated by exogenous heparin and by the 
endogenous AT-III co-factor, heparin sulphate, which is synthesised and expressed on 
endothelial cells and binds to AT-III on the cell surface.
A second anti-coagulant complex is formed between thrombin and thrombomodulin, a specific 
thrombin-binding receptor expressed in high concentrations on resting vascular cells (Esmon 
et al 1993). Subsequently, thrombin becomes conformationally altered so that it is unable to 
either recognise fibrinogen or activate platelets. The thrombin-thrombomodulin complex also 
catalyses the activation of protein C, which with its co-factor protein inhibits the coagulation 
factors Va and VIIL (Stern et al 1986) and increases plasminogen activator inhibitor (PAI) 
formation.
Thrombin can itself directly stimulate the secretion of two vasodilators from the endothelial 
cells,prostacyclin and nitric oxide. These mediators act synergistically to inhibit local platelet 
aggregation (Radomski et al 1988) and also nitric oxide can inhibit platelet adhesion, thus 
limiting the extent of platelet deposition intravascularly.
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1.23 Fibrinolysis
The fibrin clot is removed from the blood vessel when normal vascular structure and function 
is restored. The fibrinolytic system controls the degradation of fibrin and comprises an 
inactive proenzyme, plasminogen which is converted by plasminogen activators to the active 
serine protease, plasmin. The system is illustrated in Figure 2. Astrup (1956) suggested that 
balanced interactions between fibrin formation and degradation occurs even in healthy 
vasculature. Interaction with intrinsic coagulation is demonstrated by the generation of 
plasmin by activated factor XII (Francis and Marder 1986).
Two extrinsic plasminogen activators (PA) have been identified: tissue type PA (t-PA) and 
urokinase type PA (u-PA). u-PA may participate mainly in tissue remodelling and repair, 
macrophage activity and tumour invasion, through matrix degradation or growth factor 
activation. In contrast, t-PA is believed to be mainly responsible for the degradation of fibrin 
at the endothelial surface. Vascular endothelial cells synthesise and secrete t-PA into plasma 
(Van Hinsbergh et al 1994) but platelets also contain a form of t-PA. Other cells, such as 
monocytes can be stimulated to produce t-PA by the cytokine, interleukin-4 (Hart et al 1989). 
Certain stimuli, such as venous occlusion, catecholamines, exercise and bradykinin cause a 
rapid release of t-PA from cellular storage pools in endothelial cells.
Plasminogen is converted to plasmin by cleavage of a peptide bond which creates a heavy and 
a light amino acid chain. The activation rate of plasminogen by t-PA is enhanced markedly 
in the presence of fibrin and is due to three processes; fibrinopeptide A release, fibrin 
polymerisation and release of fragment X, an early fibrin degradation product (Suenson et al
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1984). A complex is subsequently formed between t-PA, fibrin and plasminogen by 
absorption onto the fibrin surface. Optimal orientation of plasminogen by the binding of t-PA 
to fibrin by kringle domains also produces enhanced catalysis of plasminogen by t-PA 
(Horrevoets et al 1994). The enzymatic activity of plasmin via binding to plasminogen 
receptors is also increased on cell surfaces (Gonzalez-Gronow et al 1991).
Regulation of fibrinolvsis
Regulation of this system occurs through plasmin inhibitors, t-PA binding to fibrin and cellular 
receptors, or via the activity of the specific t-PA inhibitors, plasminogen activator inhibitors 
(PAI). This effectively limits fibrinolysis to the site of injury and prevents systemic fibrin 
breakdown.
The main inhibitor of plasmin is alpha (a) 2 -antiplasmin, which belongs to the arproteinase 
inhibitor class of serine protease inhibitors (serpins). It forms a irreversible complex with 
plasmin in a two-stage reaction, although the speed of this reaction is influenced by the 
availability of fibrin binding sites on plasminogen (Wiman and Collen 1978). Plasmin, when 
its lysine binding sites are occupied by fibrin, is inhibited at a rate two to three times slower 
than free plasmin (Collen and Lijnen 1991). Cross-linking of (%2 -antiplasmin to fibrin, 
catalysed by factor XlIT, may enhance fibrin resistance to degradation (Aoki and Harpel 
1984). Other proteolytic inhibitors, such as a 2 -macroglobulin, ai-antitrypsin and complement 
1-inhibitor may play a secondary role in plasmin inhibition, but only when the functional 
concentration of a 2 -antiplasmin is lower than that of plasmin.
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FIGURE 2 THE FIBRINOLYTIC SYSTEM
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Regulation of fibrin breakdown is also controlled by specific t-PA cellular receptors. These 
receptors control rates of elimination of t-PA by the liver, or localise its activity to specific 
cell surfaces. Uptake of t-PA in the liver is mediated by carbohydrate-specific receptors or low 
density lipoprotein (LDL)-receptor related protein receptors. Lack of the carbohydrate, 
mannose on t-PA side chains, for example, decreases the rate of t-PA clearance time by hepatic 
endothelial cells (normally about five minutes) and hence fibrinolytic activity is effectively 
increased (Otter et al 1991).
The interaction of t-PA with cellular receptors expressed on endothelium, platelets and 
monocytes can mediate t-PA binding at these sites and increase pro-fibrinolytic activity. For 
example, t-PA binding to annexin II on endothelial cells, in conjunction with plasminogen, 
enhances plasminogen activation by supporting the formation of a ternary complex, analogous 
to that occurring on the surface of fibrin (Lijnen et al 1990).
Fibrinolysis is also regulated by specific t-PA inhibitors, (PAI). PAI are synthesised by a wide 
variety of cells and are found in plasma, platelets, placenta and in the extracellular matrix. 
There are at least four forms. PAI-1 (released from endothelial cells, hepatocytes and 
platelets), PAI-2 (found in the placenta, pregnancy, plasma and also in monocytes), PAI-3 
(found in urine) and protease-nexin 1, which is synthesised by smooth muscle cells and 
fibroblasts (Rosenblatt et al 1987). Synthesis and secretion of PAI-1 can be altered by agonists 
such as hormones, growth factors and cytokines. It is synthesised in an active form, which 
spontaneously converts to a latent form that may be reactivated on the phospholipid surfaces 
of endothelial cells when required (Emeis and Kooistra 1986)). Most PAI-1 in platelets (and 
hence in blood) occurs in the latent form.
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Active PAI-1 bound to the co-factor, vitronectin, complexes rapidly with t-PA and thus 
inhibits further plasmin formation. The binding to vitronectin is thought to stabilise PAI-1 
activity and protect it from inactivation (Seiffert et al 1990), In addition, PAI-1 strongly binds 
to fibrin and may protect it from plasmin degradation and premature clot lysis.
Fibrin degradation
The removal of the fibrin clot is controlled by the interaction between plasminogen, plasmin, 
and their specific activators and inhibitors. Cross-linked fibrin has a greater resistance to 
plasmin degradation than either fibrinogen or non cross-linked fibrin due to the stabilising 
effect of factor XlII^-induced isopeptide bonds. These bonds are also responsible for the 
unique degradation products produced in the breakdown of cross-linked fibrin. Initial 
degradation of the two-stranded protofibril is produced by cleavage of the Aa  chain, which is 
followed by cleavage of all three polypeptide chains. A series of non-covalently bound 
complexes are formed, the smallest of which consists of two cross-linked fragment D or 
terminal domains of fibrinogen, named D-dimer (Gaffney and Brasher 1973).
1 3  Fibrinogen
Fibrinogen was first described in 1836 by a Glasgow surgeon, Buchanan, who noted that 
blood appeared to coagulate because it contained 'at once fibrin and substances capable of 
reacting upon it, and so occasioning coagulation' (Buchanan 1836). A potential role for 
fibrinogen and fibrin in the pathogenesis of arterial disease was first suggested only a few 
years later when the German pathologist, von Rokitansky, concluded that atheroma in the
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arterial wall was formed by fibrin deposits from the blood (von Rokitansky 1852). In 1946, 
another pathologist, Duguid, in Aberdeen, confirmed that fibrin was incorporated both within 
and on the surface of atherosclerotic plaques and contributed to mural thrombosis (Duguid 
1946).
Although it was recognised that there was an association between thrombosis and the 
occurrence of myocardial infarction as long ago as 1952 (Gilchrist and Tulloch 1952), the 
study of haemostatic factors in the pathogenesis of arterial disease was largely ignored in 
favour of blood lipids. Only in the last twenty years has enough evidence accumulated from 
clinical, experimental and epidemiological studies to support the contribution of fibrinogen 
and other haemostatic factors to the aetiology of arterial disease.
13.1 Structure of fibrinogen
Fibrinogen is an elongated molecule which is highly asymmetrical. It is a dimeric 
glycoprotein with a molecular weight of approximately 340,000 Daltons. It is composed of 
three pairs of polypeptide chains, two A a, two B6 and two y , bound together by disulphide 
bonds (Doolittle 1981). The three dimensional structure of fibrinogen has been determined 
from electron microscopy and biochemical data and is illustrated in Figure 3. The diagram 
shows a central nodule (A) or domain connected to two identical terminal domains (D) by 
coiled chains comprised of interlocked A a, Bp, and y  chains. The smaller central domain is 
made up of the amino-teiminal ends of all six polypeptide chains, whereas the terminal 
domains consist of carboxy-teiminal regions of the p and y  chains. The fibrinopeptides A and 
B, which are released when fibrinogen is converted to fibrin, are situated at the amino-terminal
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ends of the Aa and Bp chains.
The composition of fibrinogen varies due to differences in amino acid residues in the three 
polypeptide chains. Heterogeneity is predominantly due to changes in amino acids at the 
carboxy and amino terminal ends of the A a chains. Three forms of fibrinogen have been 
identified due to Aa chain heterogeneicity - high molecular weight fibrinogen and two low 
molecular weight fibrinogen variants (Mosesson 1983). High molecular weight fibrinogen 
clots more readily than the lower weight variants because of a faster polymerisation rate (Holm 
et al 1985). Variation occurs less frequently in the y  chain at the carboxy terminal regions but 
results in differences in charge and molecular weight. Changes also occur in the Bp chain 
producing differences in sialic acid residues (Topfer-Peterson et al 1976).
13.2 Regulation of fibrinogen synthesis
Plasma fibrinogen is synthesised in the liver by hepatic parenchymal cells. Each individual 
polypeptide chain is synthesised separately and assembled into the dimer before secretion by 
hepatocytes. It circulates in plasma at a concentration of between 1.5 g/L and 4.5 g/L, which 
is well above the concentration (0.5g/L) required for normal haemostasis. About 3% of 
circulating fibrinogen is contained in platelet alpha-granules, but appears to lack the y  chain. 
The biological half life of fibrinogen is approximately 100 hours, but the main catalytic 
pathway responsible for its breakdown has not, as yet, been determined (Green and Humphries 
1989).
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individuals in response to many stimuli. It is one of a number of proteins whose plasma levels 
rise in conditions such as inflammation, infection, neoplasia and pregnancy. This systemic 
response is called the acute phase reaction. Fibrinogen levels can rise up to 20 times during 
this reaction and is due to increases in mRNA levels. Hepatic synthesis of fibrinogen is 
believed to be controlled by at least three inflammatory cytokines, interleukin-6 (IL-6), 
leukaemia inhibitory factor and oncostatin M, which are secreted by activated monocytes or 
damaged endothelial cells. In vitro experiments have shown that the addition of these factors 
to culture medium can produce up to a six fold rise in fibrinogen synthesis by the hepatoma 
cell line, HepG2 (Vasse et al 1994). There is also some evidence that the production of IL-6 
by monocytes is dependent on prior stimulation by fibrin degradation products and therefore 
may indirectly control fibrinogen levels through a positive feed-back mechanism. 
Glucocorticoid hormones (including insulin) also directly affect fibrinogen synthesis in the 
liver and may be ultimately responsible for controlling the duration of the acute phase response 
(Green and Humphries 1989).
1 3 3  Function of fibrinogen in haemostasis, atherogenesis and thrombogenesis
One of the key roles of fibrinogen in haemostasis is its polymerisation to fibrin by the action 
of thrombin. Fibrinogen is also involved in a number of other cellular interactions which are 
important in haemostasis and potentially implicated in atherogenesis and thrombogenesis.
During haemostasis, the rate of clot formation may be controlled by fibrinogen binding to 
thrombin (Liu et al 1979), but conversely, the binding of fibrinogen to fibrin can inhibit further 
fibrin formation. The stmcture of the fibrin clot also appears be influenced by the level of
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plasma fibrinogen, with tight, rigid clots being foimed at a higher fibrinogen concentration 
which may be potentially more thrombogenic (Blomback 1994). Fibrinogen also appears to 
be involved in the control of fibrinolysis in which interactions with the fibrinolytic proteins, 
plasminogen and t-PA are thought to increase the rate of clot lysis.
Fibrinogen is an essential co-factor in optimum platelet aggregation, a process which initiates 
normal haemostasis. By binding to the platelet glycoprotein receptor, Ilb/Illa, fibrinogen can 
bridge adjacent platelets previously activated by ADP, thrombin, collagen and adrenaline 
(Marguerie and Plow 1983). Data from the Northwick Park Heart Study has demonstrated a 
direct correlation between increasing fibrinogen levels and ADP-stimulated platelet 
aggregation under laboratory conditions (Meade et al 1985). When high levels of fibrinogen 
occur in vivo, the size and speed of platelet-rich clot formation may be increased in potentially 
thrombotic events, such as plaque mpture.
Fibrinogen is a major deteiminant of plasma viscosity and red cell aggregation, two factors 
which strongly influence the flow properties of blood. A two-fold increase in fibrinogen raises 
plasma viscosity by 20% and also blood viscosity by the same amount. A rise in viscosity 
may also increase blood pressure and shear stress at the vessel wall, which could promote 
platelet activation and subsequent thrombus formation in areas where there is restricted 
vasomotor activity. Where conditions of low shear predominate, such as at arterial bends and 
bifurcations, high levels of fibrinogen (and hence increased local blood viscosity) could 
contribute to atherogenesis through reduced blood flow and accumulation of atherogenic 
factors (Lowe 1986). Furthermore, under these low shear conditions, fibrinogen can contribute 
to the formation of erythrocyte aggregates which may be important in disturbed microvascular
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blood flow and may further promote ischaemia.
In vitro studies using cultured endothelial cells have also found that fibrinogen is implicated 
in arterial wall damage, a process which may initiate atherogenesis. Both fibrinogen and fibrin 
can alter endothelial permeability by disrupting endothelial cell organisation and cause their 
migration into the intima (Dejana et al 1985). Other fibrinogen or fibrin-induced mechanisms 
related to the onset of atherosclerosis, include the migration and stimulation of smooth muscle 
cell proliferation and a reduction in prostacylin synthesis (Watanabe et al 1984; Naito et al 
1992). Fibrinogen also binds to lipids, particularly Lp(a) and LDL cholesterol and provides 
a substrate for their accumulation within the lesion (Thompson and Smith 1989). The process 
of intimai thickening observed after induced vascular injury is also influenced by fibringen 
levels in vitro (van Pelt-Verkuil et al 1989).
There is also evidence that fibrinogen is implicated in the progression of arterial disease. 
Firstly, the amount of fibrin present in atherosclerotic lesions is directly correlated with plasma 
fibrinogen levels (Gurewich et al 1976). Using immunological techniques, Bini et al (1987) 
have further shown that the proportion of fibrin II (lacking fibrinopeptides A and B) rises with 
increasing severity of atherosclerotic lesions and concluded that the particular distribution of 
fibrinogen and fibrin within these lesions indicated dynamic interactions between fibrinogen, 
macrophages and smooth muscle cells within the evolving plaque.
Fibrinogen may be involved in other cell interactions which are central to the progression of 
atherosclerosis. Fibrinogen may facilitate cholesterol ester production and cholesterol transfer 
from platelets to macrophages. The process is thought to occur through the binding of
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fibrinogen to two receptors, Mac-1 on activated macrophages and the platelet receptor Ilb/IIIa, 
with subsequent uptake of fibrinogen into the macrophage. It was hypothesised that this may 
be a mechanism for the transport of cholesterol from platelets to macrophages by 
thrombophagocytosis, resulting in foam cell formation which is indicative of progression of 
atherosclerosis (Loscalzo 1992).
13.4 Measurement of fibrinogen levels
Four main types of assays are used to measure fibrinogen in clinical and epidemiological 
studies: clotting rate assays, clottable protein assays, precipitation assays and immunological 
assays.
Clotting rate assavs
The Clauss assay measures the time between the addition of thrombin to diluted plasma and 
polymerisation of clottable fibrinogen. The clotting time is calibrated against the clotting 
times of standard fibrinogen plasmas and the fibrinogen concentration of the test plasma is 
then calculated (Clauss 1957). The advantage of this assay is that it is easy to perform, but 
there may be a degree of variability associated with heterogeneity in fibrinogen structure, and 
also because other haemostatic factors, such as fibrin degradation products which can become 
attached to the clot may alter the clotting time.
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Clottable protein assavs
In this type of assay, fibrinogen is quantitated directly. Thrombin is added to a sample of 
plasma and allowed to set until a clot is foimed. The amount of fibrinogen in the clot mass 
is then estimated e.g. by spectrophotometry (optical density at 279nm or 315nm) or by 
gravimetry (dry weight). Although fibrinogen heterogeneity seems to have a minimal effect 
on measurement, this type of assay has a number of disadvantages. Like the Clauss assay, it 
requires blood dilution of approximately 10% by citrate anti-coagulants and sample processing 
within hours of blood sampling. It is also time-consuming and laborious.
Precipitation assays
Precipitation assays measure total circulating fibrinogen and hence estimated levels tend to be 
higher in this type of assay compared to clotting assays. In this method, fibrinogen is 
precipitated either by heating plasma at 56°C diluted in saline buffered at pH 6.3 (Stone and 
Thorp 1985) or by using salts, such as sodium sulphite. Fibrinogen is then measured either 
by nephelometry (change in light scatter) or by turbidometry. One limitation of this technique 
is that other plasma proteins, such as fibrin degradation products can also be precipitated and 
hence the true level of fibrinogen may be over-estimated.
Immunological assavs
This technique was originally based on polyclonal antibodies which were non-specific and 
bound to fragments of fibrinogen and fibrin, in addition to the intact molecule. An ELISA
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(enzyme linked immumosorbent assay) has been developed which uses monoclonal antibodies
'
specific to the amino and carboxy terminal ends of the A a fibrinogen chain but does not 
recognise other fibrinogen derivatives. One advantage of this particular assay is that it only 
takes one hour to complete.
13.5 Standardisation of fibrinogen
Epidemiological studies have employed a variety of different assays to measure fibrinogen
levels using a number of commercial or in-house standards. As a result, plasma fibrinogen
levels have varied widely between the studies and there has been considerable discussion about 4
which is the best assay method to employ in assessing the risk of arterial disease. For
.example, whereas the majority of studies have used clotting or clotting rate assays (which are ;
thought to represent the functionality of fibrinogen), recent evidence has suggested that the 
assay which measures total circulating fibrinogen by nephelometry may be a better predictor 
of arterial disease (Sweetnam et al 1998).
Although there has not, as yet, been agreement on the type of assay which should be routinely 
used in epidemiological studies, a WHO International Standard for fibrinogen measurement 
has been established at 2.4 g/L of clottable fibrinogen (Gaffney and Wong 1992). This should 
ensure better inter-laboratory comparability and also help to establish reference ranges which 
are important in defining what level might constitute an increase in the risk of arterial disease.
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13.6 Determinants of fibrinogen levels
Many intrinsic and extrinsic factors can affect fibrinogen levels both in the general population 
and in patients with atherosclerotic diseases. Identification of these factors is important in 
establishing the reference range within different populations and also in the interpretation of 
the relationship between fibrinogen and arterial disease. In the following section, the major 
determinants of fibrinogen are discussed based on results from epidemiological studies.
Geographical variation
Fibrinogen levels vary considerably among different populations. In general, levels increase 
with the population risk of ischaemic heart disease. Fibrinogen levels are highest among the 
Irish, Scots and Finns, intermediate among English and Caucasian Americans, and lowest 
among Asians, such as the Japanese, which is consistent with their respective degree of risk 
of ischaemic heart disease. However, there are exceptions. For example, mral Gambians and 
Greenland Eskimoes have high levels of fibrinogen and low risk of ischaemic heart disease. 
In the case of the Africans, this elevation may be attributable to parasitic infection (Folsom 
1995), whereas a high dietary intake of polyunsaturated omega-3 fatty acids may account for 
these associations in Eskimos (Bjerregaard and Dyerberg 1988).
Age
Plasma fibrinogen levels rise progressively with age in both sexes. This trend is particularly 
evident in men from the fourth decade, and in post-menopausal women from the fifth decade
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onwards. It has been estimated that in adults, fibrinogen increases at a rate of approximately
0.2g/L every ten years (Meade et al 1979; Lee et al 1990; Folsom et al 1991). This is 
consistent with the higher incidence of vascular disease among older age groups. On the other 
hand, elevations in fibrinogen recorded in healthy centenarians in a recent case-control study 
suggest that high levels are not always deleterious (Mari et al 1994 ).
Sex
Clotting fibrinogen levels are consistently higher in women compared to men, despite a lower 
risk of vascular disease in pre-menopausal women (Kannel et al 1987). Levels are reported 
to be similar in men and women, however, if fibrinogen is measured by a heat precipitation 
assay (GDO Lowe, personal communication). This suggests that there may be variation in the 
molecular structure of fibrinogen between the sexes or there is a relatively higher proportion 
of clotting fibrinogen in total circulating fibrinogen in women.
Cigarette smoking
Cigarette smoking is considered one of the most important environmental determinants of 
fibrinogen levels. Current smokers have approximately 10% higher fibrinogen levels 
compared to non-smokers (Ernst and Resch 1993). Most of the major epidemiological studies 
have found that the levels of fibrinogen are highest in current smokers and lowest in non- 
smokers, with intermediate levels found in ex-smokers (Wilhelmsen et al 1984; Balleisen et 
al 1985; Meade et al 1986; Kannel et al 1987). The effect is also dose-dependent, in that 
fibrinogen rises linearly with the number of cigarettes smoked per day (Ernst et al 1987).
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Although fibrinogen levels start to fall within two weeks of stopping smoking, it may take up 
to 10 years for levels to return to that of a never-smoker (Meade et al 1987).
It is not clear which components of cigarette smoke are responsible for stimulating fibrinogen 
synthesis. The effect may not be mediated by nicotine because levels of fibrinogen in oral 
snuff takers have been found to be similar to non-smokers, even though the snuff takers had 
higher levels of cotinine (the main metabolite of nicotine) than current cigarette smokers 
(Eliasson et al 1995). The mechanism by which smoking increases fibrinogen is not fully 
understood, but it may be through an inflammatory response to injury to pulmonary or arterial 
endothelium and involves the production of fibrin degradation products which activate 
leucocytes to release cytokines, such as interleukin-6. These in turn may stimulate liver 
hepatocytes to up-regulate fibrinogen synthesis.
Blood pressure
Most epidemiological studies have reported significant univariate associations of fibrinogen 
with systolic and diastolic blood pressure which were not maintained on multivariate analysis 
(Wilhelmsen et al 1984; Kannel et al 1987; Rosengren et al 1990). One exception is the 
Münster Study which reported an independent relationship between systolic pressure and 
fibrinogen in women (Balleisen et al 1985). In the Framingham Study, fibrinogen levels rose 
linearly with the severity of hypertension in both men and women (Kannel et al 1992). There 




Reports on the correlation between plasma fibrinogen and blood lipid levels indicate weak 
effects within the major epidemiological studies. Increases in fibrinogen have been related to 
a threshold level of serum cholesterol of 232mg/dL in the Framingham Study, which may 
account for the low overall correlations (Kannel et al 1992). The PROCAM Study found small 
positive correlations between fibrinogen and semm cholesterol and between fibrinogen and 
triglycerides, which tended to be stronger in women (Heinrich et al 1990). In contrast, the
stronger in Japanese men (r=-0.29) than in other racial groups (Iso et al 1993). However, this 
negative effect may reflect the associations of triglycerides with other factors,such as HDL 
cholesterol. Other epidemiological studies have reported inverse associations between 
fibrinogen and HDL cholesterol (Iso et al 1993).
Obesitv
Obesity is frequently associated with increases in blood pressure, total cholesterol and 
triglycerides and decreases in HDL cholesterol and physical activity. It is therefore difficult 
to determine any tmly independent association between fibrinogen and excess body weight. 
Obese subjects have demonstrated higher levels of fibrinogen compared to lean individuals 
in some cross-sectional studies, regardless of whether obesity is measured as the body mass 
index (Lee et al 1990), the Broca index (Balleisen et al 1985), or skin thickness (Meade 1981). 
In another study, the significant univariate association between fibrinogen and abdominal fat 




ARIC Study reported an inverse correlation between triglycerides and fibrinogen which was
included physical fitness (M0ller and Kristensen 1991), whereas another survey among 
working men showed no univariate relationship between fibrinogen and these variables (De 
Boever et al 1995), In post-menopausal women, fibrinogen was correlated with body mass 
index, but not with the waist-to-hip ratio (Meilahn et al 1996).
Menopause
Fibrinogen levels rise more rapidly after the onset of menopause as does the incidence of 
ischaemic heart disease in women. This suggests that sex hormones, such as oestrogen may 
have a protective effect against ischaemic heart disease, possibly through haemostatic 
mechanisms. Meade et al (1983) estimated that fibrinogen levels were between 6% and 10% 
higher in postmenopausal women compared to premenopausal women of similar age. This 
has been confirmed in other studies (Balleisen et al 1985; Meilahn et al 1992; Iso et al 1993; 
Bmnner et al 1996).
Oral contraceptives and hormone replacement therapv
Fibrinogen levels are consistently raised in women who use oral contraceptives containing 
oestrogen (Balleisen et al 1985; Lee et al 1993). In spite of these elevations, current or past 
use of low-dose contraceptives does not appear to increase the risk of ischaemic heart disease 
in healthy women (Brezinka and Padmos 1994). There is, however, a significant increase in 
the risk of myocardial infarction and stroke in women over 35 years who both smoke and use 
contraceptives. In contrast, oestrogen replacement therapy taken by post-menopausal women 
is associated with a decrease in fibrinogen of 0.1-0.15g/L compared to non-users (Iso et al
39
1993; Lee et al 1993; Meilahn et ai 1995). An interaction between fibrinogen, distribution of 
body fat and oestrogen use was also noted by Meilahn et al (1995). Women using hormone 
therapy had less abdominal fat than non-users and this was significantly associated with their 
lower levels of fibrinogen in multivariate analysis.
Earlv development and psychosocial factors
There is increasing evidence that certain factors which operate in early life may partly 
determine fibrinogen levels in adulthood. Barker et al (1992) found that men who had low 
rates of infant growth or foetal growth showed higher levels of fibrinogen in adulthood. Other 
factors associated with childhood environment (short stature, father's social class and a 
subject's level of education) were inversely related to fibrinogen levels in both men and 
women and these associations were only partly mediated by current lifestyle factors (Bmnner 
et al 1996).
The association between the risk of cardiovascular disease and low social class and 
occupational stress is well documented (Marmot et al 1978; Hein et al 1992) and this 
relationship may be partly mediated by fibrinogen (Markowe et al 1985). Emotional stress can 
directly increase fibrinogen under controlled conditions (Jem et al 1989). However, the 
influence of psychosocial factors on fibrinogen is more difficult to deteimine in the general 
population. While low social class and occupational stress has been found to be independently 
associated with increases in fibrinogen (Markowe et al 1985), other studies have suggested that 
this relationship was due to the confounding effects of smoking, body weight and physical 
activity (Baker et al 1988; Rosengren 1990). Similarly, the association between elevated
40
fibrinogen and low work control was attenuated by adjustment for these variables and also 
health status (Brunner et al 1996).
Genetic regulation of fibrinogen
Measurable environmental and personal factors account for only 20% of the differences in 
plasma fibrinogen levels observed between individuals. The extent to which genetic variation 
affects fibrinogen levels has been investigated in several recent studies. The genes that encode 
each pair of fibrinogen polypeptide chains (Aa, Bp and y chains) occur within a cluster of 50 
kb of DNA on chromosome 4 (Kant et al 1985) and in cell culture experiments, synthesis of 
the p chain has been shown to control the formation of fibrinogen (Yu et al 1983).
Using path analysis, Hamsten et al (1987) estimated that 51% of the variance of plasma 
fibrinogen among families with early myocardial infarction was due to genetic heritability. 
Humphries et al (1987) found that three different genotypes, defined as restriction fragment 
length polymoiphisms (RFLPs) at the a  and p gene loci, contributed 15% of the variance of 
fibrinogen. The authors concluded that this was probably an underestimation, since this was 
based on only one fibrinogen measurement and other RFLPs associated with fibrinogen 
genotype were not included in the analysis. In contrast, a Norwegian study found no 
association between levels of fibrinogen and the a  and P genotype (Berg and Kierulf 1989).
Exercise
Regular physical activity is considered a protective factor against the development of
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cardiovascular disease. The protective effect may be mediated metabolically, through 
reductions in weight, heart rate, blood pressure, insulin and triglyceride levels and increases 
in HDL cholesterol. In relation to haemostatic function, cross-sectional studies have 
consistently found that plasma fibrinogen is lower in subjects who exercise regularly (Morris 
et al 1990; Rosengren et al 1990; Folsom et al 1991; Elwood et al 1993). Strenuous, aerobic 
and long-term exercise appear to have the greatest effect on fibrinogen reduction (Connelly 
et al 1992; Wosomu et al 1992). In studies of individuals who have undergone exercise 
programmes lasting between 2-6 months, a reduction in fibrinogen appeared to be dependent 
on a number of factors, such as the age of the individual, period and level of activity and 
presence of other risk factors (Marmucci 1995).
Alcohol and diet
Light regular drinkers have a lower risk of cardiovascular disease than non-drinkers or heavy 
drinkers, as well as lower rates of cigarette smoking, blood pressure and body mass index. 
Moderate alcohol consumption is also associated with a decrease in levels of fibrinogen 
(possibly due to reduced hepatic fibrinogen synthesis) and may contribute to the lower overall 
risk of arterial disease (Meade et al 1979; Yarnell et al 1983; Lee et al 1990; Folsom et al 
1991; Iso et al 1993).
The influence of diet on fibrinogen levels has been more controversial. Some studies have 
found that fish oil intake reduces fibrinogen levels (Lee et al 1990; Iso et al 1993), but there 
are exceptions (Marckmann et al 1991). Dietary fat intake appears to have no significant effect 
on fibrinogen (Miller et al 1986). In a diet supplemented with soluble dietary fibre, however,
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fibrinogen levels were significantly raised, but a decrease in the density of the fibrin clot was 
observed. This suggests that the functional properties of fibrinogen may be influenced by diet 
(Veldman et al 1994).
13.7 Associations with angiographic disease
Several studies have shown elevations in fibrinogen in patients with symptomatic ischaemic 
heart disease. A causal link between fibrinogen levels and the extent of arterial disease defined 
by angiography has also been suggested. In one of the earliest studies, Lowe et al (1980) 
observed an increase in fibrinogen in men with stenoses in two or three coronary vessels 
compared to men with none or single vessel disease, which was independent of smoking 
history. Further studies have confirmed that fibrinogen is significantly related to the extent 
(the number of affected vessels) and severity (degree of stenosis) of angiographic ischaemic 
heart disease in both men and women (Hamsten et al 1986; Leschke et al 1987; Hand a et al 
1989; ECAT Angina Pectoris Study Group 1993; Heinrich et al 1995). In only one study 
(Schmitz-Huber et al 1988) was the fibrinogen level found not to correlate with the severity 
of coronary atherosclerosis. The results from the largest of these studies, the European 
Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris Study, further 
indicated that fibrinogen levels were more strongly associated with vessel occlusion rather 
than stenoses, suggesting that fibrinogen may not only play a role in the development of 
atherosclerosis, but also in thrombogenesis (ECAT Angina Pectoris Study Group 1993).
Although clinical case-control studies of patients with symptomatic peripheral arterial disease 
have consistently shown raised fibrinogen levels (Doimandy et al 1973a; Stormer et al 1974;
43
Lipinska et al 1979; Christe et al 1984), there have been few studies relating fibrinogen to the 
angiographic severity of peripheral arterial disease. Overall, results have been inconclusive. 
Lassila et al (1993) reported a strong correlation between fibrinogen (both clotting and 
nephelometric) and the severity of peripheral atherosclerosis, assessed jointly by angiography, 
ABPI and duplex ultrasonagraphy. In contrast, however, Woodburn et al (1995) reported that 
fibrinogen levels were not independently related to the extent of peripheral atherosclerosis in 
patients with intermittent claudication or severe chronic leg ischaemia.
1.4 Fibrin D-dimer
The potential role of other components of the haemostatic system in thrombogenesis is now 
being evaluated in both clinical and epidemiological studies. One factor which has attracted 
considerable interest as a possible marker of intravascular clot formation is fibrin D-dimer. 
Fibrin D-dimer is the terminal degradation product of cross-linked fibrin and measurement of 
levels of this factor in plasma is thought to reflect the degree of active fibrin formation and 
subsequent activation of fibrinolysis during thrombus formation. Elevated fibrin D-dimer 
levels have been found in other conditions associated with overt thrombosis, such as 
disseminated intravascular coagulation, pulmonary thromboembolism and deep venous 
thrombosis. Fibrin D-dimer is also derived extravascularly, and is raised in patients with 
haematoma, inflammation, tumours, liver and renal disease, in pregnancy and after surgery 
(Lip and Lowe 1995).
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1.4.1 Structure of fibrin D-dimer
The fibrin do t is broken down into a series of degradation products, and removed from the site 
of injury by the action of plasmin, after wound healing has taken place. Some of these end 
products are structurally different from the degradation products derived from fibrinogen and 
non cross-linked fibrin, because the factor Xnig-catalysed isopeptide bonds (cross-links) 
formed between adjacent y-chains (and also cc-chains) in stabilised fibrin are resistant to 
plasmin and are degraded less extensively during fibrinolysis. Under physiological conditions, 
low concentrations of soluble fibrinogen degradation and non cross-linked fibrin degradation 
products circulate in plasma, and are also found within healthy arterial intima (Smith 1994), 
suggesting that some degree of fibrin formation and degradation occurs normally, either 
intravascularly or extravascularly. These products have been identified in vitro using a variety 
of techniques, including gel electrophoresis, affinity and gel filtration chromatography. Based 
on structural studies, the sequence of fibrinogen and fibrin degradation was described 
approximately 25 years ago (Gaffney 1973).
The lysis of fibrinogen and non cross-linked fibrin by plasmin initially cleaves the Aa chain 
and removes the Aa-chain polar appendages. Another peptide fragment, B p (l-42) is released 
from the Bp chain. This forms fragment X. Progressive cleavage by plasmin produces 
fragment Y, composed of linked D (tenninal) and E (central) domains, and a single D domain 
or fragment D. The coiled chains linking the E and D domains are then broken, forming the 
terminal 'core ' fragments D and E.
Plasmic degradation of cross-linked fibrin proceeds more slowly, but also commences with
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cleavage of the A a chain and removal of the Aa-chain polar appendages from a fibrin 
polymer, whilst the y y cross-links remain intact. The remaining product is termed fragment 
XX, but progressively larger soluble complexes (X-oligomers) can be formed depending on 
the length and number of protofibrils within the fibrin clot or gel. A series of these complexes 
unique to cross-linked fibrin has been identified and their molecular weights have been 
predicted to be over 1,000,000 Daltons (Francis and Marder 1986). Flowever, clot reduction 
only occurs when X-oligomers containing fragment X are released spontaneously (Gaffney 
1973). The rigidity of the fibrin gel then gradually decreases and disintegrates into soluble 
fragments. When these high molecular soluble complexes are released into plasma, they 
continue to be degraded into a series of smaller fragments by cleavages at sites near the y y 
chain, or at the D and E domains between the coiled chains (Figure 4). Fibrin D-dimer 
(fragment DD) is the smallest terminal fragment derived from cross-linked fibrin after 
prolonged exposure to plasmin, and consists of the D domains of two adjacent fibrin 
monomers, cross-linked through the y y chains. However, in vitro studies indicate that fibrin 
D-dimer primarily circulates in plasma in a non-covalent association with fragment E, derived 
from the second fibrin strand of a protofibril (Gaffney 1973).
1.4.2 Function of fibrin D-dimer in haemostasis, atherogenesis and thrombogenesis
In normal haemostasis, interactions between fibrin and cross-linked fibrin degradation 
products may inhibit fibrin gel formation. The formation of complexes has been demonstrated 
in vitro between fragments X, Y and D with fibrin monomers, which can block the extension 
of the protofibrils and also inhibit their lateral growth. The rate of clotting and clot stability 
may therefore be reduced, since the length of the protofibrils are too short to promote adequate
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FIGURE 4 CROSS-LINKED FIBRIN DEGRADATION
(DxD)







Two lineal' fibrin polymers ai*e shown in a half-staggered overlap ai'ray 
with covalent crosslinks between chains indicated as double lines 
between adjacent D domains. Complex 1 shows D-dimer and DD apposed 
to Fragment E of the other fibrin strand. The complexes can be 
expressed as DD/E (complex 1), DY/YD (complex 2), and DXD/YY (complex 
3).
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fibre formation (Hermans and McDonagh 1982). In addition, a role in fibrinolysis is indicated 
because these fragments can increase the rate of activation of plasminogen to plasmin, the 
main fibrinolytic enzyme (Suenson et al 1984). Conversely, D-dimer can compete with 
plasminogen for surface binding sites on fibrin, thus effectively prolonging clotting time.
There is also evidence that fibrin degradation products may contribute to both plaque growth 
and thrombus formation. In immunoassay experiments, high concentrations of fibrin D-dimer 
have been found in atherosclerotic lesions, whereas in normal arterial intima, only small 
quantities of intact fibrinogen are detected. Moreover, as the lesions become more advanced, 
the proportion of fibrin D-dimer increases and are distributed around foam cells, cholesterol 
and macrophages (Bini et al 1989). Both fibrin and fibrin D-dimer are also concentrated in 
large amounts in the centre of mural thrombi, surrounding platelets and leucocytes. The 
source of fibrin and fibrin D-dimer appears to originate from within the thrombi through 
thrombin and plasmin activity, rather than originating from transport of fibrinogen into the 
arterial wall (Smith 1993).
These findings may be significant because fibrin D-dimer appears to affect a number of cell 
functions which may be relevant to atherothrombosis. Firstly, it can increase endothelial 
permeability through disorganisation and retraction of the cell monolayer (Rabbani and 
Loscalzo 1994). Other in vitro effects on the endothelium include a reduction of prostacyclin 
synthesis (Ishida and Tanaka 1982). As prostacyclin is a potent inhibitor of platelet 
aggregation occurring in response to injury at the vessel wall, this suggests fibrin D-dimer may 
be involved in the earliest stages of endothelial dysfunction. Furthermore, fibrin D-dimer can 
stimulate migration and proliferation of vascular smooth muscle cells, collagen and growth
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factors, processes which characterise the development of the fibrous plaque. Fibrin D-dimer 
is also chemotactic for monocytes, another of the major cell types found in atherosclerotic 
lesions and implicated in lipid accumulation within these lesions (Thompson and Smith 1989). 
Lastly, high levels of fibrin D-dimer may increase hepatic synthesis of fibrinogen through 
interactions with monocytes. This reaction is thought to be controlled in part by the cytokine, 
interleukin-6, released by the monocyte in response to changing levels of D-dimer. This 
relationship may partly explain the strong correlation found between fibrin D-dimer and 
fibrinogen in most epidemiological studies.
1.43 Measurement of fibrin D-dimer levels
Early assays for the detection of fibrin degradation products, such as the red cell 
haemoagglutination inhibition immunoassay or the Thrombo-Wellco test were performed on 
semm rather than plasma samples and lacked specificity for the individual fibrin fragments. 
It was also suggested that the levels of semm fibrin degradation products do not accurately 
represent levels in plasma since semm concentrations usually tend to be lower (Gaffney and 
Perry 1985).
Current methods used to measure fibrin D-dimer are based on detecting the specific structure 
of cross-linked fibrin degradation products which differ from those of fibrinogen and non 
cross-linked fibrin because of the plasmin-resistant y y  chain cross-links. The four most 
common techniques used at present to deteimine D-dimer are gel electrophoresis, 
immunoelectrophoresis, the semi-quantitative latex agglutination test and the enzyme linked 
immunosorbent assay (ELISA). However, the ELISA is now the preferred quantitative
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method employed in clinical and epidemiological surveys to assess the role of D-dimer in 
cardiovascular disorders.
Gel electrophoresis assay
In this type of assay, the proportion of D-dimer formation compared to other degradation 
products can be determined by separating the fibrin fragment from plasma samples, diluted 
with sodium dodecyl sulphate-poly aery 1 amide (SDS-PAGE) gel, at a concentration of between 
2-10%. Purified fibrinogen, labelled with radioactive ^^ i^odine is first exposed to thrombin to 
increase the amount of cross-linked fibrin protofibrils and then the fibrinogen and plasma 
samples undergo electrophoresis after addition of t-PA. After staining the gel with Coomassie 
blue dye, a procedure known as Western blotting transfers the gel pattern of the migrating 
protein onto nitrocellulose sheets, A band corresponding to the migration of fibrin D-dimer 
through the gel can be detected by autoradiography (Gaffney et al 1975). The proportion of 
fibrin D-dimer is then determined by densitometry.
Immunoelectrophoresis assay
In Immunoelectrophoresis, fibrin D-dimer is detected using a combination of 
immunoprécipitation and Western blotting. Plasma samples are incubated with thrombin and 
the resultant serum is treated with an anti-fibrinogen antibody to remove any fibrin-related 
antigens from the sera. Analysis by SDS-PAGE gel electrophoresis and blotting with a 
monoclonal antibody specific to fibrin D-dimer detects a precipitation band where the D-dimer 
antigen and antibody have reacted (Connaghan et al 1985).
50
Latex agglutination test
This technique employs a monoclonal antibody (DD-3B6) coated onto latex beads which are 
specific for fibrin cross-linked between the D-domains. These beads are mixed with plasma 
which has been centrifuged with bentonite to remove fibrinogen and left at room temperature 
for three minutes. The slide is then read against a black background for signs of agglutination, 
which indicates that the antibody has recognised and complexed with fibrin D-dimer 
(Greenberg et al 1987). The concentration of fibrin D-dimer levels are calculated semi- 
quantitatively by multiplying the highest doubling dilution of plasma showing bead 
agglutination by 200ng/mL, which is considered the sensitivity of the beads for fibrin D-dimer.
Enzyme linked immunosorbent assav
This is a simple and precise enzyme immunoassay which recognises the fibrin derivatives, D- 
dimer, D-dimer/E and high molecular weight complexes containing the D-dimer fragment. 
The reactions are carried out on microlitre plates, which have been coated with the D-dimer 
specific monoclonal antibody (the capture antibody). This binds with the D-dimer antigen in 
the plasma sample. A second antibody, (the tag antibody) conjugated with horse-radish 
peroxidase enzyme is added and complexes with the bound antigen and any residual untagged 
antigen. A colour reaction is produced by adding hydrogen peroxide and a substrate, 2,2- 
azino-di-3-ethylbenzthiazoline sulphinate. The absorbance of each microtitre well is then 
determined at 405-420nm and values calculated with reference to a standard curve.
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1.4.4 Determinants of fibrin D-dimer levels
There is relatively little published data on the factors which can influence fibrin D-dimer levels 
in the general population and therefore normal values within the community are not clearly 
known. At present, only three population surveys have examined associations between fibrin 
D-dimer and its possible deteiminants (Giansante et al 1994; Lee et al 1995; GDO Lowe, 
personal communication). There is also evidence of associations between fibrin D-dimer and 
cardiovascular risk factors based on patients with atherosclerotic disease, but it is probable that 
interactions between fibrin D-dimer and other factors may be different in these patients 
compared to healthier subjects.
Geographical variation
There are no specific reports at present on variation in levels of fibrin D-dimer among different 
populations or by race, in the community. However, the ARIC Study reported that there was 
an increase in the risk of early carotid atherosclerosis across quartiles of D-dimer in whites, 
but not in blacks, although the differences in fibrin D-dimer levels were non-significant 
(Salomaa et al 1995). Conversely, Gaines et al (1992) found that raised fibrin D-dimer levels 
were more common in black patients who suffered a stroke than in white patients.
Age
Age appears to be a major determinant of plasma fibrin D-dimer levels in both men and 
women in the general population. Fibrin D-dimer levels rise linearly with increasing age,
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although the trend is slightly stronger in men (GDO Lowe, personal communication; 
Giansante et al 1994; Lee et al 1995 ). Strong correlations have also been reported between 
D-dimer concentrations and increasing age in men with ischaemic heart disease (Heinrich et 
al 1995) and in patients with more extensive atherosclerosis (Panchenko et al 1995).
Sex and the menopause
Overall, women tend to have higher levels of fibrin D-dimer than men (Lee et al 1995). 
Higher fibrin D-dimer levels have also been reported in pre-menopausal women compared to 
men of similar age (GDO Lowe, personal communication). This sex difference is not 
maintained after the menopause. This may be due to an increase in extravascular fibrin 
turnover during menstruation. Also, fibrin D-dimer levels rise in women after the onset of the 
menopause. This suggests that sex hormones, such as oestrogen may influence fibrin D-dimer 
levels.
Oral contraceptives and pregnancv
The use of oral contraceptives containing oestrogen has been associated with an increase in 
plasma fibrin D-dimer levels (Lip and Lowe 1995). This has also been observed in healthy 
pregnancy and also in women who develop pre-eclampsia. Furthermore, pre-eclamptic 
pregnant women who have significantly raised fibrin D-dimer levels had higher blood 
pressures, more abnormal liver function, higher protein levels in the urine and a greater risk 
of early caesarean section and premature delivery than those with lower fibrin D-dimer levels.
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Blood pressure
Relatively low correlations have been reported between fibrin D-dimer and blood pressure in 
two population sui*veys. In the larger Edinburgh Artery Study, age adjusted correlations 
between fibrin D-dimer and both systolic and diastolic blood pressure were stronger in women 
than in men (Lee et al 1995). In contrast, the WHO MONICA survey found that fibrin D- 
dimer correlated more highly with blood pressure in younger men (GDO Lowe, personal 
communication). A significant association was also demonstrated with systolic blood pressure
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Cigarette smoking
Two studies in the general population have observed that fibrin D-dimer levels are higher in 
male current and ex-cigarette smokers compared to never smokers (Giansante et al 1994; GDO 
Lowe, personal communication). No consistent relationship was shown between fibrin D- 
dimer levels and smoking habit in women. In the Trieste Study, however, there was an 
interaction between age and smoking with fibrin D-dimer in women. A progressive significant 
increase in fibrin D-dimer levels in women smokers was demonstrated with each successive 
decade between 25 and 64 years (Giansante et al 1994). The association between long-term 
smoking and fibrin D-dimer levels appeared to be stronger than the relationship between D- 
dimer levels and current smoking, both in population surveys (Salomaa et al 1995), and in 
subjects (particularly men) with peripheral arterial disease (Smith et al 1993; Lassila et al 
1993; Lee et al 1995). Other studies have found no relationship between fibrin D-dimer levels 
and cigarette smoking in claudicants or patients with severe chronic leg ischaemia (Al-Zahrani 
et al 1992; Lee et al 1996).
in a pooled case-control analysis investigating early carotid atherosclerosis from the ARIC 
Study (Salomaa et al 1995), but conversely, no relationship was found in men with prevalent 
ischaemic heart disease (Heinrich et al 1995). Elevations in plasma levels of fibrin D-dimer 
have also been shown in hypertensive patients (Varizi et al 1993; Giansante et al 1994; Lip and 
Beevers 1994) and this has been suggested as a contributory factor in the increased risk of 
stroke and thrombotic episodes obseived in hypertensive individuals.
Blood lipids
Evidence is also conflicting regarding the relationship between fibrin D-dimer and se mm 
lipids in the general population. Whereas Giansante et al (1994) found no significant 
correlations between fibrin D-dimer levels and serum lipids in analysis in which the sexes 
were combined, only a significant inverse correlation between D-dimer and triglycerides in 
men, and a positive association with fibrin D-dimer and total cholesterol among women were 
reported (GDO Lowe, personal communication). The Edinburgh Artery Study, on the other 
hand, found that the strongest correlations were between fibrin D-dimer and low HDL 
cholesterol in both sexes, but significant associations were also observed with other lipids, 
particularly in women (Lee et al 1995).
Ridker et al (1994a) suggested that the relationship between fibrin D-dimer and serum lipids 
may be non-linear, in that a significant increase in fibrin D-dimer only occurs at high threshold 
levels of cholesterol and triglycerides, and at a low level of HDL cholesterol. It is also 
possible that a sex differential effect exists in associations between fibrin D-dimer and lipids.
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1.4.5 Associations with angiographie disease
Evidence that fibrin D-dimer may have pathological significance in peripheral arterial disease 
has been provided by recent prospective, epidemiological and hospital-based studies. Elevated 
fibrin D-dimer levels have consistently been demonstrated in subjects \vith asymptomatic or 
symptomatic peripheral arterial disease, both in clinical practice and in the general population 
(Al-Zahrani et al 1992; Cortellaro et al 1993; Smith et al 1993; Herren et al 1994; Heinrich et 
al 1995; Panchenko et al 1995). The Edinburgh Artery Study has further shown that fibrin D- 
dimer was independently related to the severity of peripheral arterial disease (as determined 
by the ABPI), after adjustment for a range of cardiovascular risk factors, including smoking 
consumption (Lee et al 1995).
These findings have been confirmed in two clinical studies of patients in whom the extent of 
peripheral arterial disease was measured directly by angiography. The first of such studies 
described a linear relationship between fibrin D-dimer levels and severity of disease, although 
the presence of peripheral atherosclerosis was assessed by angiography in only 38% of 
patients, with the remainder assessed by non-invasive techniques (ABPI and duplex scanning) 
(Lassila et al 1993). However, no account was taken of the effect of cigarette smoking on this 
association. In a more recent angiographic study of patients diagnosed as having intermittent 
claudication or severe chronic leg ischaemia, fibrin D-dimer showed the strongest association 
of any haemostatic or risk factor with increasing severity of peripheral arterial disease, which 
was independent of smoking habit (Woodburn et al 1995). Overall, these findings are 
indicative of a role of intravascular fibrin turnover in the development of peripheral arterial 
disease, which may be related to increased formation of cross-linked fibrin thrombi.
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1,4.6 Prediction of thrombotic events
The role of fibrin D-dimer in the prediction of thrombotic vascular events has not been widely 
studied, either in the general population or in patients with prevalent peripheral arterial disease. 
From data derived from the the Edinburgh Artery Study, fibrin D-dimer was independently 
related to the risk of stroke after five years of follow-up, in analysis which adjusted for 
cigarette smoking, LDL cholesterol, systolic blood pressure and pre-existing ischaemic heart 
disease (Smith et al 1997). Fibrin D-dimer was also predictive of ischaemic heart disease 
(especially myocardial infarction), although the relationship was weaker and not maintained 
on multivariate analysis. These findings were in contrast to findings from the Caerphilly 
Study (Lowe et al 1998), and the Physicians Heart Study (Ridker et al 1994a). Comparison 
of these studies suggests that there are differences in the age structures, end points and the 
covariates entered into the analysis which may account for the conflicting results.
At present, few studies have investigated the associations between fibrin D-dimer and adverse 
outcome in symptomatic peripheral arterial disease. In the PLAT Study, baseline levels of 
fibrin D-dimer were associated with the incidence of thrombotic events, such as myocardial 
infarction and stroke in patients with peripheral atherosclerosis, after one year of follow-up 
(Cortellaro et al 1994). Levels of fibrin D-dimer, measured pre-operatively, have also been 
shown to have predictive value in patients who suffered graft occlusion or death following 
reconstructive surgery for severe peripheral arterial disease (Woodburn et al 1996).
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1.5 Background to Research
Thrombosis is an important pathogenic factor in the causation of cerebral and myocardial 
infarction (Davies and Thomas 1984) and thrombus formation has been related to high 
systemic levels of haemostatic factors, particularly fibrinogen. The relationship between 
haemostatic function and peripheral arterial disease is attracting interest, partly because the 
pathogenesis of disease in the lower limb is less well understood, but also because it is 
recognised as a disease associated with a high risk of mortality from thrombotic ischaemic 
heart disease and stroke events.
In the research described in this thesis, the author decided to investigate two haemostatic 
factors, fibrinogen and fibrin D-dimer for the following reasons. Firstly, plasma fibrinogen 
has been related to the development of ischaemic heart disease and stroke in several studies, 
but the relationship with peripheral arterial disease is less well established. Secondly, fibrin 
D-dimer is a relatively new factor to be investigated in terms of cardiovascular risk and little 
evidence is available on peripheral arterial disease. Measurement of fibrin D-dimer levels 
may indicate the level of cross-linked fibrin turnover formed in arterial thrombi and hence may 
have prognostic value as a marker of intravascular thrombosis.
Previously, the author conducted a case-control study on men and women, aged 55-74 years, 
who were selected from the Edinburgh Artery Study. This study began as a cross-sectional 
survey investigating the prevalence of symptomatic and asymptomatic peripheral arterial 
disease in the general population in 1988. The purpose of the nested case-control study was 
to determine the relationship between the haemostatic factors, fibrinogen, fibrin D-dimer, von
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Willebrand Factor and plasminogen activator inhibitor and peripheral arterial disease. The 
influence of cigarette smoking on these associations was also considered, for two reasons. 
Firstly, smoking is probably the most impoilant risk factor in the development and progression 
of peripheral arterial disease. Secondly, it may affect plasma levels of haemostatic factors, 
such as fibrinogen (Leng and Fowkes 1993), and hence might influence the strength of the 
relationships between haemostatic function and disease.
Interpretation of the results from the case-control study indicated that neither life-time or 
current smoking had any real impact on the increased risk of peripheral arterial disease 
associated with raised fibrinogen levels. Rather, the main effect of smoking on peripheral 
atherosclerosis appeared to be more through fibrin foimation than through fibrinogen levels 
(Smith 1993). In view of these findings, which suggested differing associations of haemostatic 
function in peripheral arterial disease compared to that of ischaemic heart disease, two further 
studies, the subject of this thesis, were proposed to examine the inter-relationships between 
cigarette smoking, haemostatic factors (in particular fibrinogen and fibrin D-dimer) and 
peripheral arterial disease.
The first study, the Sites of Atheroma Study, was conducted by the author between January 
1992 and January 1993. This study was designed to investigate the relationship between 
haemostatic factors and the site and severity of atherosclerosis of the lower limb to confirm 
whether the above relationships were sustained in patients with more severe disease, as defined 
by angiography. The effect of smoking was again considered, since risks due to smoking 
appear to differ by site. For example, in addition to being a stronger risk factor for peripheral 
arterial disease compared with ischaemic heart disease (Fowkes et al 1992), smoking is more
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strongly associated with aorto-iliac disease than with disease in the femoral vessels (Sackett 
et al 1968; Lawton 1973; Strong and Richards 1976).
The second study, the Prognostic Study of Intermittent Claudication, was established in 1989 
to determine whether haemostatic factors were associated with the future development of acute 
vascular events in individuals with intermittent claudication. The author was employed in 
1995 to conduct a follow up study of events occurring within the six years since baseline.
1.6 Sites of Atheroma Study: Aim and Objectives
Aim
To determine whether plasma fibrinogen , fibrin D-dimer and other haemostatic factors (von 
Willebrand Factor and plasminogen activator inhibitor-type 1) are related to the angiographic 
site and severity of atherosclerosis in the arteries of the lower limb, in order to enhance 
understanding of aetiological mechanisms.
Objectives
I To determine mean differences in levels of plasma fibrinogen, fibrin D-dimer and other 






II To determine associations between the above haemostatic factors and the severity of 
disease separately within the aorto-iliac and femoro-popliteal arteries.
III To determine differences in cigarette smoking and other vascular risk factors between 




IV To detennine the influence of cigarette smoking on the associations between plasma 
fibrinogen, fibrin D-dimer and other haemostatic factors, and severity of disease within 
the aorto-iliac and femoro-popliteal arteries.
1.7 Prognostic Study of Intermittent Claudication; Aim and Objectives
Aim
To determine whether plasma fibrinogen, fibrin D-dimer and other haemostatic factors, and 
cardiovascular risk factors are related to the incidence of atherothrombotic events in subjects 
with intermittent claudication, in order to identify possible mechanisms involved in the 
aetiology and progression of disease.
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Objectives
I To determine in patients with intermittent claudication, univariate associations
between the following haemostatic factors:
1. Plasma fibrinogen
2. Fibrin D-dimer
3. von Willebrand Factor
4. Tissue plasminogen activator
and the development of vascular events during six years, in terms of :
1. Ischaemic heart disease events (fatal and non-fatal)
2. Stroke (fatal and non-fatal)
II To deteimine in patients with inteimittent claudication, univariate associations between 
the above haemostatic factors and the progression of peripheral arterial disease, in 
terms of:
1. Vascular intei'vention
2. Severe chronic leg ischaemia
III To determine multivariate associations between the above haemostatic factors and the 
incidence of ischaemic heart disease and stroke events in those patients with 
intermittent claudication, taking into account the possible effects of life-time cigarette 
smoking and other cardiovascular risk factors.
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IV To detennine multivariate associations between the above haemostatic factors and 
progression of peripheral arterial disease in patients with intermittent claudication, 




SITES OF ATHEROMA STUDY: METHODS
2.1 Study Design
The Sites of Atheroma Study comprised a consecutive case series of patients in the form of 
a cross-sectional study, which is an obseiwational epidemiological study in which the risk 
factors and disease status of individuals in a defined population are assessed simultaneously. 
The defined population of consecutive cases of intermittent claudication or rest pain consisted 
of both new and existing cases, and their current health status was examined in respect to the 
risk factors of interest. The data collected were used to determine the distribution of 
physiological and biochemical measurements and the characteristics of disease within this 
defined population at a specific time.
2.2 Sample Size
In a recent study designed to classify 300 patients by retrospective examinations of 
angiograms into groups with predominantly disease in either the aorto-iliac or femoro- 
popliteal segments, one-third of patients were categorised as dual-site because they did not 
have disease predominantly in one site or the other (M Why man, unpublished obsei-vations). 
Of the remaining 200 subjects, more than 100 had disease in the femoro-popliteal arteries and 
less than 100 had disease in the aorto-iliac arteries. The angiograms were coded by site and 
severity of disease described by Bollinger et al (1981). In the present study, it was therefore
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assumed that three approximately equal sized groups defined according to site of disease 
would be identified.
The sample size had to be adequate to detect significant differences between the groups in the 
main variables of interest, plasma fibrinogen and fibrin D-dimer. From data derived from the 
Edinburgh Artery Study, mean levels of plasma fibrinogen were as follows:
Mean Standard Deviation
Fibrinogen (g/L) 2.72 0.80
Based on the following formula:
Number of patients in each group 
2
n= ......... -  X f (a, P)
(F2“ Fi?
where (p,2  - Fi)^ is the difference in mean fibrinogen which is important to detect, 
o is the standard deviation of fibrinogen 
a is the type I error, normally 0.05 
P is the type II error, or power, 0.1 in this case.
It was estimated that a sample size of 200 would have 90% power to detect a mean difference 
of plasma fibrinogen 0.26g/L between groups at 5% level of significance.
23  Study Population
The study population comprised men and women with ischaemic symptoms in the lower limb.
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The study sample was selected prospectively from consecutive patients referred for 
angiography to the Royal Infirmary of Edinburgh. These patients were experiencing 
symptoms of chronic ischaemia, that is, inteimittent claudication in the calf, buttock or hip, 
or more severe symptoms, such as pain at rest in the foot or toes. Referral of these patients for 
angiography had been made either from the Peripheral Vascular Clinic (out-patients), or the 
Vascular Surgery Unit (in-patients). The clinical symptoms of these patients were assessed 
by a vascular consultant over a period of several months to determine the probable site and 
severity of disease. If it was considered that their condition had worsened significantly or 
severely affected their life-style, they were then referred for angiographic investigation.
2.4 Study Exclusions
Patients with ischaemic symptoms of ulceration and gangrene were excluded from the study 
because infection and inflammation induce a systemic rise of acute-phase reactant levels. 
Patients who had undergone amputation or reconstmctive surgery were also excluded because 
the removal of a severely diseased limb, or the replacement of occluded arterial segments, 
would not give a tme reflection of the severity or site of arterial disease when assessed by 
angiography.
2.5 Patient Selection
Before the study commenced, permission to recmit patients from the vascular wards was 
obtained from the senior consultant. Professor CV Ruckley. The author was introduced to the 
ward nursing and other staff who were informed about the study. The Radiology department
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was also visited and permission was obtained from Dr I Gillespie, consultant radiologist, to 
remove angiographic X-rays from the film store when required for coding purposes.
The patients were selected prospectively from a list of patients undergoing radiological 
investigations during the forthcoming week. This list was issued at approximately 4 pm on 
Friday afternoon in the Radiology department. The day and date of procedure, name of 
patient, ward number, and type and time of procedure were given. Any patient who was listed 
as undergoing aortography, femoral or iliac angiography or femoral or iliac angioplasty was 
noted and considered a potential recruit for the study. This list was also checked on each 
weekday because appointment cancellations frequently occurred and new patients were then 
listed.
In addition to this list, patients with symptoms of severe chronic leg ischaemia were 
occasionally admitted without prior notification to the vascular wards. Therefore, regular 
assessment of all admissions to these wards was required, and hence the numbers potentially 
suitable for inclusion to the study varied from week to week. Once a list of potential subjects 
had been drawn up, the patients' notes were examined within the vascular wards to ensure that 
they had none of the exclusion criteria.
2.6 Sample Recruitment
Patients undergoing angiography or angioplasty were normally admitted on the day before, or 
the day of the procedure, and discharged 24 hours later. Men or women with more acute 
symptoms of limb ischaemia who were scheduled for vascular surgery were in-patients on the
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vascular wards. Patients with less severe symptoms of peripheral arterial disease were 
admitted for a short stay to a Programmed Investigation Unit.
There were only certain times available for recmitment of subjects. This could only take place 
after the patients had been admitted and interviewed by the nursing staff and after they had 
been 'clerked in' by the ward House Officer, who gave them a full medical examination, 
including palpation of peripheral pulses, blood pressure measurements, electrocardiogram, and 
a venepuncture. Also, no recruitment was possible during consultant ward rounds between 
9am and 10 am, at lunch-time between 12.15 pm and 1.30 pm, tea-time between 5 pm and 6  
pm and visiting times between 3 pm and 4 pm.
It was also important that the patients had sufficient time to recover from the initial 
examination by the ward doctor, because the examination required by the present study 
involved a second venepuncture and blood pressure recordings. However, it was essential to 
recruit patients before angiography because the contrast media could activate platelets, 
leucocytes and other blood factors.
2.7 Examination Procedures
The ward sister was approached to ascertain whether the patient scheduled for angiography 
had arrived and had been examined by nursing staff and the house officer. If so, and a 
reasonable amount of time had elapsed since their last examination, the patient was 
approached prior to their angiography. The purpose of the study and the examination 
procedure was explained to the patient. If they were willing to take part in the study, they
68
were then asked to complete a consent form which emphasised the anonymity and the 
confidentiality of the results. This form is shown in Appendix I. The subjects were infoimed 
that the study had been given ethical approval by a Medical Ethics sub-committee of Lothian 
Health Board and the examination then took place.
Patients were recruited and examined over a period of 13 months, between January 1992 and 
January 1993. Equipment and patient foims were kept at the Vascular Studies Unit which was 
situated in close proximity to the vascular wards. When a patient was recruited from any 
ward, the equipment required for the examination was taken by a small portable trolley to the 
ward. The patient was examined in the ward at the bed-side. Each examination took 
approximately 45 minutes and consisted of venepuncture, blood pressure measurements and 
administration of a questionnaire.
A blood sample was taken following ten minutes rest in the supine position. A total of 25 mLs 
of blood was withdrawn from the ante-cubital vein using a 2 1 g butterfly infusion set and 
without tourniquet wherever possible to prevent platelet lysis. The needle was held in position 
using micropore tape. Bruising was prevented after withdrawal of the needle by pressure on 
the vein, with the arm held in a vertical position for 20 seconds. Details of the venepuncture 
procedure were recorded on a form which identified the subject by name and study number 
(Appendix II). Time of venepuncture was also recorded because certain haemostatic factors 
e.g. plasminogen activator inhibitor are subject to diurnal variation. The form was designed 
to record whether venepuncture was successful, because slow venepuncture can lead to 
spuriously high levels of some haemostatic factors. If venepuncture was not possible, the 
subject was excluded from the study.
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Blood pressure measurements were taken after venepuncture, when the subject had rested in 
the supine position for a further 10 minutes. The systolic and diastolic (phase V) blood 
pressures were taken in the right arm using an adult size latex inflation cuff and a Hawksley 
random zero sphygmomanometer. The ankle systolic blood pressure was recorded on each leg 
by a cuff inflated proximally to the ankle, and the return of blood flow detected using a 
Sonicaid doppler probe placed over the posterior tibial or dorsalis pedis artery. The ankle 
brachial pressure index (ABPI), which is the ratio of ankle to brachial systolic pressure was 
calculated as a measure of severity of peripheral atherosclerosis (Appendix III).
Following blood pressure measurements, a self-administered questionnaire was completed by 
the subject. The questionnaire was then checked and assistance given if there was difficulty 
in answering any of the questions. The questionnaire is shown in Appendix IV. The subject 
was asked to provide their name and date of birth and the questionnaire was then divided into 
five sections. Firstly, details of past medical history were sought, including questions on 
previous myocardial infarction, angina, stroke and other cardiovascular disease.
The second section was to ascertain whether the subjects were prescribed regular medication 
from their general practitioner. It was important to quantify those who were receiving aspirin 
or anti-coagulant medication because these can affect haemostatic function. Thirdly, the 
subject was asked to provide details on family history of heart attack, angina and intermittent 
claudication. This section was included because it is recognised that cardiovascular disease 
in first-degree relatives is a risk factor, especially for ischaemic heart disease, although this 
infoimation was not subsequently used in the study analysis. The smoking section was 
designed to elicit detailed information on current smoking status and to distinguish clearly
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between current, ex- and never cigarette smokers. Questions were listed sequentially to 
quantify the amount of tobacco consumption, duration of smoking in current users and those 
who had quit smoking. For ex-smokers, the length of time since cessation of smoking was 
requested.
The Edinburgh Claudication Questionnaire was also administered (Leng and Fowkes 1992). 
Finally, details on previous arterial surgery was obtained. Tliis was to ensure that subjects had 
not undergone previous reconstructive surgery or angioplasty which would have excluded 
them from the study.
2.8 Blood Assays
2.8.1 Preparation of anti-coagulants
Tri-sodium citrate
This anti-coagulant was prepared by the author in the Cardiovascular Research Unit, 
Department of Biochemistry, University of Edinburgh. The absolute concentration required 
was 0.32 g/mL. Two hundred and fifty white topped Z5  plastic tubes with 0.5 mL tri-sodium 
citrate solution were prepared. Using a Sauter balance, 8.0 g tri-sodium citrate crystals were 
weighed out into a 250 niL conical flask. The crystals were dissolved by shaking gently in 
distilled water and more distilled water was added until the 250 mL mark was reached.
Using an Oxford pipette fitted with a plastic disposable tip, 0.5 mL of tri-citrate solution was
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measured into each Z5 tube. The tubes were then placed in racks and immediately frozen in 
a -40°C freezer. If not used immediately, liquid coagulants must be frozen to prevent 
deterioration and resulting changes in anti-coagulant activity.
Tri-sodium citrate trasvlol
Two hundred and fifty Z^ o tubes were filled with 1.0 mL solution of 3.8% tri-citrate and
100,000 units of trasylol per 100 mL of tri-sodium citrate solution. To formulate this solution,
3.8 g tri-sodium citrate was measured into a 100 mL conical flask. Distilled water was added 
to dissolve the crystals and water added to the 100 mL mark. One ampoule of trasylol, 
equivalent to 100,000 units was then added using a 5 mL syringe and 21 g needle, and mixed 
into the solution.
A further 250 mL of the solution was prepared. 9.5 mL of tri-sodium citrate were measured 
into a 250mL conical flask again using a Sauter balance, and 12.5 mL trasylol were added. 
One mL of the 250 mL tri-sodium citrate trasylol solution was added to the Zjg 10 mL tubes 
using an Oxford pipette and the tubes were placed in the -40°C freezer.
2.8.2 Blood processing
The procedure for handling and carrying out the initial processing of blood specimens is 
detailed in Appendix V. For estimation of levels of plasma fibrinogen, von Willebrand Factor 
and fibrin D-dimer, 9 mL of blood from the 30 mL syringe were added to a Z^ g 10 mL tube 
containing 1 mL tri-sodium citrate trasylol anti-coagulant. The tube was inverted five times
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to ensure adequate mixing of blood and anti-coagulant and placed on a roller for 1 0  minutes. 
The sample was then centrifuged at 2800 RPM for 10 minutes at 4°C. Five 0.5mL aliquots of 
plasma were removed from the supernatant plasma and pipetted into red microtubes using a 
plastic disposable syringe. The tubes were then labelled with the patients' study number and 
immediately placed onto dry ice and stored in the -40®C freezer.
For plasminogen activator inhibitor, 4.5 mL of blood were added to a Z5 plastic tube, which 
contained 0.5 mL of the anti-coagulant tri-sodium citrate (9:1 V:V, O.llM ). This tube was 
also inverted five times and centrifuged at 2800 RPM for 10 minutes at 4°C. Two 0.5 mL 
aliquots of plasma were removed from the supernatant plasma and pipetted into two green 
micro tubes. These were placed onto dry ice and then placed into the -40°C freezer.
Serum for assay of total cholesterol, HDL cholesterol, serum thiocyanate and serum cotinine 
was prepared by adding lOmL of blood to a Zjg glass tube without anti-coagulant, and this was 
left to stand for approximately one hour until clotting had taken place. The sample was then 
centrifuged at 4®C and 2800 RPM. After centrifugation, 3 mLs of serum were removed, 
pipetted into a clear plastic Z5  tube and placed in the freezer for subsequent determination of 
lipid levels. In addition, two 0.5 mL aliquots of serum were placed in blue 0.5 mL micro tubes 
for estimation of serum thiocyanate and serum cotinine levels.
2.83 Laboratory assays
The assays of the haemostatic factors were carried out in the Haemostasis, Thrombosis and 
Vascular Medicine Unit, Glasgow Royal Infirmary, University of Glasgow, under the direction
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of Professor GDO Lowe.
Fibrinogen
Fibrinogen levels were measured in this study by two different types of assay. The Clauss 
clotting method (Clauss 1957) was perfoimed on a Coag-U-Mate analyser using appropriate 
reagents and standards (Organon Technika). It was based on a modified Clauss method in 
which the clotting time of fibrinogen was not measured directly, but increase in turbidity was 
measured after addition of thrombin. The coefficient of variation was 6 %.
In the nephelometric heat precipitation assay (Stone and Thorp 1985), fibrinogen was 
aggregated by heating plasma diluted in saline buffered at pH 6.3 at a temperature of 56°C. 
The concentration of the suspension was estimated by nephelometry which measures the light 
scattering intensity of fibrin in diluted plasma. The coefficient of variation was 6%.
Fibrin D-dimer
Fibrin D-dimer was assayed using a commercial enzyme-linked immunosorbent assay 
(ELISA) supplied by AGEN (Parsippany, New Jersey) based on a monoclonal antibody. The 
immunological reactions were carried out in microlitre plates. Two antibodies, one tagged 
with an enzyme (horse radish peroxidase) specific to the target antigen were added to the plate. 
The untagged antibody bound any antigen present in the plasma sample, and the second tagged 
antibody was then added to the plate which complexes with the bound antigen and residual 
untagged antigen. A substrate, hydrogen peroxide, and a colour detector, phenyiene diamine,
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was then added. The colour generated was proportional to the concentration of fibrin D-dimer 
present. The coefficient of variation was 5%.
Plasminogen activator inhibitor
Plasminogen activator inhibitor activity levels were measured by an amidolytic assay (Kabi, 
Stockholm). A fixed amount of tissue plasminogen activator was added in excess to undiluted 
plasma where it formed an inactive complex with PAI. Plasminogen was activated to plasmin 
by the residual t-PA in the presence of a stimulator (3.3 mg human fibrinogen fragments). The 
amount of plasmin was directly proportional to the residual t-PA activity and therefore 
conversely proportional to the PAI activity within the plasma sample. The amount of plasmin 
was determined by measuring the amidolytic activity with the chromogenic substrate S-2251. 
The release of p-nitro-aniline was determined at 405 nm in a photometer.
von Willebrand Factor
von Willebrand Factor antigen levels were also assayed using an ELISA assay based on a 
monoclonal antibody (DAKO, Copenhagen, Denmark). The coefficient of variation was 5%.
Serum lipids
Semm total cholesterol and HDL cholesterol were assayed in the University of Pathological 
Biochemistry Laboratory, Department of Medicine, Glasgow Royal Infirmary under the 
direction of Professor CJ Packard,
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Total cholesterol was measured on the BM Hitachi 704 analyser by the CHOD-PAP method 
using reagents supplied by Boehringer-Mannheim. HDL cholesterol was also measured on 
the BM analyser after precipitation with heparin manganese.
Serum thiocvanate and semm cotinine
To validate self-reporting levels of smoking consumption, two biochemical markers of tobacco 
inhalation were assayed, serum cotinine and serum thiocyanate. These were carried out in the 
Cardiovascular Epidemiology Unit, University of Dundee under the direction of Dr R 
Tavendale. Serum thiocyanate was estimated on a COB AS BIO centrifugal analyser, by 
precipitation with trichloracetic acid. The supernatant was reacted with ferric chloride and 
absorbance measured at 450 nm. Serum cotinine was measured by gas-liquid chromatography 
based on the method of Feyerabend and Russell (1980), except that lidocaine was used as the 
internal standard.
2.8.4 Quality control
To assess laboratory reproducibility, a small number of patients at recruitment were asked to 
donate twice the usual quantity of blood. The venepuncture technique was similar to the 
routine method, except that after withdrawal of the first 25 mL of blood, the 30 mL syringe 
was replaced by a second 30 mL syringe in the 21 g butterfly infusion set and a second 25 mL 
of blood withdrawn. Each sample was placed into a duplicate set of tubes and identified by 
different patient study numbers. The tubes were centrifuged at 2800 rpm at a temperature of 
4°C for 10 minutes. The separated plasma was pipetted into two sets of 0.5 mL micro-tubes
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using a different plastic disposable pipette for each tube. The tubes were then placed into a 
-40°C freezer and sent to the University of Glasgow, Haemostasis, Thrombosis and Vascular 
Medicine Unit for analysis. The laboratory was unaware as to the source of these split plasma 
samples. A total of 11 patients donated a double quantity of blood.
2.9 Angiography
2.9.1 Angiographic technique and procedure
The preferred method used for investigating peripheral atherosclerosis at the Royal Infirmary 
of Edinburgh Radiology Department is percutaneous transfemoral catheterisation. This 
technique permits serial examination of the aorta for inflow disease, and multiple views of the 
pelvic, thigh and distal calf vessels.
Patient preparation
Patients referred for angiography were examined by the resident house officer on the vascular 
wards to evaluate their clinical need for angiography, and to ascertain their physical status by 
a number of tests including palpation of peripheral pulses and measurement of blood pressure. 
They were also required to sign a consent form after being infoimed of the procedure and risks 
of the technique. If the subject was receiving anti-coagulant medication, such as warfarin, this 
was discontinued to prevent excess bleeding and haematoma fomiation. In addition, the 
patient was required to fast for 4-6 hours prior to angiography, since ingestion of contrast 
media can induce nausea and vomiting.
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Procedure
The arterial puncture site for catheterisation was determined by presence or absence of femoral 
pulses. The femoral artery approach was used if a femoral pulse was palpable in either leg. 
However, if not, entry into the brachial artery was used. The groin was then shaved and 
cleaned with an antiseptic solution of betadine and then draped with sterile towels. Following 
injection of 10 mLs 1% solution of local anaesthetic, lidocaine, the femoral artery was 
punctured using a 18 g needle below the inguinal ligament. A cannula was inserted after 
incision by a scalpel blade after first checking that the artery had been penetrated. A guide 
wire with a flexible tip was then manoeuvred through the femoral and iliac arteries and into 
the abdominal aorta.
A catheter was introduced through a teflon sheath, once the guide wire was in place in the 
abdominal aorta. Either a size 4 or 5 French Lodis pigtail catheter was used (preferably the 
smaller outer diameter of catheter whenever possible). The function of the catheter was to 
divert radio-opaque contrast medium through its side-holes into the aortic side branches at the 
T12-L1 interspace opposite the renal branches. Once the catheter was in place, the guide-wire 
was withdrawn through the sheath at the puncture site.
Injection of 90 mL contrast media, niapam 300 delivered at a rate of 10 mL per second 
triggered the filming mechanism which involved an automatic serial film change and a 
programmable moving table-top with synchronised kilovoltage regulation. Exposure of the 
peripheral arteries was carried out by a stepping mechanism in which the exposure was
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decreased by half, as the arteries were filmed sequentially down the lower limb. At 80 KV, 
the pelvic vessels were filmed at 40 mAs, the femoral arteries at 20mAs, the calf arteries at 
10mAs and the ankle arteries at 5mAs. The film exposure rate at the pelvis was one per 
second for 4 seconds, one per second for 3 seconds at the thigh, one per second at the knee and 
one per second for 4 seconds below the knee. Factors such as filming rates, contrast quality 
and clearance rate, pattern of disease and patient size were also assessed for optimal 
visualisation of the peripheral arteries.
The procedure was concluded by withdrawal of the catheter and by applying pressure at the 
puncture site for approximately ten minutes to minimalise bleeding and the formation of 
haematoma. A pressure dressing was applied to the site and the patient was kept at bed rest 
in the recumbent position for 24 hours. The procedure lasted approximately one hour.
2.9.2 Collection of angiograms
All angiograms were stored initially in the X-Ray film store situated in the Radiology 
Department of the Royal Infiimary of Edinburgh. The X-rays were filed by the day and month 
of date of birth initially, and then each section was arranged sequentially in ascending year of 
birth. However, if patients were retained on the vascular wards for further treatment after 
angiography, their angiograms were filed there for consultation. In addition, the angiograms 
of patients attending the Surgical Consultation Department for follow-up examination were 
removed from the film store a week before their appointment.
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2.93 Arterial segment definition
The arterial segments evaluated by the scoring system are shown in Figure 5. A total of 13 
segments were coded in each patient. These were the abdominal aorta (standardised to the 
distal 5cm before bifurcation), and both the left and right sides of each of the following; 
common iliac arteiy (beginning at the aortic bifurcation and ending at the origin of the internal 
iliac artery); external iliac artery; internal iliac artery (origin to the first branching); profunda 
femoris (the first 15 cm of its main descending branch); superficial femoral and the popliteal 
artery.
2.9.4 Grading of angiograms
At the end of patient recruitment, a final list of all patients in the study was drawn up and 
identified by patient number, name and date of birth. Their angiograms were collected in 
groups of six from the radiology film store, or vascular wards. These were taken to the 
University Medical School and coded by the author on a portable viewing box using the 
Bollinger scoring system. The data were recorded on a standard form which is shown in 
Appendix VI. The time taken to code each angiogram varied between 30 minutes and one 
hour, depending on the quality, complexity and number of previous angiograms. If a patient 
had had prior angioplasty, the treated arterial segments were identified. Coding of these 
segments was taken from X-rays prior to angioplasty since this was considered more 
representative of the tme disease status of the artery. At the end of each day, the angiograms 
were returned to the radiology film store. The names of the patients who had their angiograms 
coded were listed on the computer and any difficulties noted.
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2.9.5 The Bollinger scoring system
The site and severity of atherosclerotic disease was assessed by uniplanar angiographic images 
obtained from each patient, using a scoring system developed by Bollinger et al (1981). 
Biplanar views, although requested, could not be provided by the Radiology Department of 
the Royal Infirmary of Edinburgh.
This system was developed primarily for evaluation of disease progression and regression 
occurring in the peripheral arteries. However, it is also suitable for the assessment of the 
severity and location of disease because it codes both narrowing of the lumen and the pattern 
of disease numerically at one point of time without requiring a comparison of successive 
angiograms.
The system consists of an additive score for each defined arterial segment. This score is the 
summation of code numbers each corresponding to the degree of percentage reduction of the 
lumen for lesions within the segment. Four categories of lesions were defined: i) complete 
occlusion of the segment; ii) stenoses narrowing more than half of the diameter of the lumen 
(stenoses > 50%); iii) stenoses narrowing the lumen by more than 25% but less than or equal 
to 50% (stenoses < 50%) and iv) plaques narrowing the diameter by a maximum of 25% 
(plaque < 25%).
The system was designed to differentiate between perceived clinical severity of stenoses 
because the overall additive score for plaques and stenoses in a segment is never as high as a 
single occlusion score. Several rules are implemented during scoring. Firstly, when
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occlusions are present, plaques and stenoses are not scored. The additive score of an arterial 
segment with an occlusion along half or less the length of the segment will be 13, even with 
stenoses in the remainder of the segment. Secondly, if there are stenoses of > 50% or < 50% 
present in the same segment, plaques are not coded. Thirdly, only one occlusion is coded in 
each segment.
2.10 Data analysis
Univariate analysis was carried out by the author using the SPSS-X statistical package on the 
mainframe computer at the University of Edinburgh. Chi-square analysis was used to test for 
differences in categorical variables within each class of disease. Analysis of covariance was 
carried out with age and sex as covariables to test for differences in mean levels of 
cardiovascular and haemostatic risk factors across the three sites of disease. Partial correlation 
coefficients adjusted for age and sex reflected the linear association between each haemostatic 
factor and the additive score within the femoro-popliteal and aorto-iliac segments for all 
patients in the study. Multiple linear regression was used to examine the independence of each 
haemostatic factor on additive score at each site. All factors were entered simultaneously with 
the additional variables age, sex and time of venepuncture having forced entry. The magnitude 
of the unstandardised regression coefficients indicated the average increase or decrease in 
additive score for every relevant unit change in the haemostatic factors. The model for the 
femoro-popliteal additive score was repeated with the forced entry of packyears and then 
semm thiocyanate (to assess the effect of adjusting for life-time and current cigarette smoking, 
respectively). The residuals of the multiple regression model were approximately normally 
distributed.
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FIGURE 5 ARTERIAL SEGMENT DEFINITION
i n t o
Definition of ai*terial segments evaluated by the Bollinger scoring 
system. 1) Abdominal aorta; 2) common iliac; 3) external iliac; 
4) internal iliac; 5) profunda femoris; 6) superficial femoral; 
7) popliteal. L=Left, R=Right.
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CHAPTER THREE
PROGNOSTIC STUDY OF INTERMITTENT CLAUDICATION: METHODS
The Prognostic Study of Intermittent Claudication was established in 1989 and consisted of 
two phases. Subjects were initially followed-up over a one year period and an interim analysis 
was conducted (Fowkes et al 1993). An overall analysis was then conducted after the total 
follow-up period of six years from baseline was completed, and the results are described in the 
present thesis. A research nursing sister conducted the baseline and one year clinical 
examination, and collected information on incident vascular events on the subjects during the 
initial one year period. The author was responsible for identifying and confirming any 
vascular events occurring within the study population during the six year follow-up period, 
including events which occurred during the first year of follow-up.
3.1 Study Design
The Prognostic Study of Intermittent Claudication is an example of a prospective cohort study, 
which is sometimes referred to as a follow-up, longitudinal or prospective study. In this type 
of study, a sample from a defined population is identified and the subjects are then followed 
over a specified period of time to determine the incidence of a particular outcome of interest. 
Prognostic factors which are considered to influence the development of the specified outcome 
are determined and measured at baseline. Differences in the baseline characteristics of those 
who develop the outcome and those who do not, can then be analysed to establish whether the 
factors are related to the outcome under investigation.
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3.2 Sample Size
The sample size had to be sufficiently large so that clinically significant differences in
fibrinogen levels and other variables at baseline could be detected between those who would
or would not have a vascular event at one year (and six years) of follow-up. Using information 
based on the variability of fibrinogen in a previous case-control study of intermittent 
claudication, it was calculated that 600 subjects would be required to have 90% power at 5% 
level of significance to detect a 9% difference in mean levels of plasma fibrinogen (0.32g/L) 
between those who would and would not have a vascular event. The formula is as follows:
Number of patients in each group 
2
n= -  X f  ( a ,  p)
(F2 - hi)^
where (p2  - Pi)^ is the difference in mean fibrinogen which is important to detect, 
a  is the standard deviation of fibrinogen 
a is the type I error, normally 0.05 
p is the type II error, or power, 0.1 in this case.
3 3  Study Population
The study population comprised men and women with symptoms of intermittent claudication 
in the calf, thighs or buttocks. The study sample was a consecutive series of patients who had 
been diagnosed as suffering from intermittent claudication by a vascular consultant at the 
Peripheral Vascular Clinic, Royal Infirmary of Edinburgh. As this hospital provides the only
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vascular service for the Lothian Health Board area in Scotland, these patients were probably 
representative of those with moderate to severe claudication, referred from this defined 
population. Subjects with minor symptoms often do not seek medical help, or if they do, are 
less likely to be referred by their general practitioner and were therefore not represented in the 
study sample.
3.4 Exclusion Criteria
Patients were excluded from entry into the study if they had symptoms of severe chronic leg 
ischaemia, defined as rest pain, ulcer or gangrene. Ulcer and gangrene are necrotic conditions 
associated with high levels of acute phase reactants, such as fibrinogen. Since these conditions 
may therefore affect the levels of haemostatic factors, they were considered to be potentially 
confounding factors, and therefore only patients with symptoms of uncomplicated peripheral 
arterial disease (intermittent claudication) were selected. Previous or impending arterial 
surgery (including angioplasty) and amputation also precluded patients from selection, because 
these procedures may alter the natural history of peripheral arterial disease and hence affect 
the progression of vascular disease. Those with a serious disability that would make attending 
follow-up difficult were also considered unsuitable to participate.
3.5 Patient Selection
The study sample was selected from patients attending the Peripheral Vascular Clinic between 
January 1989 and December 1990. These included newly diagnosed claudicants referred by 
letter by their general practitioner, and also patients who had been diagnosed with claudication
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at the clinic during the previous two years. The patients were examined at their first visit by 
a consultant vascular surgeon or physician to establish whether intermittent claudication was 
present based on their medical history, peripheral pulse palpation and WHO diagnostic criteria. 
If confirmed, the probable site of disease was then allocated a diagnostic code, according to 
criteria used in the Lothian Surgical Audit.
This code was recorded on a form by the attending consultant and identified the patient by 
name, address, date of birth and general practitioner. These forms were subsequently sent to 
the Vascular Surgery Office within the hospital and the data was entered onto a vascular 
register using a micro-computer. A second form was completed by the consultant which 
recorded the date of the first visit to the clinic and also indicated whether the patient was 
suitable for inclusion in the study. These latter foims were then foiwarded to the research 
nursing sister at the University of Edinburgh Medical School.
The Vascular Surgery Office provided a monthly computer print-out from the vascular register 
of new patients attending the Peripheral Vascular Clinic with the specified diagnostic codes 
indicating either claudication in the aorto-iliac or femoro-popliteal arteries. This was used by 
the research sister, in conjunction with hospital records and the out-patient diagnosis forms to 
ensure that all possible patients were identified. A total of 742 patients diagnosed with 
intermittent claudication were identified as initially suitable to participate in the study. As 
each patient was selected, their name, address, date of birth, name and address of their general 
practitioner and date of first appointment at the Peripheral Vascular Clinic and date of 
appointment for the baseline examination was entered onto a Dbase IV database.
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3.6 Sample Recruitment
Following selection of patients from the Peripheral Vascular Clinic, patients were recruited 
retrospectively between January 1989 and December 1990. Each patient was identified by a 
computerised subject number. Patients were then sent a letter of invitation (Appendix VII ), 
signed jointly by the consultant vascular physician (Dr E Housley) and the research sister, 
asking them if they would be willing to return to the Peripheral Vascular Clinic to take part 
in the study. The letter explained the purpose of the research and the nature of the clinical 
examination. In order to maximise response, the appointment date, day, time and place of 
examination were printed on the letter for each patient. Travel expenses were offered.
The patient was required to indicate on the enclosed reply slip whether they would attend the 
clinic at the appointment time suggested, if the appointment was not suitable or if they would 
require an alternative appointment. If necessary, the patient was transported to the clinic by 
ambulance. Non-responders to the first appointment letter were sent a second letter inviting 
them to attend the clinic at a later date. Those who had refused to participate or did not reply 
to this second invitation were not contacted again. Patients who had accepted the invitation 
but did not subsequently attend the clinic were contacted by telephone and offered another 
appointment.
3.7 Baseline Clinical Examination
Examinations conducted by the research sister were held on Wednesdays and Fridays, between 
9am and 2pm. Two physiological measurement technicians assisted in these clinical
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examinations. A maximum of ten patients was invited to each clinic; two appointments spaced 
at one hourly intervals and commencing at 9 am in the morning. Occasional home visits were 
organised if requested.
On arrival at the clinic, the subjects were informed of the procedures, and given a consent form 
to sign (see Appendix I) which explained the purpose of the research and the examination they 
would undergo. It also emphasised the anonymity and confidentiality of the results. The form 
indicated that the study had been given ethical approval by a Medical Ethics Sub-Committee 
of Lothian Health Board.
In an examination room within the clinic, the patient underwent measurement of the brachial 
and diastolic (phase V) blood pressures in the right arm, after 10 minutes rest in the supine 
position, using a Hawksley random zero sphygmomanometer and stethoscope. The femoral, 
posterior tibial and dorsalis pedis pulses were palpated, but the results were subsequently 
considered to be too variable to be of any practical use. Ankle systolic pressures were 
recorded on each leg at the posterior tibial artery whenever possible, using a Sonicaid doppler 
probe and the same sphygmomanometer. The results of the measurements were recorded on 
a form which also enabled the observer to insert the value of the ABPI on each leg (see 
Appendix III).
A 12.5 mL specimen of venous blood was then obtained from the ante-cubital vein, using a 
20 mL syringe and 23 g needle following a further ten minutes rest for estimation of the 
haemostatic factors. Details of the venepuncture were recorded on a form (see Appendix II), 
which identified the patient by name and study number. The name of the technician was
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recorded, since it was not always possible for the research sister to take blood on every 
occasion. The form was designed to record the success of venepuncture and the quantity of 
blood removed from the patient and time of venepuncture. A 12-lead electrocardiogram was 
also obtained from the patient, if a recent copy was not available from the patients' case notes. 
A blood sample for measurement of glucose and total cholesterol levels had previously been 
obtained by the vascular consultant at the Peripheral Vascular Clinic on the patients' first 
attendance.
Following the ECG recording, patients were requested to complete a questionnaire, with the 
assistance of the research sister. This is shown in Appendix VIII. The questionnaire was 
divided into six sections. Firstly, the sex and date of birth were recorded. The patients were 
then asked whether they were receiving any regular medication prescribed by their doctor and 
details of past medical history were sought, including questions on heart disease, stroke, 
diabetes and thrombosis and embolism. To assess the presence and current severity of 
peripheral arterial disease, and the presence or absence of angina, the WFIO questionnaires on 
inteimittent claudication and angina were included. Lastly, the smoking section was designed 
to elicit detailed information on current smoking status and to distinguish clearly between 
current, past and never cigarette smokers. The amount of tobacco consumption and duration 
of smoking in current and in ex-smokers was quantified. The length of time since cessation 
of smoking in ex-smokers was also noted.
3.8 Exclusions
Several patients who had been diagnosed with intermittent claudication in the preceding two
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years were found to have symptoms of severe chronic leg ischaemia (rest pain, ulceration or 
gangrene), or had other exclusion criteria discovered at the baseline examination. In addition, 
several patients refused to take part or did not arrive for their appointment. Subsequently, one 
hundred and twenty five patients were excluded from the baseline cohort of 742 patients. A 
total of 617 patients from the baseline cohort of 742 was thus followed-up prospectively.
3.9 Blood Processing
For estimation of plasma fibrinogen, von Willebrand Factor, tissue plasminogen activator and 
fibrin D-dimer, 5mL from the 20 mL syringe were added to a Z5  white plastic tube containing 
3.8% tri-sodium citrate trasylol anti-coagulant and inverted five times. The tube was placed 
on a roller for two minutes. The sample was then centrifuged at 2800 rpm for 10 minutes, at 
4®C in a Denley BR 401 refrigerated centrifuge. Five 0.5mL aliquots were pipetted into five 
microtubes labelled by the identifying study number, and placed on dry ice and stored in a -40° 
C freezer. The tubes were sent to Professor GDO Lowe at the University of Glasgow every 
four weeks by Red Star delivery for laboratory assay.
3.9.1 Laboratory assays
The assays for the haemostatic factors were carried out in the Haemostasis, Thrombosis and 
Vascular Medicine Unit, Glasgow Royal infiimary, under the direction of Professor GDO 
Lowe. The assays for clotting fibrinogen, von Willebrand Factor and fibrin D-dimer have 
previously been described in Chapter Two.
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Tissue plasminogen activator
Plasma levels of tissue plasminogen activator (t-PA) antigen were measured by a commercial 
enzyme linked immunosorbent assay (ELISA) obtained from Biopool AB, Umea, Sweden. 
Both human single chain and two chain t-PA antigen were quantified. Each plasma samples 
were added to two wells of a microtitre plate, one containing the normal goat antibody IgG and 
the other containing goat anti-human t-PA antigen IgG. After initial binding to the pre-coated 
well, the second antibody, conjugated to the enzyme horseradish peroxidase, was applied, 
which bound to the target t-PA antigen. After a period of incubation, a specific peroxidase 
substrate, orthophenylenediamine dihydrochloride was added. The colour generated was 
proportional to the concentration of t-PA present.
Total cholesterol and glucose
Total cholesterol and glucose were assayed in the Department of Clinical Biochemistry, Royal 
Infirmary of Edinburgh, under the direction of Dr J Roulston. Total cholesterol was measured 
on the BM/Hitachi 737 analyser by the CHOD-PAP method. This is an enzymatic 
colorimetric test in which free cholesterol was produced by the action of the enzyme, 
cholesterol esterase on cholesterol ester from the se ram sample. Oxidation of cholesterol 
produced a substance which reacts with a chromogenic receptor. The optical density of the 
resulting solution was proportional to the total cholesterol concentration of the sample 
measured at a wavelength of 505 nm.
Glucose was measured by the GOD-PAP assay, supplied by Randox Laboratories. Glucose
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concentrations were determined after enzymatic oxidation in the presence of glucose oxidase. 
Formed hydrogen peroxide reacts with phenol and 4-aminophenazone to foim a red-violet 
quinoneimine dye as indicator. The absorbance of the sample was measured at a wavelength 
of SOOnm,
3.10 One Year Follow-Up Examination
After one year, all surviving patients were invited by letter to attend a second clinical 
examination at the Peripheral Vascular Clinic. The procedure was similar to the baseline 
examination, except that a blood specimen was not taken. A second questionnaire was 
administered which enquired about any new illnesses or conditions occurring during the year 
since the baseline examination, and also current medication status. Any new treatment for 
claudication, including vascular surgery was documented. Changes in the severity of their leg 
pain or chest pain or new occurrence of chest pain were ascertained. Finally, the patient was 
asked about any changes in smoking habit since their last visit to the study.
3.11 Follow-up of Vascular Events
Subjects were followed over a total period of six years to determine the incidence of the 
following fatal and non-fatal vascular events: angina pectoris, myocardial infarction, stroke, 
and coronary vascular procedures, including angiography, angioplasty and coronary by-pass 
grafting. Progression of peripheral arterial disease was determined by the development of 
severe chronic leg ischaemic events (rest pain, ulceration, gangrene and amputation) and the 
perfoimance of peripheral arterial procedures, such as angiography, angioplasty, lumbar
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sympathectomy and by-pass grafting. Data were collected from five main sources:
i Scottish National Health Service Central Registry




Multiple sources of information were used to ensure that as many events as possible were 
identified and subsequently verified.
3.11.1 Identification of fatal events: Scottish National Health Service Central Registry
To identify all fatal events occurring in the study sample, each patient's record was flagged at 
the Scottish National Health Seivice Central Registry at baseline. This ensured that all death 
certicates were provided automatically. The name, address, date of birth, sex and study 
number of each patient was typed onto an index card and foiwarded to the Central Registry, 
When notification of death was received by the Central Registry, the death certificate was sent 
to the author (after a period of approximately two months) at the University of Edinburgh 
Medical School. The primary and secondary causes of death were recorded on the database 
in a file restricted to deceased patients. All causes of death had been allocated a diagnostic 
code according to International Classification of Disease, version 9 (ICD-9). In addition, the 
cause of death was allocated a code indicating whether the patient had died of myocardial 
infarction (code 1), stroke (code 2), other cardiovascular disease (code 3), or non- 
cardiovascular causes (code 4).
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3.11.2 Fatal events: autopsy reports
When the cause of death is unknown, or there are suspicious circumstances, or the patient has 
been an in-patient at a hospital for less than 24 hours prior to death, an autopsy (post-mortem) 
may be requested by the Procurator Fiscal. Also, post-mortems may be carried out at the 
request of the clinician in charge if the relatives give their consent. Post-mortem reports were 
used to verify the underlying cause of death in six patients participating in this study, because 
confirmation of cause of death could not be confirmed from hospital case notes, or through 
notification from Central Registry.
3.113 Fatal and non-fatal events: Information and Statistics Division of the Common 
Services Agency
The Information and Statistics Division of the Common Services Agency (ISD) of the Scottish 
Office in Edinburgh holds patient data derived from summaries created when patients are 
discharged from general, maternity, geriatric and psychiatric hospitals. An application was 
submitted in November 1995 to ISD to obtain access to Scottish Morbidity Records (SMR) 
on all patients in the study, dating from the time of recruitment. The procedure entailed record 
linkage to computerised ISD data with our own patient data. The merged file was then 
released in the form of a computer print-out, with the cases listed in a specified order.
To complete the application, a summary of the study aim, background and study methods was 
requested in addition to identifying the range of data to be supplied for each individual case 
requiring linkage. The study number, surname, initials, sex, date of birth and postcode was
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provided for each patient within the study.
Criteria for selection of cases from the SMR were defined as:
1. New outpatients and inpatients attending hospitals between 1989 and 1996.
2. The age range of the study participants (bom between 1st January 1902 and 
31st December 1941).
3. Area and post-code of residence.
4. Diagnosis (both fatal and non-fatal) according to specified vascular I CD 
codes.
5. Any hospital attended for treatment of a vascular event and the dates of 
admission and discharge.
Following acceptance of the application by the Privacy Advisory Committee of the ISD, data 
identifying patients were transferred to an ASCII file onto a diskette from our database and 
sent to ISD. The Information and Statistics Division subsequently provided a computer 
printout in January 1996, identifying all study subjects (listed alphabetically) who had attended 
a hospital for a vascular event according to the specified ICD codes, in addition to the relevant 
hospital and dates of admission and discharge.
3.11.4 Fatal and non-fatal events: general practitioners
To ensure that as many events as possible were identified, each siuviving patient's general 
practitioner was also contacted by letter. The Primary Care Division of the Lothian Health 
Board was first contacted and asked to supply a list of all general practioners and practice
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addresses in the Lothian Health Board area in Scotland. This allowed the names and existing 
addresses of general practitioners on the database files to be updated from their initial entry 
in 1989. A letter was sent to each listed doctor from the database file explaining the purpose 
of the study which was signed by a clinical research fellow and the author, as study co­
ordinator. A separate form for each named patient with their date of birth was enclosed, 
requesting whether the patient was still attending the practice and also requesting information 
concerning any new cardiovascular events, hospital admissions (including date of attendance), 
and changes in medication occurring within the last six years (Appendix IX and X). A pre­
stamped envelope was also included for the reply. Non-responders were not contacted again. 
One medical practice had previously intimated that they did not want to be contacted on 
matters concerning research, and were therefore not contacted.
3.11.5 Non-fatal events: self-administered questionnaires
In Febmaiy 1996, each surviving patient was sent a questionnaire to complete, with a covering 
letter reminding them of their participation in the study between 1989 and 1990 and asking 
them for information about their health since that time (Appendix XI). The first section 
inquired about any new vascular-related illnesses or medical conditions which they may have 
had within the last six years. Details of hospital attendances and current medication were 
sought. The Edinburgh Claudication questionnaire was included, and a self-assessment made 
by the subjects to ascertain whether their symptoms of peripheral arterial disease had changed. 
They were also asked whether they had had any new treatment for their leg pain, and for 
information on any hospital attendances relating to this treatment. A modified WHO 
questionnaire on angina was used to determine whether they had developed angina within the
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six year follow-up period and self-assessment was made of chest pain since recruitment. The 
last section was designed to determine changes in smoking history since baseline.
3.12 Retrieval of Hospital Records
Patients who had a vascular event identified during follow-up, from either the ISD computer 
print-out, the general practitioner event form, or the self-administered questionnaire were 
listed, so that their medical records could be investigated. It became apparent, however, from 
preliminary examination of records, that there were omissions in the reported number, or errors 
in diagnoses of events in the three sources used for event identification. It was therefore 
decided that hospital records of all study patients who had at least one event reported from any 
of the three sources should be examined. Hospital records were not examined if patients had 
no events reported in the ISD data, GP forms and patient questionnaires. In these instances, 
patients were contacted by telephone (where possible) to confirm that they had had no events 
during the six years since recruitment.
The records were first sought at the Royal Infirmary of Edinburgh, because the patients had 
initially attended the Peripheral Vascular Clinic within the hospital for diagnosis of 
intermittent claudication. In the Royal Infiimary records department, hospital records were 
grouped by patients with the same day of date of birth, and within these groupings, 
alphabetically by surname. The records of deceased patients were stored separately and were 
allocated a special number. A patient management information system, termed RHOMER, 
was used to access the deceased number, by micro-computer. The records of patients who had 
not attended the Royal Infirmary for at least three years had been sent to the Princess Margaret
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Rose (PMR) hospital in Edinburgh for storage.
To retrieve these records, a separate tracer card was completed for each patient and the 
relevant records were collected and delivered to the Royal Infirmaiy on Fridays for checking. 
However, case notes of patients who had not attended hospital for ten years or more had been 
systematically destroyed. Study patients whose records had been destroyed or whose case 
notes could not be traced or had been destroyed at other hospitals were excluded from the 
study, since the reported events could not be confirmed.
If patients had attended an out-patient clinic, or were admitted for in-patient treatment within 
the Royal Infirmary (or at other relevant hospitals) during the previous month, or were due for 
treatment in the forthcoming week, their records were removed from the Records Department 
for consultation at the relevant department. Tracer cards were completed in the records 
department indicating the whereabouts of the records. In these cases, patient records were 
traced and examined within the particular ward, or ward office after the hospital attendance 
had taken place.
If patient records were incomplete or could not be located at the Royal Infirmary, other 
hospitals cited in the ISD print-out, general practitioner forms or patient questionnaire were 
contacted between May and June 1996. Pemiission to visit hospitals was requested by letter 
at eight other hospitals within the Lothian and Border regions. One particular hospital, St 
Johns in Livingston, required a further application to the Director of Vascular Surgery for 
permission to examine case notes. Over a period of six months, the following hospitals were 
visited and the case notes examined; Western General Hospital,Eastem General Hospital, City
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Hospital, Royal Victoria Hospital, Liberton Hospital, Royal Edinburgh Hospital, Borders 
General Hospital, St. Johns Hospital (Livingston).
Also, requests were made to several other hospitals for records to be sent by recorded delivery 
when only a small number of patient records was lodged and the hospital was outwith the 
District of Edinburgh. The hospital was reimbursed for recorded delivery costs.
3.13 Criteria for Diagnosis of Vascular Disease and Death
Criteria used to diagnose fatal and non-fatal myocardial infarction and fatal and non-fatal 
stroke were adapted from those proposed by the American Heart Association (Gillum et al 
1984) and for angina from the World Health Organisation (Rose 1962) and were as follows:
3.13.1 Myocardial infarction
Non-fatal, definite
Two of the following criteria:
a) Prolonged cardiac pain anywhere in the anterior chest, left arm, or jaw (possibly also 
affecting the back, shoulder, right arm, or abdomen) and lasting at least 2 0  minutes.
b) Diagnostic electrocardiographic codes, including Minnesota codes: 1.1.1-1.2.5,1.2.7, 
or 9.2 plus 5.1 or 5.2;
(c) Raised enzyme concentrations (creatine phosphokinase greater than twice the upper
limits of normal, and one of the following also greater than twice the upper limits of
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normal: lactate dehydrogenase, aspartate aminotransferase, or the MB isoenzyme of 
creatine phosphokinase).
The enzymes must have been measured within 72 hours of the acute event.
Non-fatal. possible
(a) One of the above definite criteria plus either equivocal electrocardiographic codes 
(1.2.8-1.3.6 ,4.1-4.3,5.1-5.3, or 9.2) or equivocal enzyme levels (above normal but not 
twice normal, or one above twice normal but could be attributed to another cause; or
(b) Equivocal electrocardiographic codes and enzyme concentrations.
Fatal, definite
(a) Postmortem evidence of acute myocardial infarction; or
(b) Definite criteria for myocardial infarction within the four weeks before death; or
(c) ICD-9 codes for cause of death 410-414 plus history of a definite or possible
myocardial infarction or 410-414 plus definite or possible criteria for myocardial 
infarction immediately preceding death or 410-414 plus post-mortem evidence of 
severe coronary atherosclerosis or previous myocardial infarction.
Fatal, possible




(a) History of onset of symptoms of less than 48 hours, plus clinical confirmation of a
focal or global disturbance of cerebral function lasting more than 24 hours; or
(b) Computed tomography showing evidence of cerebral infarction or haemorrhage.
Non-fatal. possible
(a) Primary or secondary discharge diagnosis including ICD-9 codes, 431,432,434,436,
or 437.
Fatal, definite
One of the following criteria:
(a) Post-mortem evidence of cerebral infarction or haemorrhage;
(b) Criteria for definite stroke met within six weeks before death.
Fatal, possible
(a) Death certificate codes of underlying or immediate cause of death were ICD-9 431-
437, but no other evidence.
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3.13.3 Other vascular events
Other fatal vascular events (such as ruptured aortic aneurysm or thromboembolism) were 
recorded if the diagnosis was confirmed by laboratory, radiological, surgical or postmortem 
evidence.
Transient ischaemic attack
History of rapid onset of clinical signs of focal (or global) disturbance of cerebral function 
lasting less than 24 hours.
Angina pectoris
This was defined as pain or discomfort in the centre of the chest, or left anterior chest and left 
arm when walking up hill or hurrying requiring the person to stop or slow down for ten 
minutes or less, whereupon the pain is relieved.
Thrombosis and embolism
Clinical diagnosis confirmed by laboratory, radiological or surgical evidence.
Amputation
Amputation of any part of the lower limb due to only diabetes, or vascular causes.
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3.14 Recording of Vascular Events
All possible cardiovascular events occurring since the patient was recruited into the study were 
followed up by direct examination of the relevant hospital records. Events were included in 
the data analysis if they met the predeteimined diagnostic criteria.
Two separate forms were designed for the recording of the fatal or non-fatal events 
(Appendices XII and XIII). In both cases, a patient identification section was included, with 
the name and address of the patient's general practitioner. The information source for the 
reported event and the provisional diagnosis was required. The final diagnosis with the 
relevant ICD-9 code was recorded and was entered into the database. Vascular surgical 
procedures were coded using the Office of Population Censuses and Surveys' Classification 
of Surgical Operations 4th revision manual. For fatal events, the source of confirmation was 
noted.
Prior to examination of the hospital records, a separate form for each new non-fatal event 
reported in either the ISD printout, the general practitioner event form, or the self-administered 
questionnaire was prepared for every listed patient. The name, study number and provisional 
diagnosis was inserted. Diagnosis was then finalised from examination of the hospital records. 
If a patient's hospital record or a reported event could not be traced, it was coded as missing 
(code 99).
Nine non-fatal event files and one fatal event file were subsequently created when the data was 
entered onto computer. Each confirmed non-fatal event per patient was entered onto a separate
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data file. The record structure for each non-fatal event file consisted of the study number of 
the patient, date of birth, date of event, ICD code and final diagnostic code. A file restricted 
to deceased patients recorded study number, date of birth, date of death, primary and 
secondary ICD death codes and final diagnostic code. Another file listed patients who did not 
have a vascular event or deterioration of limb ischaemia during follow-up. Patients who were 
excluded from the study because of missing data were also identified.
3.15 Definition of Ischaemic Heart Disease and Stroke Categories
Four categories of ischaemic heart disease and stroke were defined which were used in the data 
analysis: combined fatal and non-fatal stroke, non-fatal myocardial infarction, coronary death 
(fatal myocardial infarction and deaths from ischaemic heart disease), and total coronary 
events which included fatal and non-fatal myocardial infarction and deaths from ischaemic 
heart disease. Cases of fatal and non-fatal stroke were combined because of the low numbers 
in each group. Multiple events of the same type in a subject were recorded only once.
3.16 Definition of Progression of Peripheral Arterial Disease Categories
In this part of the analysis, patients were divided into two groups: those whose symptoms had 
deteriorated sufficiently to require vascular intervention, but did not develop symptoms of 
severe chronic leg ischaemia (defined as rest pain, ulceration or gangrene) during follow-up, 
and secondly, those who developed definite symptoms of severe chronic leg ischaemia during 
the six years follow-up period.
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3.17 Data Analysis
Univariate analysis was carried out by the author on the University of Edinburgh mainframe 
computer using the SPSS-X statistical package. Means and percentages for baseline risk factor 
characteristics were calculated for the whole study population. Differences in medians of each 
haemostatic factor were tested across the four categories of ischaemic heart disease and stroke 
and categories of progression of peripheral arterial disease, relative to a group who had no 
coronary or cerebrovascular disease and no deterioration of limb ischaemia during follow-up.
Multiple logistic regression was carried out by Dr AJ Lee, the study statistician, using the 
statistical package SAS on the University mainframe computer. Associations between 
prognostic factors and incidence of vascular events and progression of peripheral arterial 
disease were expressed as an increase in risk of outcome for a given change in the prognostic 
factor. Relative risks were estimated which adjusted for age and sex and then further adjusted 
for other risk factors.
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CHAPTER FOUR
SITES OF ATHEROMA: RESULTS
This chapter presents the results of the Sites of Atheroma Study. The results are divided into 
four main sections describing (i) the study sample, (ii) the distribution of angiographic disease, 
(iii) the relationship b etween cardiovascular risk factors and site of peripheral arterial disease, 
and (iv) the relationship between haemostatic factors and site and severity of peripheral arterial 
disease. The tables and figures are presented at the end of each of these four main sections.
4.1 Description of Study Sample
One hundred and fifty men and fifty women were recruited to the study. Six patients were 
subsequently excluded from the study sample because their angiograms could not be located 
within the hospital. Two further patients were excluded because they showed no evidence of 
significant atherosclerotic disease in any of the 13 arterial segments under consideration. The 
overall number of subjects participating in the study was therefore 192, which was composed 
of 144 men and 48 women.
4.1.1 Mean age and sex distribution of study sample
Table 4.1 shows the age and sex distribution of the study sample. The proportion of males was 
exactly three times higher than that of females (75% to 25% respectively). The age range of 
the study sample was between 37 and 81 years. The mean overall age was 63.7 years. The
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mean age of females was approximately three years greater than that of males (66.2 v 62.9 
years).
4.1.2 Clinical measures of severity of peripheral arterial disease in study sample
Symptoms of peripheral arterial disease in the 192 subjects were assessed by responses to the 
Edinburgh Claudication Questionnaire, a modified foim of the WHO Intermittent Claudication 
Questionnaire, and are shown in Table 4.2. Overall, females reported significantly more 
severe symptoms of peripheral arterial disease than the males (p< 0.05), Although a similar 
proportion of males and females had intermittent claudication grade II, i.e. symptoms 
occurring while walking ’at an ordinary pace on the level', 34.8% of women had symptoms of 
more severe limb ischaemia (rest pain) compared to 28.2% of men. Comparison of the mean 
ABPI, as a more objective measure of peripheral arterial disease, showed only a slightly lower 
level in women (0.54) than in men (0.56, p> 0.5) which suggested that the severity of disease 
may be similar in women and men in the study sample.
4.2 Distribution of Angiographic Disease
The angiograms of the patients were examined to deteimine the distribution of lower limb 
disease. A total of 2496 arterial segments (13 segments per patient x 192 patients) from the 
study sample was evaluated. The number of segments which was coded as missing values was 
relatively small. Forty two segments (1.7 %) could not be graded because of poor visualisation 
on angiogram. The percentage of segments which were coded was therefore 98.3%.
108
Table 4.1





Number % Study Sample
Age
Mean Years (SE) 62.9 (9.7) 6 6 . 2  ( 1 0 .0 )
< 49 years 16 1 1 . 1 5 10.4
50 ~ 59 years 37 25.7 2 4.2
60 ~ 69 years 54 37.5 2 2 45.8
 ^ 70 years 37 25.7 19 39.4
Sex
% Male 144 75
% Female 48 25
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Table 4.3 shows the frequency of arterial occlusions in the study sample. Only 57 (29.7%) of 
the patients did not show occlusions within the 13 coded arterial segments. One hundred and 
thirty five (70.3%) patients had at least one occlusion. One patient had as many as nine 
segments occluded.
4.2.1 Site and severity of occlusions
A total of 335 arterial occlusions was recorded (Table 4.4). There was no real difference in 
the prevalence of occlusion in the right leg compared to the left leg. The right superficial 
femoral artery was the most common occlusion site, with 20.7% of the total number of 
occlusions recorded in the study sample within this segment. The left profunda femoris artery 
was least often occluded (apart from the abdominal aorta which was never completely 
occluded) with 2.7% of the total occlusions.
The severity of occlusions in the study sample is shown in Table 4.5. An occlusion less than 
or equal to half the length of a segment was coded by an additive score of 13. A score of 15 
was recorded if the occlusion was longer than half the length of the segment. Only one 
occlusion (the more severe) was coded in each segment. Out of the total of 335 occlusions 
recorded, 192 (57.3%) were longer than half the length of the arterial segment. When shorter 
occlusions occurred, there were more occlusions in the right leg (n-84) than the left (n=59). 
In contrast, the left leg was the preferred site (or where disease progressed more rapidly) of 
longer occlusions, with the exception of the profunda femoris and superficial femoral arteries. 
The distribution of disease within the arteries also varied, depending on the severity of 
occlusion. Although the superficial femoral artery was the most common site of occlusions
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of both lengths, longer occlusions were present more often in the common, external and 
internal iliac arteries.
4.2.2 Site and severity of stenoses
Table 4.6 shows sites of arterial stenoses graded by an additive score > 3, indicating that the 
patient had at least one lesion narrowing the lumen of an arteiy by > 25%. There were 853 
(34.2% of the total graded segments) moderate to severe stenoses recorded. The left internal 
iliac was the most commonly affected vessel with 10.6% of total stenoses > 3, whereas the 
abdominal aortic segment showed the least number of stenoses (2.0%). The sites of arterial 
stenoses graded by a score < 3 are also shown (Table 4.7). This score indicates that there is, 
at most, one stenosis narrowing the vessel lumen by between 25-50%. As expected, the 
prevalence of these less severe stenoses was higher than that of both more severe stenoses 
> 25%, and occlusions. The abdominal aortic segment (13.6%) and the right common iliac 
(10.7%) had the most number of mild stenoses. The superficial femoral segments had the 
fewest stenoses which reflected the high overall severity of disease within these vessels.
4 3  Classification of Patients bv Site
The patients were classified into three groups, aorto-iliac, femoro-popliteal or dual-site by 
assessing the additive scores of the abdominal aorta, combined left and right leg iliac 
segments and left and right leg femoro-popliteal segments separately. The worst additive 
score for each of the six iliac (common, external and internal) segments, six femoro-popliteal 
(femoral, profunda and popliteal) segments and the total score for the six segments in each
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group were compared. The aorta was compared separately so as to give an equal weighting 
of six segments in each of the two groups. If any segment was occluded in one of the two 
groups of arteries or abdominal aorta, or had a moderate to severe stenosis (additive score > 
3) in these segments, the patient was assigned to that group. If there were occlusions or 
stenoses with an additive score > 3 present in both the aorto-iliac and femoro-popliteal 
segments, the patient was classified as having dual-site disease.
The classification of patients by site of disease is shown in Table 4.8. Seventy three patients 
(38%) were classified as having multi-segment disease at more than one site (dual-site 
disease). Eighty five (44%) of patients were identified as having substantially more disease 
in the femoral, profunda, or popliteal arteries compared to the aorta and the common, external 
and internal iliac arteries. The third group comprised 34 (18%) subjects who were considered 
to have predominately more atherosclerotic disease in the aorta and iliac segments. Table 4.8 
also shows that 28 patients (82.4%) were classified into the aorta-iliac and 75 patients (88.2%) 
into the femoro-popliteal groups on the sole criterion of an occlusion (an additive score of 13 
or 15). Only 32 subjects (43.8%) of those with dual-site disease were so classified due to the 
presence of occlusions at both sites. Several patients were grouped according to the criterion 
of stenoses only (lesions with an additive score > 3). Ten patients from the femoro-popliteal 
and six from the aorto-iliac group were categorised in this way. In contrast, 41 (56.2%) of the 
subjects with dual-site disease were classified by stenoses only, rather than occlusion.
43.1 Mean additive scores by site
In Table 4.9, the mean total additive score for the aorta-iliac and femoro-popliteal segments
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are shown in relation to subjects in the three sites of classification. Some overlap occurred 
between the three groups because of the diffuse distribution of peripheral atherosclerosis in 
the study sample. The aorto-iliac patient group had significantly higher additive scores in 
those segments than in their femoro-popliteal segments. Likewise ,the femoro-popliteal group 
had relatively higher scores in the femoro-popliteal segments. The dual-site group had a 
slightly higher mean additive score in the femoro-popliteal segments than in the other group 
of segments but this difference was not statistically significant. Seventeen patients classified 
into the dual-site disease group had far more severe and extensive disease in the femoro- 
popliteal segments than in the iliac segments, suggesting some bias in the dual-site group 
towards femoro-popliteal disease.
4.4 Cardiovascular Risk Factors
In this section, age, sex, the presence of clinical cardiovascular disease, and risk factors 
(cigarette smoking, serum lipids and blood pressure) are described in the three groups of 
patients with different sites of peripheral atherosclerosis.
4.4.1 Age and sex
Table 4.10 at the end of this section (4.4) shows the distribution of age and sex in patients with 
predominately aorto-iliac, femoro-popliteal and dual-site disease. Chi-square analysis was 
used to test for differences in categorical variables within each class of disease. The 
distribution of age was significantly different between the three groups. Those with aorto-iliac 
disease were approximately eight years younger than patients from the other two groups (p<
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0.001). The mean age of the femoro-popliteal group was only marginally higher than that of 
the dual-site group (65.55 years compared to 64.98 years). There was a greater proportion of 
women in the aorto-iliac group compared to either the femoro-popliteal or dual-site group. 
Differences in sex distribution across the three classes were not statistically significant.
4.4.2 Vascular diseases
Clinical findings of peripheral arterial disease in the three groups of patients are shown in 
Table 4.11. All three groups reported a far higher prevalence of grade II symptoms of 
intermittent claudication (pain walking on the flat and uphill) than the less severe grade I (pain 
walking uphill only). The aorto-iliac group had relatively more rest pain and a slightly higher 
ABPI than the other two groups. The femoro-popliteal group showed the least percentage of 
patients with rest pain, but the lowest ABPI. However, none of the obseived differences were 
statistically significant (p> 0.05). No patient reported symptoms of severe chronic leg 
ischaemia, such as ulceration or gangrene or had a previous amputation.
The prevalence of other cardiovascular diseases is reported in Table 4.12. The dual-site group 
showed more evidence of a history of angina pectoris and previous myocardial infarction (both 
p< 0.05), stroke and diabetes mellitus than the other groups which probably indicates a higher 
degree of generalised atherosclerosis. Angina pectoris and myocardial infarction occurred less 
frequently in the aorto-iliac group than in the femoro-popliteal group. There were no cases of 
stroke in the aorto-iliac group. Likewise, diabetes mellitus was less common in the aorto-iliac 
group than in either of the two other classes of disease. However, the differences for stroke 
and diabetes mellitus were not statistically significant (p> 0.05).
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Table 43
FREQUENCY OF ARTERIAL OCCLUSIONS IN STUDY SAMPLE





3 2 2 11.5
4 9 4.7
5 9 4.7
6 4 2 . 1
7 4 2 . 1
8 1 0.5
9 1 0.5
Total 192 1 0 0
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Table 4.4




Abdominal Aorta 0 0
Common Iliac Left 15 4.5
Right 1 0 3.0
External Iliac Left 19 5.7
Right 2 2 6 . 6
Internal Iliac Left 2 2 6 . 6
Right 2 0 6 . 0
Profunda Femoris Left 9 2.7
Right 1 2 3.6
Superficial Femoral Left 63 18.9
Right 70 20.7
Popliteal Left 37 1 1 . 0
Right 36 10.7
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SITE OF STENOSES WITH ADDITIVE SCORE >3 
IN STUDY SAMPLE
Arterial Segment
Stenoses with Additive Score >3 
Number % of Total
Abdominal Aorta 17 2 . 0
Common Iliac Left 54 6.3
Right 69 8 . 1
External Iliac Left 81 9.5
Right 56 6 . 6
Internal Iliac Left 90 1 0 . 6
Right 75 8 . 8
Profunda Femoris Left 47 5.5
Right 65 7.6
Superficial Femoral Left 69 8 . 1
Right 71 8.3
Popliteal Left 85 1 0 . 0
Right 74 8.7
All Segments 853 1 0 0 . 0
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Table 4.7
SITE OF STENOSES WITH ADDITIVE SCORE <3 
IN STUDY SAMPLE
Arterial Segment
Stenoses with Additive Score <3 
Number % of Total
Abdominal Aorta 172 13.6
Common Iliac Left 123 9.7
Right 135 10.7
External Iliac Left 102 8.1
Right 103 8.1
Internal Iliac Left 78 6.2
Right 96 7.6
Profunda Femoris Left 124 9.8
Right 106 8.4
Superficial Femoral Left 37 2.9
Right 35 2.8
Popliteal Left 76 6.0
Right 79 6.2
All Segments 1266 100.0
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Table 4.8
PATIENTS BY SITE OF DISEASE : PERCENTAGE IDENTIFIED 
BY OCCLUSIONS OR STENOSES
Site of Disease
Number of Patients 
by Site
% Patients by Site 
Identified by 
Occlusion Stenoses
Aorto-iliac 34 82.4 17.6 f
Femoro-Popliteal 85 88.2 11.8
Dual-Site 73 43.8 56.2
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Table 4.9






Mean ± SD P-valuet
Aoito-Iliac 39.7 (±13.4) 20.7 (±11.8) <0.001
Femoro-Popiiteal 24.6 (±9.1) 42.8 (±13.2) <0.001
Dual-Site 36.9 (±17.3) 40.5 (±17.5) NS
t  - Significance of differences between additive scores 
SD - Standard deviation
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4.43 Cigarette smoking
In the study sample, semm thiocyanate and serum cotinine were highly positively skewed and 
were transformed by taking the natural logarithm to produce a more normal distribution. This 
allowed for valid statistical assumptions of significance to be made from the sample data. The 
mean levels of the transformed factors were presented as geometric means by taking the anti­
log values. The confidence intervals were also transformed back to geometric units.
Life-time smoking was modelled using pack-years (the average number of packs of 20 
cigarettes smoked per day multiplied by the number of years as a smoker). The distribution 
of packyears was slightly skewed and so the square root of this variable was used to reduce 
the influence of a few heavy smokers. The definition of a smoking 'deceiver' was any 
individual with a level of serum thiocyanate above 63.7 /.^mol/L and above 17.5 ng/ml for 
serum cotinine who had declared themself to be a non-smoker. The distributions of total 
cholesterol, systolic and diastolic blood pressure were approximately noimal and levels were 
therefore presented as the arithmetic means. Analysis of covariance was carried out with age 
and sex as covariates to test for differences in levels of the risk factors within each class of 
disease. The mean values were adjusted for age and sex to control for any confounding effects 
on the levels of the cardiovascular risk factors and on peripheral arterial disease.
Self-reported smoking status, mean levels of biochemical smoking measures and packyears, 
adjusted for age and sex by site of disease are shown in Table 4.13. There were no significant 
differences in cigarette smoking between the three classes. As expected with patients with 
clinically confirmed peripheral arterial disease, few individuals had never smoked. The high
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percentage of ex-smokers occurring in all three classes of disease possibly indicated cessation 
of smoking because of the onset of intermittent claudication or symptomatic ischaemic heart 
disease or cerebrovascular disease. The aorto-iliac group had more current smokers (44.1 %) 
and fewer ex-smokers (41.2%) than the other groups. The percentage of smoking 'deceivers' 
was approximately the same in each group of patients and ranged from 9.6% in dual-site 
patients to 11.8% in the aorto-iliac patients. Serum cotinine and serum thiocyanate levels were 
also higher in the aorto-iliac patients, reflecting the greater percentage of current smokers in 
this group. Packyear levels, as a measure of life-time smoking consumption were slightly 
higher for patients with femoro-popliteal disease than for aorto-iliac disease, suggesting that 
the femoro-popliteal patients may have smoked more heavily and/or had begun smoking at an 
earlier age,
4.4.4 Lipids and blood pressure
Mean serum lipid and blood pressure levels adjusted for age and sex were also compared 
(Table 4.14). As with cigarette smoking, the differences in levels of these risk factors between 
the three groups were not statistically significant. Of the three groups of patients, those with 
aorto-iliac disease had the lowest mean levels of total cholesterol, but the highest levels of 
HDL cholesterol (5.75 mmol/L and 1.27 mmol/L respectively). The levels of total cholesterol 
in the femoro-popliteal and dual-site groups were approximately the same at 6.08 mmol/L and
6.04 mmol/L. The levels of total cholesterol in all groups was only marginally higher than the 
clinically accepted ’normal'level of 5.2 mmol/L. Examination of hospital records showed that 
only two individuals took lipid-lowering drugs, although it is possible that other patients with 
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Systolic blood pressure was highest in those with dual-site disease and diastolic pressure was 
highest in the aorto-iliac group (Table 4.14). It should be noted, however, that the intake of 
anti-hypertensive medication was highest in the dual-site group, with 20.5 % of patients taking 
these drugs, compared to 11.8% in the femoro-popliteal and 8.8% in the aorto-iliac groups.
4.5 Haemostatic Factors
The distributions of von Willebrand Factor, fibrin D-dimer, plasminogen activator inhibitor 
were highly positively skewed and logarithmic transfonnations were used in the analyses. 
Both clotting fibrinogen and nephelometric fibrinogen were normally distributed and levels 
were therefore presented as the arithmetic means (Figures 6-10).
4.5.1 Univariate analysis of haemostatic factors and site of disease
Mean levels of the haemostatic factors across the site of disease groups were examined using 
analysis of covariance with age and sex as covariates. There were no significant differences 
in mean levels of haemostatic factors between patients in the three groups (Table 4.15). This 
lack of statistically significant differences could have occurred because of the small numbers, 
particularly in the aorto-iliac group. However, with the exception of fibrin D-dimer, levels of 
the factors tended to be highest in the dual-site group and lowest in patients with 
predominately aorto-iliac disease. In contrast, fibrin D-dimer showed the highest levels in the 
aorto-iliac group. In all three groups, the levels of heat precipitated fibrinogen measured by 
nephelometry were higher than clotting fibrinogen estimated by the modified Clauss assay.
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4.5.2 Univariate analysis of haemostatic factors and severity of disease
Partial correlation coefficients adjusted for age and sex were calculated to examine 
associations between the haemostatic factors and severity of disease within the femoro- 
popliteal and aorto-iliac segments. Disease severity was estimated by a quantitative variable 
(the additive score) in all 192 patients which enabled examination of linear relationships 
between the variables and hence permitted more power to detect significant associations.
The range of additive scores for both groups of segments was identical (5 to 86), but the mean 
additive score for the femoro-popliteal segments was significantly higher than the mean score 
for the aorto-iliac segments (38.09 compared to 31.95, p< 0.001). Table 4.16 shows that 
increasing severity of disease within the aorto-iliac segments was significantly associated with 
nephelometric fibrinogen (r=0.12, p< 0.05). There were no significant relationships between 
the other haemostatic factors and the additive score in the aorto-iliac segments. Both 
nephelometric fibrinogen and fibrin D-dimer were significantly correlated with increasing 
disease severity in the femoro-popliteal segments (r=0.20, p< 0.01 and r=0.22, p< 0.001 
respectively). A weaker positive association was found with von Willebrand Factor (r=0.14, 
p< 0.05). Plasminogen activator inhibitor (PAI) showed a weak non-significant negative 
correlation with increasing additive scores in both groups of segments.
4.53 Multivariate analysis of haemostatic factors and severity of disease
Multiple regression analyses were carried out to identify any statistically independent 
associations of the haemostatic factors with disease severity within each of the two groups of
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segments. The regression coefficients were obtained from the statistical package BMDP and 
represented changes in the dependent variable (the additive score) when a haemostatic factor 
(the independent variable) increased in value by approximately one standard deviation.
Since PAI activity showed a significant linear trend with time of venepuncture (p< 0.001), this 
was used as a covariate together with age and sex. Aspirin consumption or other anti-platelet 
medication showed no relationship with any of the haemostatic factors and these were 
therefore not included in the model. Table 4.17 shows that none of the haemostatic factors had 
a statistically independent effect on disease severity within the aorto-iliac segments. Therefore 
no further analysis was carried out on this group of segments.
Table 4.17 also shows that, for the femoro-popliteal segments, both nephelometric fibrinogen 
and fibrin D-dimer were independently related to disease severity in the femoro-popliteal 
segments (both p< 0.05). In the case of PAI, the regression coefficient was negative, 
suggesting that higher PAI activity was associated with a lower severity of disease. The 
association between PAI and disease severity was only just non-significant (p= 0.08).
In Table 4.18, the relationships between nephelometric fibrinogen, between fibrin D-dimer and 
between PAI and the severity of disease within the femoro-popliteal segments were estimated 
after further adjustment for life-time smoking (packyears) and for current smoking (serum 
thiocyanate) in the multiple regression model. On adjusting for packyears, nephelometric 
fibrinogen remained independently associated with disease severity. Adjustment for serum 
thiocyanate also had little effect on the association of fibrinogen with disease. Adjustment for 
packyears had a greater effect on the relationship between PAI and disease severity than
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current smoking (thiocyanate), although the association remained non-significant (p= 0.06). 
The negative association between PAI activity and additive score in the femoro-popliteal 
segments was examined further and found to be due to a strong inverse correlation between 
men, whereas women showed a weak positive correlation (Figure 11). There was no 
significant difference in additive scores within the femoro-popliteal segments between the 
sexes. However, packyears were significantly higher in men (mean = 2.31, SE = 0.06) 
compared to women (mean = 2.05, SB = 0.10, p=0.02).
The magnitude of the relationship between fibrin D-dimer and disease severity (Table 4.18) 
was reduced when life-time smoking (packyears) was taken into account, and the association 
became non-significant (p= 0.06). On the other hand, there was no influence of current 
smoking on the relationship between fibrin D-dimer and severity of disease in the femoro- 
popliteal segments and the value of the regression coefficient was unchanged (3.95) on 
adjustment for serum thiocyanate.
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Table 4.16
AGE AND SEX ADJUSTED CORRELATION COEFFICIENTS 
BETWEEN HAEMOSTATIC FACTORS AND ADDITIVE SCORE 





Fibrinogen : clotting (g/L) 0.08 0.06
nephelometric (g/L) 0J2* OJW**
von Willebrand Factor (iu/dL)t 0.08 0T4*
Fibrin D-dimer (ng/mL)t 0.10 0.22***
Plasminogen Activator 
Inhibitor (% Pool)t -0.05 -0.07
t  - Logged values used 
* p<0.05; *** p<0.001
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Table 4.17
MULTIPLE REGRESSION MODELS OF HAEMOSTATIC FACTORS 












von Willebrand Factor (+1 Log iu/dL) 1.50 (2.78) 369 (2.58)
Fibrin D-dimer (+1 Log ng/mL) 0.82 (1.55) 3.36 (1.48)*
Plasminogen Activator Inhibitor 
(+ Log % Pool)
-0.19 (4.81) -7.82 (4.47)
All values are unstandardised regression co-efficients and standard errors 
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4.6 Summary of Results
1. One hundred and ninety two patients (144 men and 48 women) with either intermittent 
claudication or rest pain were recruited into the study.
2. Thirty four (18%) patients were identified using the Bollinger angiographic scoring 
system as having predominantly aorto-iliac disease, 85 (44%) femoro-popliteal disease 
and 73 (38%) patients were classified as having dual-site disease.
3. Levels of cardiovascular risk factors (blood pressure, lipids and cigarette smoking) 
differed between patients with different sites of peripheral atherosclerosis, although the 
differences were statistically non-significant.
4. With the exception of fibrin D-dimer levels (which were highest in aorto-iliac disease), 
haemostatic factor levels were highest in patients with dual-site disease, although the 
differences were statistically non-significant.
5. Plasma fibrinogen, as measured by nephelometry, fibrin D-dimer and von Willebrand 
Factor were significantly correlated with increasing disease severity (additive score) 
in the femoro-popliteal arteries. There were no significant associations between any 
haemostatic factors and additive score in the aorto-iliac arteries, after adjusting for age 
and sex.
6. On multiple regression, fibrinogen remained independently associated with disease
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severity in the femoro-popliteal arteries, when life-time smoking, or current smoking 
were taken into account. There was no influence of current smoking on the association 




PROGNOSTIC STUDY OF INTERMITTENT CLAUDICATION; RESULTS
This chapter describes the results from the Prognostic Study of Intermittent Claudication. The 
results are divided into four main sections describing (i) the baseline characteristics of the 
study sample, (ii) the incidence of vascular events, (iii) the relationships between severity of 
peripheral arterial disease, cardiovascular risk factors, and haemostatic factors to incident 
ischaemic heart disease and stroke events and (iv) the relationships between cardiovascular 
risk factors and haemostatic factors to progression of peripheral arterial disease.
5.1 The Study Sample
Ten patients were excluded from the baseline cohort of 617 patients because on examination 
of hospital records by the author, six were found to have evidence of previous or impending 
arterial surgery and four had symptoms of severe chronic leg ischaemia (rest pain, gangrene 
or ulceration) at the time of recmitment to the study. A total of 607 patients was therefore 
followed up prospectively over the six year period.
5.1.1 Age, sex and clinical characteristics
The mean age and sex distribution and clinical characteristics of the study sample at baseline 
are shown in Table 5.1. The mean age of the 607 patients in the study was 65,5 years. There 
were proportionally more males (n=389,64.1%) than females (n=218,35.9%). Symptoms of
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intermittent claudication were assessed by responses to the WHO Claudication Questionnaire 
(Rose 1962) which was completed at the time of the baseline clinical examination. A total of 
47.1% of the patients had moderate intermittent claudication (grade 1), whereas 52.5% had 
symptoms of more severe claudication (grade II). The mean ABPl of the sample was 0.57.
5,1.2 Cardiovascular risk factors by sex
Baseline risk factor characteristics of the study sample are shown in Table 5.2. Most of the 
patients had a history of cigarette smoking (91.3%), and at recruitment, current cigarette 
smokers comprised 38.2%, ex-smokers 48.9% and never smokers 8.7% of the study sample. 
The high percentage of ex-smokers possibly indicated cessation of smoking when intermittent 
claudication was first diagnosed. Mean levels of systolic and diastolic blood pressure were
152.4 mmHg and 83.9 mmHg respectively. The mean level of total cholesterol in the study 
sample was relatively high at 6.7 mmol/L.
Comparison of the mean age between males and females (Table 5.3) showed that females were 
approximately two years older and the sex difference was statistically significant (p< 0.05). 
The males in the study sample had a higher prevalence of more severe grade II symptoms of 
intermittent claudication than females (54.3% compared to 50.0% respectively, p> 0.05). The 
ABPI was almost identical in the sexes, 0,57 in males and 0.56 in females.
Cigarette smoking status and mean levels of cardiovascular risk factors were compared in 
males and females (Table 5.4). Smoking status was very different between the sexes. 
Although the proportion of current smoking was similar, there were more ex-smokers in
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males, so that only 4.9% had never smoked compared to 16.3% in females. The square root 
of packyears was used to reduce the effect from 'outliers' (occasional results with extremely 
high or low values). Mean levels of packyears, as a measure of life-time smoking 
consumption were also significantly higher in males than females (p< 0,001), and reflected 
the higher percentage of current and ex-smokers in males. In contrast, females showed higher 
mean levels of systolic blood pressure (155.2 mmHg compared to 150.8 mmHg in males, p< 
0.05), and a slightly lower diastolic pressure, which was not statistically significant. Also, 
mean levels of total cholesterol were far higher in females, 7.1 mmol/L compared to 6.4 
mmol/L (p< 0.001), which was as expected in these mainly post-menopausal women. Random 
glucose levels were also higher in females, but the difference was not significant.
5.13 Associations between cardiovascular risk factors and severity of disease
The relationships between cigarette smoking and other cardiovascular risk factors to severity 
of peripheral arterial disease in the study sample at baseline were examined. Partial correlation 
coefficients were calculated to examine associations between the risk factors and the ABPI, 
which was used as a measure of the severity of disease. Table 5.5 shows that only systolic 
blood pressure was significantly related to the ABPL The strength of the correlation was 
moderate (r=-0.21) but highly statistically significant (p< 0.001), probably because of the 
relatively large numbers in the study sample. The direction of the correlation was negative, 
indicating that as systolic blood pressure increased, the ABPI decreased (or severity of disease 
increased). However, an association was not unexpected because ABPI and systolic blood 
pressure are not independent variables. Estimation of the ABPI involves using systolic 




The distributions of the haemostatic factors are illustrated in Figures 12-15. Clotting 
fibrinogen and von Willebrand Factor were positively skewed and were square root 
transformed. Tissue plasminogen activator and fibrin D-dimer required logarithmic 
transformations to normalise their distributions.
The medians and inter-quartile ranges of the haemostatic factors for the study sample are 
shown in Table 5.6. In Table 5.7, the extent to which baseline levels of the haemostatic factors 
might be related to cardiovascular risk factors was examined univariately by calculating partial 
correlation coefficients. These were adjusted for age and sex because of possible confounding. 
Transformed variables were used where appropriate. There were no significant correlations 
between fibrinogen and any of the cardiovascular risk factors, including cigarette smoking, 
von Willebrand Factor was inversely related to levels of total cholesterol (r=-0.09, p< 0.05). 
Significant associations were found between t-PA and packyears, systolic blood pressure, 
diastolic blood pressure and total cholesterol, but not random glucose levels. Fibrin D-dimer 
was significantly correlated with both measures of blood pressure (systolic, r-0.10, p< 0.05; 
diastolic, r=0.11,p< 0.01).
In Table 5.8, univariate relationships between haemostatic factors and ABPl at baseline 
adjusted for age and sex are presented. Calculation of partial correlation coefficients showed 
that all the factors were significantly related to increasing severity of disease. The strongest
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Table 5.1
AGE, SEX AND CLINICAL CHARACTERISTICS OF 
STUDY SAMPLE AT BASELINE
Study Sample 
(n=607)
Age mean years (SE) 65.5 (0.4)
Sex % Male 64.1
% Female 35.9
Intermittent Claudication : Grade I % 47.1
Grade 11 % 523
Ankle Brachial Pressure Index mean (SE) 0.57 (0.01)
SE - Standard error
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Table 5.2
MEAN CARDIOVASCULAR RISK FACTOR LEVELS OF 
STUDY SAMPLE AT BASELINE






Packyears ( / )  mean (SE) 4.8 (0.12)
Blood Pressure (mmHg)
Systolic Pressure mean mmHg (SE) 152.4 (1.0)
Diastolic Pressure mean mmHg (SE) 833» (03)
Total Cholesterol mean mmol/L (SE) 6.7 (0.1)
Random Glucose mean mmol/L (SE) 6.0 (0.1)



























PARTIAL CORRELATION COEFFICIENTS ADJUSTED FOR AGE 
AND SEX BETWEEN CARDIOVASCULAR RISK FACTORS AND 
ANKLE BRACHIAL PRESSURE INDEX AT BASELINE
Factor ABPI
Packyears (V) -0.07
Systolic Blood Pressure -0.21**»
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MEDIANS (INTERQUARTILE RANGES) OF HAEMOSTATIC 
FACTORS IN STUDY SAMPLE AT BASELINE
Haemostatic Factor Study Sample 
(n=607)
Fibrinogen (g/L) 2.89 (2.49,3.37)
von Willebrand Factor (iu/dL) 138.0 (105.0,179.0)
Tissue Plasminogen Activator (ng/mL) 11.0 (8.2,13.6)




0\ SOo o o
(NOo
o T-1t—Io o o
T—I o
o o o o
00hH
SO





PARTIAL CORRELATION COEFFICIENTS ADJUSTED FOR AGE 
AND SEX BETWEEN HAEMOSTATIC FACTORS AND ANKLE 
BRACHIAL PRESSURE INDEX AT BASELINE
Haemostatic Factor ABPI
Fibrinogen ( / ) -0.08'=
von Willebrand Factor (V") -0.09'=
Tissue Plasminogen Activator (log) -0.18***
Fibrin D-dimer (log) -0.14'"**
p<0.05; *** p<0.001 
log - logarithm
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inverse correlations with ABPI were found with factors associated with fibrin breakdown, t-PA 
(r=-0.18, p< 0.001) and fibrin D-dimer (r=-0.14, p< 0.001). Weak correlations were also 
shown between fibrinogen and ABPI (r=-0.08) and between vWF and ABPI (r=-0.09). Both 
associations were significant at the 5% level.
5.2 Incidence of Vascular Events
5.2,1 Fatal events by sex
A total of 210 patients (34.6 % of the study sample) died during the six year follow-up period. 
The cause of death could not be confirmed in two patients and these patients were therefore 
not included in any subsequent analysis. The mortality rate in males for all causes of death 
was higher than in females, with the exception of stroke. In total, 39.8% of males in the study 
sample died compared to 24.2% of the females. Figure 16 shows the survival curves for men 
and women separately. A comparison of the survival experience between the sexes was highly 
statistically significant (Wilcoxon statistic 17.47 with one degree of freedom, p< 0.0001), with 
the men dying at a faster rate than the women.
Causes of death in males and females during the six years of follow-up are shown in Table 5,9. 
Results are expressed as number of events and as the percentage of total number of males and 
females in the study sample. Mortality was primarily due to vascular disease in both sexes. 
The most common cause of death was due to ischaemic heart disease and a higher mortality 
rate was found overall in males compared to females. A total of 64 subjects died from a 
myocardial infarction. Of these, 48 (12.3%) were male and 16 (7.3%) were female. There
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were a further 26 deaths due to ischaemic heart disease other than myocardial infarction (n=19, 
4.9% males and n=7,3.2% females). These included deaths due to coronaiy atherosclerosis. 
In contrast, the mortality rate from stroke was almost identical in males (n=19, 4.9%), 
compared to females (n=10,4.6%). It should be noted that stroke cases were not differentiated 
by ischaemic or haemorrhagic origin because of the small number on whom computed 
tomography (CT) scans or necropsy were performed. An additional 27 patients died from 
vascular causes other than ischaemic heart disease or stroke, for example, ruptured aortic 
aneurysm. There were 62 deaths due to non-cardiovascular causes and 31 of these were from 
cancer. There was also a predominence of male deaths in this category, 48 (12.3%) compared 
to 14 (6.4%) which were female.
5.2.2 Non-fatal events by sex
The number of non-fatal vascular events occurring during the six year follow-up period for 
each subject is shown in Table 5.10 and is illustrated in Figure 17. Two hundred and three 
subjects (33.4% of the total sample) did not have a new vascular event and their limb 
ischaemia did not deteriorate during follow-up. Almost half of the subjects in the study 
(47.6%) had at least one event during the six years. The maximum number of confirmed 
events was nine, which was recorded by one patient.
The number of incident non-fatal events due to ischaemic heart disease, and cerebrovascular 
disease in males and females is shown in Table 5,11. During the six years follow-up period, 
a total of 56 subjects (9.2%) developed new symptoms of angina pectoris. This comprised 
38 males (equivalent to 9.8% of the total number of males in the study sample) and 18,8.3%
159
of the study sample of females. Ninety three subjects had a non-fatal myocardial infarction; 
65 (16.7%) men and 28 (12.8%) women.
The incidence of self-reported or clinically diagnosed transient ischaemic attacks was higher 
than the incidence of hospital-diagnosed strokes in men. Overall, men developed slightly 
more cerebrovascular disease events than women. Thirty four men (8.7%) reported that they 
had had a transient ischaemic attack compared to 13 (6.0%) women during the six years of 
follow-up. In contrast, out of a total of 61 non-fatal strokes occurring during follow-up, 40 
(10.3%) were male and 21 (9.6%) were female.
5.23 Progression of peripheral arterial disease by sex
The study subjects were also followed up over the six year period to determine the incidence 
of severe chronic leg ischaemia (rest pain, ulceration, gangrene and amputation), and 
peripheral vascular procedures, including angiography, angioplasty, lumbar sympathectomy 
and by-pass grafting. Events related to the progression of peripheral arterial disease by gender 
are shown in Table 5.12.
A total of 45 subjects (7.4%) underwent hospital investigations for treatment for peripheral 
arterial disease; 19 of these had femoral angiography; 9 femoral angioplasty; 1 iliac 
angiography; 6 iliac angioplasty; 1 iliac embolectomy; 4 aortic angiography and 1 subject 
underwent a lumbar sympathectomy. Three patients had femoral by-pass grafting and one 
patient aortic by-pass grafting. Although information was not collected on the particular leg 
requiring inteivention, it is probable that vascular investigations were mostly performed on
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the leg which had the lower ABPI at baseline. None of these patients progressed to severe 
chronic leg ischaemia or required leg amputation during the follow-up period. Eight of these 
patients died during follow-up, five from vascular causes. Thirty five men (9.0% of the study 
sample) required vascular inteivention compared to ten women (4.6%) during the six years.
The worst outcome in patients who developed severe chronic leg ischaemia during the six 
years was also recorded. Sixty four patients (10.5%) progressed to symptoms of severe 
chronic leg ischaemia; 20 developed rest pain only ; 30 further progressed to leg ulceration, and 
13 to gangrene. One patient had a below knee amputation because of severe peripheral arterial 
disease. This event was reported separately because there was no evidence in the hospital case 
notes of any prior symptoms of severe chronic leg ischaemia. A further 18 patients within this 
disease category subsequently required leg amputation and 32 died, 27 from vascular causes 
(data not shown).
Table 5.12 shows that, in contrast to the vascular inteivention group, in which the ratio of 
males to females undergoing treatment was approximately 2:1, slightly more women than men 
(other than the group who developed leg ulceration) showed deterioration to severe chronic 
leg ischaemia in the study sample. The percentage of men who developed ulceration of the 
lower limb was approximately the same in men (5.4%) and women (4.8%). Given that 
baseline levels of ABPI were similar between the sexes, these results suggest that the rate of 
deterioration of symptomatic peripheral arterial disease may be slightly faster in women than 

































































DISTRIBUTION OF INCIDENT NON-FATAL 
VASCULAR EVENTS IN STUDY SAMPLE




















INCIDENCE OF VASCULAR INTERVENTION AND SEVERE 







Vascular Intei*vention 35 9.0 10 4.6
Rest Pain 10 2.6 10 4.6
Ulcer 21 5.4 9 4.8
Gangrene 6 1.5 7 3.2
Amputation 1 0.3 0 0
PAD - Peripheral Arterial Disease
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5.2.4 Univariate analysis of baseline severity of peripheral arterial disease and incident 
ischaemic heart disease and stroke events
The univariate relationship between the severity of baseline peripheral arterial disease (ABPI), 
and the relationship between severity of symptoms of intermittent claudication to ischaemic 
heart disease and stroke events are shown in Table 5.13. Four categories of vascular events 
were defined: combined fatal and non-fatal stroke (n=79), non-fatal myocardial infarction 
(n=93), fatal ischaemic heart disease (fatal myocardial infarction and deaths due to other 
ischaemic heart disease) (n=90) and total ischaemic heart disease events, which included fatal 
and non-fatal myocardial infarction and deaths due to ischaemic heart disease (n=160). 
Student's t-test, or chi-square analysis were used to test for differences across the categories 
of disease relative to a group who had no new vascular event or deterioration of limb 
ischaemia during follow-up (n=203).
The mean baseline level of ABPI in claudicants who had no vascular event during follow-up 
was 0.59 (Table 5.13). In comparison with the no event group, the mean ABPI was 
significantly lower across all categories of disease with the exception of the non-fatal 
myocardial infarction group. The lowest ABPI (0.51) was recorded in those who subsequently 
suffered a stroke (p< 0.01) or who died from ischaemic heart disease (p< 0.001).
The relationship of severity of self-reported symptoms of intermittent claudication to incident 
ischaemic heart disease and stroke events is also presented in Table 5.13. In the no event 
group, the proportion of those who reported moderate grade 1 symptoms (49.8%) was similar 
to those who had more severe grade 11 symptoms of intermittent claudication (50.2%).
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Although the stroke group had recorded the lowest mean ABPI, these subjects reported 
significantly less severe symptoms of claudication than the no event group (55.7% grade I, 
44.3% grade 11; p< 0.05). In contrast, all categories of patients who developed ischaemic heart 
disease had more severe symptoms of intermittent claudication at baseline than the comparison 
group, although the differences were non-significant.
5,2.5 Univariate analysis of age, sex, cardiovascular risk factors and incident ischaemic 
heart disease and stroke events
Table 5.14 shows mean age, percentages of males and mean levels of cardiovascular risk 
factors across the categories of events. Clustering of elevated risk factors occurred particularly 
in the stroke and fatal ischaemic heart disease categories. For example, in those who 
subsequently had a fatal or non-fatal stroke, baseline levels of both systolic (163.45 mmHg, 
p< 0.001) and diastolic pressure (87.24 mmHg, p< 0.01) were significantly higher than in the 
no event group and were also the highest recorded in any event category. Life-time cigarette 
consumption (packyears) and total cholesterol were also highest in this category of disease, 
but the elevations in the levels were not statistically significant in relation to those who 
experienced no events. The mean age (70.82 years, p< 0.001), the percentage of males 
(74.4%, p< 0.001) and random glucose level (6.86 mmol/L, p< 0.001) in the group who died 
of ischaemic heart disease during follow-up were significantly elevated compared to levels in 
the no event group, and were also higher than in the other event groups. Conversely, baseline 
levels of total cholesterol and packyears in the fatal ischaemic heart disease group were lowest 
compared to other categories of disease and the no event group, but this may have reflected 
more active inteivention in this group which had more evidence of baseline ischaemic heart
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disease than the other disease categories (data not shown).
5.2.6 Multivariate analysis of cardiovascular risk factors, ABPI and incident ischaemic 
heart disease and stroke events
Table 5.15 shows the multivariate relationship between baseline cardiovascular risk factors 
and between ABPI and subsequent risk of ischaemic heart disease and stroke throughout the 
six year follow-up period. As expected, given the strength of the univariate association, the 
risk of stroke associated with a standard deviation increase in systolic blood pressure was 
statistically significant, after adjusting for age and sex (RR 1.57,95 % Cl 1.23,2.01 p< 0.001). 
The relative risk of stroke associated with a unit increase in random glucose levels was also 
substantially raised (RR 2.65,95% Cl 1.35,5.18 p^ 0.01). For a standard deviation increase 
in ABPI (or decreased severity of lower limb disease), the relative risk related to stroke was 
significantly less than one, suggesting that increasing severity of peripheral arterial disease 
may increase the risk of stroke.
With the exception of random glucose, there were no significant relationships between any of 
the cardiovascular risk factors and the risk of all ischaemic heart disease events, after 
adjustment for age and sex. Random glucose was significantly related to the risk of ischaemic 
heart disease, across all categories of events. The strongest association was between glucose 
levels and risk of myocardial infarction (RR 2.22,95% Cl 1.24,3.95 p< 0.01). A higher ABPI 
was associated with a significant decrease in the risk of total ischaemic heart disease events 
(RR 0.83, 95% Cl 0.69, 0.99 p< 0.05).
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53  Haemostatic Factors
53.1 Univariate analysis of haemostatic factors and incident ischaemic heart disease 
and stroke events
Median levels and inter-quartile ranges for each haemostatic factor across the four categories 
of ischaemic heart disease and stroke are presented in Table 5.16. Differences in medians 
across the categories of disease relative to the group who had no coronary or cerebrovascular 
events and no deterioration of limb ischaemia during follow-up were tested by the 
Kolmogorov-Smirnov test.
The results show that in those who subsequently died of ischaemic heart disease, baseline 
levels of fibrinogen (p< 0.01), von Willebrand Factor (p< 0.05) and fibrin D-dimer (p< 0.001) 
were significantly raised compared to levels in the no event group. The levels of these 
haemostatic factors were also the highest recorded in any disease category. Fibrin D-dimer 
levels were also markedly elevated in the other ischaemic heart disease groups. In those who 
suffered a stroke during the follow-up period, only t-PA antigen levels showed any significant 
elevation at baseline (12.0 ng/mL, p< 0.01) compared to those who experienced no events 
(10.3 ng/mL).
53.2 Multivariate analysis of haemostatic factors and incident ischaemic heart disease 
and stroke events
Relative risks of each event group for a unit increase in each haemostatic factor level were
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estimated by multiple logistic regression models that adjusted for age and sex, and then further 
adjusted for life-time cigarette smoking (packyears), systolic blood pressure, glucose and 
baseline evidence of ischaemic heart disease (angina and/or myocardial infarction). Baseline 
angina and myocardial infarction were defined according to a positive response to the WHO 
questionnaire and recall of a doctor's diagnosis. Relative risks were calculated using the 
statistical package, SAS.
Table 5.17 shows that fibrinogen was significantly related to total ischaemic heart disease 
events, after adjusting for age and sex (p< 0.05). There were no significant associations 
between vWF and the risk of any vascular event, after adjusting for age and sex. The relative 
risk of stroke, associated with a unit increase in t-PA antigen was statistically significant after 
adjusting for age and sex, (RR 1.87, 95% Cl 1.04, 3.34 p< 0.05), but not after other 
cardiovascular risk factors and baseline evidence of ischaemic heart disease were taken into 
account. The risk, however, on multivariate analysis remained substantially greater than one 
(RR 1.60, 95% Cl 0.88,2.92 p> 0.05).
The relationship between fibrin D-dimer and non-fatal myocardial infarction, and between this 
factor and total ischaemic heart disease events also appeared to be partly attributable to the 
confounding effects of the risk factors and baseline ischaemic heart disease. The magnitude 
of the relative risk of myocardial infarction was reduced on multiple adjustment from 1.50, 
(95% Cl 1.09,2.06 p< 0.01) to 1.37 (95% Cl 0.97,1.92 p> 0.05). Similarly, the relative risk 
of total ischaemic heart disease events associated with fibrin D-dimer dropped from 1.37 to 
1.26, p> 0.05, when all factors were taken into account.
172
Figure 18 shows the relative risk for combined fatal and non-fatal stroke across tertiles of t- 
PA antigen after adjusting for all risk factors. Subjects with values of t-PA antigen in the 2nd 
and 3rd tertiles had increased relative risks of 1.22 (95% Cl 0.63,2.35) and 1,79 (95% Cl 0.99, 
3.26) respectively when compared with those in the lowest teifile. A similar pattern for the 
relative risks of total ischaemic heart disease events according to tertile of fibrin D-dimer level 
is shown in Figure 19. The highest relative risk was found in the top tertile of fibrin D-dimer 
(RR 1.46,95% Cl 0.93,2.29). The relative risk of subjects in the 2nd tertile of fibrin D-dimer, 
however, was similar to that in the lowest tertile (RR 1.03, 95% Cl 0.65,1.63).
The extent to which the associations between each factor and ischaemic heart disease and 
stroke events could be explained by interactions with other components of the haemostatic 
system was also estimated (Table 5.18). The relative risks of each disease category were 
recalculated in the multiple logistic regression model for each haemostatic factor, adjusting 
for all the haemostatic factors simultaneously, as well as age and sex. After further adjustment 
for the effects of the other haemostatic factors, the relative risk of every category of ischaemic 
heart disease and also stroke for each haemostatic factor was reduced and most became non­
significant. However, fibrin D-dimer remained independently associated at the 5% level of 
significance to the risk of non-fatal myocardial infarction.
5.4 Progression of Peripheral Arterial Disease
For this part of the analyses, two groups of patients were identified: those whose symptoms 
had deteriorated sufficiently to require vascular inteiwention, but did not develop severe 
chronic leg ischaemia during follow-up (n=45), and secondly, a group comprising those who
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developed definite symptoms of severe chronic leg ischaemia, defined as rest pain, ulceration 
or gangrene during the six years (n=64).
5.4.1 Univariate analysis of baseline severity of peripheral arterial disease and 
progression of disease
Mean levels of the ABPI and the percentages of grade I and grade II symptoms of intermittent 
claudication at baseline were calculated for each of the two follow-up categories of peripheral 
arterial disease, and compared with the group who had no cerebrovascular or coronary events, 
or deterioration of limb ischaemia during follow-up. Table 5.19 shows that the mean ABPI 
of those who underwent vascular inteiwention was slightly higher than the no event group, but 
the difference was not statistically significant (0.62 compared to 0.59, p> 0.05). As expected, 
the group who developed more severe symptoms of limb ischaemia had a significantly lower 
ABPI at baseline (p< 0.001) than those who did not deteriorate, or than those who had required 
vascular intervention. Conversely, the vascular intei-vention group reported a far higher 
percentage of more severe grade II symptoms of intermittent claudication at baseline, 
according to responses to the WHO claudication questionnaire than the no event group (70.5 % 
compared to 50.2%, p< 0.05) and also than the group which developed severe chronic leg 
ischaemia (53.1%).
5.4.2 Univariate analysis of cardiovascular risk factors and progression of disease
Baseline characteristics of the vascular intervention group and those patients who developed 
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in Table 5.20. The vascular intervention group was significantly younger (61.9 years 
compared to 65.1 years, p< 0.05) and had a far higher proportion of males (77.8% compared 
to 49.5%, p< 0.001) than the no progression group. The severe chronic leg ischaemics had a 
lower mean level of total cholesterol at baseline than the group which had not deteriorated (6.3 
mmol/Lcompared to 6.8mmol/L, p< 0.001), even although none were receiving lipid-lowering 
medication. There were no significant differences in life-time smoking consumption 
(packyears), random glucose or blood pressure levels between either of the two event groups 
compared with those who showed no progression, although the mean levels of these factors 
were slightly higher in the severe chronic leg ischaemia group. There was also a higher 
percentage of current smokers in this group. A history of smoking was particularly common 
among those proceeding to vascular intervention, in that only 2.2% were never smokers, 
although a relatively high percentage had given up (71% of the vascular intervention group).
5.43 Multivariate analysis of cardiovascular risk factors, ABPI and progression of 
disease
Relative risks of the two disease groups for a unit increase in each of the cardiovascular risk 
factors and ABPI were estimated by multiple logistic regression models which adjusted for 
age and sex. Table 5.21 shows that the risk of vascular inteivention associated with a 
1.3mmol/Lincrease in total cholesterol was substantially less than one (RR0.70,95% Cl 0.52,
0.95 p^ 0.05), suggesting that an elevated cholesterol level may reduce the risk of requiring 
vascular intervention. Random glucose was associated with an increased risk of vascular 
inteivention (p< 0.01) but not severe chronic leg ischaemia. Neither cigarette smoking, 
systolic blood pressure nor the ABPI were independently associated with the risk of
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intervention, after adjusting for age and sex. In contrast, only a standard deviation increase 
in the ABPI was significantly and inversely related to the risk of developing severe chronic 
leg ischaemia (RR 0.57,95% Cl 0.43,0.76 p< 0.001).
5.5 Haemostatic Factors
5.5.1 Univariate analysis of haemostatic factors and progression of peripheral arterial 
disease
The median levels and interquartile ranges of each haemostatic factor across the two groups 
whose peripheral arterial disease had worsened, relative to those who showed no progression 
are shown in Table 5.22. Differences in medians of the haemostatic factors were tested by the 
Kolmogorov-Smimov test across the two categories, relative to the group which showed no 
deterioration.
The results show that there were no significant differences in baseline levels of fibrinogen, 
vWF, fibrin D-dimer or t-PA antigen between the vascular intervention group and the 
comparison group. Levels of fibrinogen were slightly lower in the severe chronic leg 
ischaemia group than in the no progression group but not significantly so. vWF levels were 
significantly higher in patients who developed severe chronic leg ischaemia compared with 
the no event group (154.0 iu/dL compared to 131.0 iu/dL, p< 0.01) and were also higher than 
in the vascular inteivention group (138.0 iu/dL).
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5.5.2 Multivariate analysis of haemostatic factors and progression of peripheral arterial 
disease
Relative risks of the two disease groups for a unit increase in each of the haemostatic factors 
were estimated by multiple logistic regression models which adjusted for age and sex, and then 
further adjusted for life-time smoking consumption (packyears). The confounding effect of 
cigarette smoking on the risk of disease progression was examined separately from the other 
cardiovascular risk factors because smoking may strongly influence the relationship between 
certain haemostatic factors and peripheral arterial disease.
Table 5.23 shows that after adjustment for age and sex, there were no significant relationships 
between any of the haemostatic factors and the risk of vascular intervention. However, after 
further adjustment for cigarette smoking, the magnitude of risk of vascular intervention 
increased slightly for fibrinogen and became statistically significant (RR 1.33,95% Cl 1.00, 
1.77 p< 0.05). Similarly, no haemostatic factor was independently related to the risk of severe 
chronic leg ischaemia on adjustment for age and sex, but when smoking history was taken into 
account, the relative risk of severe chronic leg ischaemia associated with a unit increase in 
vWF levels rose from 1.24 (p> 0.05) to 1.27 and became significant at the 5 % level. However, 
the associations between the haemostatic factors and progression of peripheral arterial disease 
after adjustment for smoking were only marginally altered.
Further adjustment for the other cardiovascular risk factors on the risk of vascular intervention 
and severe chronic leg ischaemia associated with the haemostatic factors in the multiple 
logistic regression models is shown in Table 5.24. In comparison with adjustment for smoking
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only, the magnitude of each of the risk estimates in the vascular inteivention group, with the 
exception of fibrinogen increased slightly. None reached statistical significance, however.
In those with severe chronic leg ischaemia, adjusting for all cardiovascular risk factors 
increased the magnitude of risk associated with fibrinogen and this became statistically 
significant (RR 1.35, 95% Cl 1.02,1.79 p< 0.05). Further analysis showed that this effect 
probably reflected the negative age and sex adjusted correlations between fibrinogen and 
cholesterol (r=-0.1) and between fibrinogen and glucose (r=-0.05) (data not shown).
The influence of the other haemostatic factors on the relationships between each haemostatic 
factor and peripheral arterial disease progression was also estimated in the logistic regression 
models. No real effect was noted on the risk of vascular intervention on inclusion of all the 
factors, although the relative risk of intervention for each haemostatic factor was reduced 
marginally (Table 5.25). Similarly, inclusion of the haemostatic factors into the model had 
little impact on the magnitude of risk of severe chronic leg ischaemia. This resulted in a 
reduction of relative risk for all factors other than vWF. The relative risk for vWF rose 
slightly reflecting the negative correlation with fibrin D-dimer (r=-0.1) and the significance 
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5.6 Summary of Results
1. Six hundred and seven patients (389 men and 218 women) with intennittent 
claudication were recruited into the study, and followed up prospectively over a six 
year period.
2. Two hundred and ten patients died during follow-up, with a higher mortality rate in 
men than in women. Mortality was primarily due to vascular disease in both sexes.
3. Fifty six patients developed angina pectoris, 93 patients had a non-fatal myocardial 
infarction, and 61 patients had a non-fatal stroke during follow-up. Forty five patients 
underwent vascular intei'vention for possible progression of peripheral arterial disease, 
and 64 patients developed clinically confirmed symptoms of severe chronic leg 
ischaemia (rest pain, ulceration and gangrene). Two hundred and three patients had 
no incident cardiovascular or cerebrovascular events, or deterioration of limb 
ischaemia.
4. Baseline median levels of plasma fibrinogen, fibrin D-dimer and von Willebrand 
Factor were significantly higher in patients who subsequently died from ischaemic 
heart disease. Tssue plasminogen activator was significantly elevated in patients who 
developed a stroke, compared to those who had no vascular events during follow-up.
5. In multivariate analysis adjusting for age, sex, cigarette smoking, random blood 
glucose, systolic blood pressure and baseline evidence of ischaemic heart disease, all
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the relationships between haemostatic factors and future events became weaker and 
were no longer statistically significant.
6. There were no significant differences in the baseline levels of haemostatic factors 
between patients who underwent a vascular intervention due to deterioration of 
peripheral arterial disease, in comparison to the group of patients who experienced no 
deterioration of limb ischaemia. von Willbrand Factor levels were significantly raised 
in patients who subsequently developed severe chronic leg ischaemia.
7. When life-time smoking was taken into account, plasma fibrinogen became 
significantly associated with the risk of vascular intervention and von Willebrand 




In this chapter, the limitations of the methods employed in each study are evaluated separately, 
The principal results of each study are also discussed separately and the findings from other 
comparable studies in peripheral arterial disease, ischaemic heart disease and stroke are 
described. Finally, there is a brief discussion on the potential for using plasma fibrinogen and 
fibrin D-dimer as routine measures in clinical practice.
6.1 Sites of Atheroma Study: Methods
The Sites of Atheroma Study consisted essentially of a consecutive series of patients with a 
concomitant cross-sectional design. This study design has several inherent limitations. Its 
main disadvantage is that, because potential aetiological factors and disease are assessed at one 
point in time, it cannot usually distinguish between whether the factor preceded the disease in 
question, or whether levels were altered as a result of development of the disease. Hence, 
cross-sectional studies can provide information on associations between disease and other 
factors, but the direction of any causal relationship may be difficult to interpret. Cross- 
sectional studies are also susceptible to bias, defined in this context as any systematic error in 
design or analysis that results in incorrect estimates of risk factor associations with disease. 
In this study, potential major sources of bias might have arisen in the representativeness of the 
study sample in the measurement of disease using angiography, to score the site and severity 
of atherosclerosis, in the classification of patients and in the measurement of aetiological
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factors. Each of these sources are discussed briefly.
6.1.1 Representativeness of study sample
It is important to ascertain whether the study sample was representative of subjects referred 
from the defined population of interest for angiography because of symptoms of peripheral 
arterial disease. If not, the severity and distribution of peripheral arterial disease, and the 
occurrence of possible aetiological factors in the subjects would not reflect those of the defined 
population. Since the subjects were all referred to the Royal infirmary of Edinburgh, which 
provides the only vascular service for the population resident in the Lothian and Borders 
Health Board areas, it is probable that these subjects were reasonably representative of patients 
referred from that defined population. Very few, if any patients would have been referred 
from elsewhere in Scotland.
In addition to referral bias, representativeness might have been affected if the characteristics 
of those who participated were different from those who were eligible but did not take part in 
the study. Although the study population was a consecutive series of patients, a few would 
not have been picked up because of cancellation. Only three subjects refused to participate in 
the study at the time of recmitment, and a blood sample could not be obtained from two 
patients who had agreed to participate. A further six subjects were subsequently excluded 
from the study because their case notes could not be traced and two subjects were also 
excluded because they showed no evidence of atherosclerotic disease on angiography. Out of 
a total of 205 subjects who were eligible to take part in the study, 13 subjects (6.3%) were 
therefore excluded. Although bias was possible, it was unlikely to be strong enough to affect
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associations between exposure and disease, given the low percentage of non-participation.
6.1.2 Limitations of angiography
Angiography has traditionally been considered as the 'gold standard' for the measurement of 
atherosclerosis in the lower limb, but the technique has limitations. A main source of error in 
angiography is derived from the subjective interpretation of the X-ray images, particularly in 
the identification of what constitutes a 'normal' reference artery and in estimating a percentage 
stenosis (Thiele and Strandness 1983). These problems were demonstrated in one study 
investigating variability between 11 observers in the interpretation of angiographic images of 
21 patients with intermittent claudication. Agreement on the degree of atherosclerosis was 
poor for the aorta, iliac arteries and origin of the profunda femoris artery. Reasonable 
agreement was found only in the detection of occlusion in the superficial femoral artery 
(Bruins Slot et al 1981).
In this study, only single plane views were available and this may have led to errors in 
estimating the true extent of disease. For example, atheroma at the origin of the profunda 
femoris and in the iliac vessels (where atheroma tends to develop eccentrically) can be under­
estimated unless projections in more than one plane are assessed (Strandness and Stabler 1966; 
Lea Thomas and Andress 1972; McDonald et al 1976). Angiography is also known to over­
estimate occlusion length and fail to adequately opacify areas both distal and proximal to 
occlusion (Cossman et al 1989). An additional problem was the variable length of the 
abdominal aorta shown for each patient, which made it difficult to standardise disease in this 
segment. Overall, however, the technical quality of the angiograms produced by the hospital
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was typical and adequate for the puqDOses of the research. Nevertheless, 21 patients had 
incomplete results, which was usually attributable to inadequate film contrast in one or more 
of their X-rays.
One of the main difficulties in the interpretation of the angiograms was in estimating the 
percentage stenosis. This is dependent on identifying a normal part of the segment as a 
reference point to estimate the degree of narrowing but in severely diseased segments, it was 
difficult to locate any part which was not atherosclerotic. Standardising the width and length 
of an artery is not possible because of anatomical variation in these parameters. Another 
difficulty lay in grading the abdominal aorta and the iliac vessels when they showed dilatation. 
Such changes are associated with atherosclerotic disease, but were difficult to quantify as the 
lumen diameter is increased relative to normal.
In this study, patients with symptomatic peripheral arterial disease could not be easily 
classified by a predominant site of disease because of the diffuse distribution of atherosclerosis 
within their lower limb arteries. Only five patients had a single focal lesion within the arterial 
segments. The majority had lesions which were multi-segmental and ranged in severity from 
intimai plaques to total occlusion. Moreover, as angiography can only provide morphological 
information and not infoimation about pressure and flow changes caused by narrowing of the 
lumen, the site of the lesion responsible for production of symptoms could not be identified.
6.13 The Bollinger scoring system
When reading and coding the angiograms, the author became aware that the Bollinger coding
199
system underestimated the volume of disease, especially if the surface area was extensively 
diseased. The system was devised to primarily measure the degree of luminal narrowing 
(severity of disease) and weights the importance of lesions so that the additive score for 
plaques and stenoses do not reach that of an occlusion. According to the system's rules, when 
one occlusion is present within a segment, other occlusions and stenoses are not coded. When 
stenoses which both narrow the lumen by more than 50% and between 25-50% are present, 
plaques are not coded. As a result, the volume of atherosclerosis was not fully quantified in 
each patient. This underestimation may have been consistent across the study sample, but was 
more likely to have been greater in those with femoro-popliteal disease, given the relatively 
longer length and hence greater surface area of these segments. Hence, it could have led to 
inaccuracies in classifying by site.
6.1.4 Classification of patients
The Bollinger scoring system was used to classify patients by site of disease to permit a more 
objective comparison between both the extent and severity of disease between the aorto-iliac 
and femoro-popliteal segments. In categorising patients by site, firstly occlusions and 
secondly at least one stenosis narrowing the diameter of the lumen by more than 25% were 
used. The latter criterion was considered as indicative of atherosclerotic changes greater than 
those which would be typically be present in a normal population of comparable age. This 
method of classification had the advantage of being relatively simple to apply and would 
appear to have been reasonable, in that the proportion of patients identified by each site was 
roughly that expected in clinical practice. Also, the distribution of additive scores between the 
groups of segments accorded with the selection into predominate site of disease.
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However, it should be recognised that such criteria were chosen simply because of their face 
validity; different methods of classification might have led to different results. For example, 
in another angiographic study of 67 patients with a similar mean age and with rest pain or 
intermittent claudication, the criteria used were occlusions and a critical stenosis (i.e. greater 
than 50% narrowing of the lumen diameter). Only 11% of these subjects were classified as 
having aorto-iliac disease compared to 18% in the present study, although a similar percentage 
(42%) as in the present study were classified as having femoro-popliteal disease. Only 16% 
in comparison to 38% in the present study were classified as dual-site, but this difference may 
be partly explained by the presence of a fourth group which were described as simply having 
'generalised disease' (i.e. no occlusions or critical stenoses) and were not grouped by a 
particular site of disease (Aston et al 1992).
6.1.5 Measurement of aetiological factors
There was potential bias in the collection of data on some aetiological factors reported by the 
participants, because the information provided by the subjects occurred after the onset of 
peripheral arterial disease. For example, as the subjects were all claudicants, it is likely that 
they were advised to stop smoking on diagnosis, and would certainly have been advised to stop 
smoking just prior to being admitted to hospital for angiography. This could have caused an 
underestimation in the reporting of current cigarette consumption. However, such biased 
recall would probably have caused a reduction in the exposure effect and would not detract 
from any positive findings between smoking and peripheral arterial disease in the study.
Most of the haemostatic factors measured in the study show considerable inter- and intra­
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individual variability. A single measurement of each factor may therefore have led to 
misclassification of the usual haemostatic levels of an individual and could bias the relative 
risks associated with vascular disease. The components of variability in levels of clotting 
fibrinogen were determined in one study of healthy volunteers, based on measurements made 
during one day, over five days and six weeks (Rosenson et al 1994). Laboratory error 
accounted for 10.7% of the variability when repeat measures were made on the same day. The 
intra-individual coefficient of variation increased from 14.2% over the five day period to 
17.8% at six weeks, which was equivalent to only 68% of the subjects being correctly 
classified from one fibrinogen measurement. It was concluded that four repeat measurements 
over several weeks are required to accurately determine the 'true' fibrinogen level in an 
individual.
6,2 Sites of Atheroma Study: Results
6.2.1 Angiographic disease in study sample
The arterial segments demonstrated marked differences in the prevalence of occlusion. The 
most common occlusion site was the superficial femoral artery which has also been reported 
in other angiographic studies of patients with intermittent claudication (Mavor 1956; 
Haimovici 1967; Walden et al 1985; Bergqvist and Karacagil 1994). Distal to the superficial 
femoral artery, the popliteal artery also showed a high prevalence of occlusion, whereas 
occlusive disease was far less common in the more proximal iliac vessels. The severity of 
occlusion also varied between the arteries. Although the iliac vessels were occluded less 
frequently than the femoro-popliteal arteries (with the exception of the profunda femoris
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arteries), the length of the occlusion in the iliacs was more likely to be greater than half the 
segment. Given the relatively short length of the iliac segments, it is not clear whether this 
indicates that the rate of propagation of occlusion is comparable throughout the lower limb 
arteries or whether the progression of atherosclerosis is perhaps more extensive in the iliac 
arteries.
The reasons why atherosclerosis only occurs at certain sites in the lower limb arteries are 
unknown. It is possible that mechanical and haemodynamic factors may contribute to the 
localisation of disease by affecting endothelial biology (Mavor 1956; Nerem et al 1993). In 
vitro studies have shown that the endothelium is capable of altering both its structure and 
function in response to high shear stresses, resulting in the release of vasoactive substances and 
inflammatory mediators that have been associated with the occurrence of atherosclerosis 
(Nerem 1993).
6.2.2 Cardiovascular risk factors and site of peripheral arterial disease
In this study, the levels of the three main cardiovascular risk factors (blood pressure, serum 
lipids and cigarette smoking) varied in patients, depending on the main site of peripheral 
atherosclerosis. Although the differences were not statistically significant, this may have been 
due to the small numbers of subjects, particularly in the aorto-iliac group.
The patients with aorto-iliac disease were on average younger, and more likely to be female 
and to be current smokers compared to those in the other two groups. In contrast, duration of 
smoking and higher levels of total cholesterol were perhaps more important in those who
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developed femoro-popliteal disease. On the other hand, patients with dual-site disease had the 
highest levels of systolic blood pressure and the lowest levels of HDL cholesterol of any 
group. In addition, they were more likely to have a history of ischaemic heart disease, stroke 
and diabetes mellitus, suggesting a higher degree of generalised atherosclerosis.
Although some differences across the three groups could have been due to variation in the 
overall severity of atherosclerosis, adjusting for history of ischaemic heart disease and for the 
number of occlusions had little effect on the absolute levels of risk factors (data not shown). 
It is therefore conceivable that different combinations or single risk factors may be selective 
in the initiation and/or progression of peripheral atherosclerosis.
Cigarette smoking
In the present study, current cigarette smoking was more strongly associated with aorto-iliac 
disease and life-time consumption (packyears) with femoro-popliteal disease. Any such 
differences are difficult to interpret particularly as the amount and presence of current smoking 
is correlated with life-time consumption. One possible explanation is that patients with 
femoro-popliteal disease had more severe symptoms and were more likely to give up smoking. 
Alternatively, differences in smoking variables more strongly related to disease may have 
occurred by chance. There is, however, good evidence that the site of disease within the 
cardiovascular system is influenced by smoking. In one population survey, the Edinburgh 
Artery Study, cigarette smoking was found to be more strongly related to the risk of peripheral 
arterial disease than to ischaemic heart disease, independently of the severity of underlying 
atherosclerosis (Fowkes et al 1992).
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The association between cigarette smoking and particularly aorto-iliac disease has been well- 
documented in other clinical and autopsy studies. It has consistently been shown that the 
severity of aortic atherosclerosis increases both with the number of cigarettes smoked and the 
duration of smoking. In addition, the angiographic studies have reported that smoking appears 
more strongly associated with aortic and iliac atherosclerosis than with disease in the femoral 
vessels (Sackett et al 1968; Weiss 1972; Lawton 1973; Strong and Richards 1976). However, 
most of this early research had methodological limitations in that it did not allow for the 
possible confounding effects of other risk factors, nor did it adjust for underlying severity of 
disease. It also relied solely on self-reported cigarette smoking which is known to under­
estimate true levels of consumption. In this present study, for example, about 10% of self- 
declared non-smokers were found to be probable smokers, based on cut-off points for serum 
cotinine and thiocyanate (Woodward and Tunstall-Pedoe 1992).
Why the aorta might be particularly vulnerable to the effects of cigarette smoking, or indeed 
why the peripheral arteries may be more susceptible than the coronary arteries is unknown. 
Reasons may be related to differences in wall composition or haemodynamics at certain sites, 
differential responses to the toxic smoke constituents or because of interactions with other risk 
factors (Allen et al 1988; Fowkes 1989).
Blood Pressure
In the present study, raised systolic blood pressure appeared to be more strongly related to 
diffuse (but less severe) disease within the lower limb arteries and a raised diastolic pressure 
was associated more with disease in the aorto-iliac vessels. However, any relationships shown
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between blood pressure and site of disease should be inteipreted with caution. Blood pressure 
may rise as a consequence of peripheral arterial disease through increases in peripheral 
vascular resistance, or because of a decrease in aortic compliance (Levenson et al 1982). 
Furtheimore, the levels of blood pressure in the study are likely to be an underestimate of the 
true values because approximately 15% of all patients were receiving anti-hypertensive 
medication. Although considered to be a relatively weak risk factor for the development of 
intermittent claudication (Schroll 1982; Schurtleff 1983; Davey-Smith et al 1990), elevated 
systolic pressure is a recognised risk factor for ischaemic heart disease and is one of the 
primary risk factors for ischaemic stroke (Kannel et al 1970). It is also associated with the 
development of carotid intimal-medial thickness (Mowbray et al 1997). Blood pressure 
therefore does appear to have an effect on the site of atherosclerosis. However, there is, at 
present, no other published data relating either systolic or diastolic blood pressure to a 
particular site of lower limb atherosclerosis, and thus the results of the present study must be 
interpreted with caution and cannot be corraborated.
Blood lipids
There is little conclusive evidence on the relationship between semm lipids and site of disease. 
Previous reports have suggested that patients with coronary and peripheral atherosclerosis 
differ in the pattern of lipoprotein and apolipoprotein abnormalities (Greenhalgh et al 1971; 
Rajput-Williams et al 1988; Fowkes et al 1992; Leng and Fowkes 1992). Whereas elevated 
LDL cholesterol has been particularly strongly associated with disease in the coronary arteries, 
hypertriglyceridaemia is considered to be relatively more pathogenic for peripheral 
atherosclerosis (Greenhalgh et al 1971; Leng and Fowkes 1991), although this may only be
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applicable for severe disease (Fowkes et al 1992). Also, in most studies, the regression models 
do not take into account the high degree of correlation between the lipoprotein fractions and 
triglyceride levels. However, variation in levels of apolipoproteins by site have also been 
noted, including relatively high levels of apolipoprotein B in ischaemic heart disease and 
peripheral arterial disease (Rajput-Williams et al 1988; Powell et al 1997), and elevated levels 
of apolipoprotein C III in patients with early carotid artery disease (Wiseman et al 1991).
In most of these studies investigating cardiovascular risk factors and site of disease, non- 
invasive techniques have been used to assess the severity of peripheral arterial disease which 
detect perfusion effects rather than the degree or site of stenoses within individual arteries. 
The number of studies which have used angiography to evaluate the precise anatomical 
location of lesions and thus able to make valid comparisons of the risk factors which might be 
associated with a particular site of disease are limited. Also, the differences in the risk factor 
profiles in these patients with different sites of peripheral atherosclerosis does not necessarily 
mean that the levels of the factors precede or are causally related to a site of disease, but may 
occur as a consequence of disease or from associations with other factors. The possibility of 
confounding by factors which were not measured in the study, such as serum triglycerides, 
obesity, alcohol consumption, menopausal status and insulin resistance should also be 
considered.
6.23 Fibrinogen, fibrin D-dimer and disease
The main objective of the study was to determine the relationships between the haemostatic 
factors, particularly fibrinogen and fibrin D-dimer, with severity of disease within the femoro- 
popliteal and the aorto-iliac arteries. Disease severity was estimated by a quantitative variable
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(the additive score) which enabled examination of linear relationships between the variables 
and hence permitted more power to detect significant associations.
Plasma fibrinogen (measured by nephelometry), von Willebrand Factor and fibrin D-dimer 
were more strongly related to the severity of disease in the femoro-popliteal than in the aorto- 
iliac segments. On multivariate analysis, both nephelometric fibrinogen and fibrin D-dimer 
remained independently related to disease. However, it is possible that these findings could 
be related to differing severities of disease between the segments because the mean additive 
score was significantly higher for the femoro-popliteal than aorto-iliac arteries.
The results imply that elevated fibrinogen, endothelial disturbance and fibrin turnover may 
contribute to the extent of atherosclerosis at different sites within the lower limb arteries. 
Alternatively, these findings may partly reflect an inflammatory response to the presence of 
atheroma (Stuart et al 1981) or to the extent of endothelial damage, rather than contributing 
to the development of atherosclerosis.
In a previous study, Lassila et al (1993) reported a strong correlation between fibrinogen (both 
clotting and nephelometric) and functional severity of peripheral atherosclerosis. In 
accordance with the findings in the present study, Woodburn et al (1995) found that there was 
no relationship between clotting fibrinogen and the angiographic extent of peripheral arterial 
disease. However, nephelometric fibrinogen was not measured in that study and 
nephelometric fibrinogen has been shown to have a stronger relationship with arterial disease 
than either clotting fibrinogen or fibrin D-dimer (Smith et al 1993; Sweetnam et al 1998). A 
level of nephelometric fibrinogen above 6.1g/L has recently been implicated in the
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development of symptomatic peripheral arterial disease in smokers (Powell et al 1997). 
Fibrinogen has also been found to be independently associated with mortality, primarily from 
ischaemic heart disease in claudicants (Baneqee et al 1992). As coronary death is known to 
be mediated by thrombosis, following the rupture of an atherosclerotic plaque (Fuster et al 
1990), it is therefore noteworthy that the femoro-popliteal segments were characterised by a 
far higher prevalence of occlusion than in the other segments.
This study was the first to examine variation in the levels of several haemostatic factors at 
different sites of peripheral atheroclerosis in patients with severe limb ischaemia. The results 
show that there were no significant differences in the mean levels of the haemostatic factors 
among patients with disease affecting the femoro-popliteal arteries, aorto-iliac arteries or with 
dual-site disease. However, relatively small numbers in each of these sub-groups may have 
affected the power to detect significant differences. Furthermore, the three groups were not 
differentiated exclusively by site because of the diffuse distribution of atherosclerosis in the 
lower limb. Differences in the levels of factors across the three groups were, with the 
exception of von Willebrand Factor, quite small and thus probably not of biological 
significance.
The levels of fibrinogen measured by heat precipitation were more than Ig/L higher than 
clotting fibrinogen levels across all three groups, which is comparable to findings in other 
studies of peripheral arterial disease (Baker et al 1982; Smith et al 1993). However, the 
difference was greatest in those with dual-site disease which was characterised by a lesser 
prevalence of occlusion. It is therefore conceivable that a relatively higher percentage (or 
ratio) of nephelometric fibrinogen to clotting fibrinogen may predispose individuals to more
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extensive but less severe peripheral atherosclerosis. Alternatively, the characteristics of 
lesions, such as their composition or compliance may be altered making them less likely to 
occlude.
6.2.4 Smoking, fibrinogen, fibrin D-dimer and disease
Adjustment for either life-time or current smoking had no real effect on the relationship 
between fibrinogen and femoro-popliteal disease, whereas life-time smoking appeared to 
partly explain the association between fibrin D-dimer and severity of disease in these 
segments. This is in accordance with results from an earlier case-control study in which 
smoking appeared to influence peripheral arterial disease more through fibrinolytic disturbance 
and fibrin formation and breakdown than through a direct effect on fibrinogen levels (Smith 
et al 1993). One reason for the lack of an association between fibrinogen and smoking in 
severe peripheral arterial disease may be that interactions between the two variables may be 
stronger at an earlier stage of disease.
Nevertheless, increasing fibrinogen levels have been associated with a greater reduction in the 
ABPI in smokers than in non-smokers (Lowe et al 1993) and the magnitude of the relative risk 
of inteimittent claudication appears to be related to an interaction between cigarette smoking 
and fibrinogen levels (Fowkes et al 1996). This effect may be due to smoking-induced 
endothelial damage causing a greater infiltration of fibrinogen through the arterial wall, or 
through an interaction between smoking and genotype which may influence the functional and 
structural characteristics of fibrinogen (Humphries 1995). Such changes may be related to the 
foimation of an abnormal fibrin gel consisting of long, densely packed fibrin strands which
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are resistant to lysis and may contribute to thrombogenesis (Curran et al 1995).
There are conflicting reports on the relationship between fibrin D-dimer, smoking and 
peripheral arterial disease. In one large case-control study of hospital claudicants who also 
attended the Royal Infirmary of Edinburgh, and with comparable mean ABPI and smoking 
consumption to this study, life-time smoking appeared to have little effect on the association 
between fibrin D-dimer and the risk of claudication (Lee et al 1996). The Edinburgh Artery 
Study also found that fibrin D-dimer was independently related to the risk of intermittent 
claudication, after adjustment for a range of risk factors, including packyears, although the 
number of claudicants was low (n=45) (Lee et al 1995).
The association of fibrin D-dimer with severity of peripheral arterial disease, using the 
continuous variable ABPI was reduced to non-significance in women (but not men) on 
multiple adjustment in this study. Among men, the relationship between fibrin D-dimer and 
the ABPI was strongly related to the amount of smoking consumption, especially in those who 
had a packyear level of 25 or more (Lee et al 1995). Conversely, a previous study found no 
correlation between cigarette smoking and fibrin D-dimer among claudicants, but no details 
were given on either smoking status or current levels of smoking consumption (Al-Zahrani et 
al 1992).
Fibrin D-dimer was the strongest predictor (among several haemostatic factors) of 
symptomatic peripheral arterial disease in the only other study which has used the Bollinger 
scoring system to quantify the extent of peripheral atherosclerosis and the inter-relationship 
with haemostatic factors and cigarette smoking (Woodburn et al 1995). The results were,
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however, not directly comparable with the present study because cigarette smoking was 
included in the regression model only as smoking status (classified as current, ex- or non­
smoking), and life-time smoking consumption was not considered. Furthermore, the inclusion 
of patients with previous revascularisation surgery or leg amputation may not have given a true 
reflection of the current severity of atherosclerosis within the study sample.
The elevated fibrin D-dimer levels shown in this study may thus reflect increased turnover of 
fibrin in advanced peripheral arterial disease, which may occur in response to thrombus 
formation. However why cigarette smoking should be more strongly associated with fibrin 
formation and breakdown rather than fibrinogen is not clear. It is possible that high levels of 
thrombin (or suppression of thrombin inhibitors) resulting from chronic smoking-induced 
endothelial damage could be responsible for extensive generation of fibrin which implies 
activation of coagulation and generation of thrombin (Lowe et al 1993).
6.2.5 Smoking, other haemostatic factors and disease
The interaction between cigarette smoking and vWF has been investigated in several studies 
(Blann and McCollum 1993; Conlan et al 1993). von Willebrand Factor levels are used as an 
indication of endothelial damage and are raised in current smokers compared to non-smokers, 
and in subjects with peripheral arterial disease (Blann and McCollum 1992; Smith et al 1993). 
It has been suggested that smoking may be responsible for a major part of endothelial 
dysfunction in peripheral arterial disease (Smith et al 1993). However, the univariate 
association of vWF with disease severity found in the present study was not sustained on 
multivariate analysis and hence may simply reflect the presence of other confounding factors,
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such as hypertension or the extent of endothelial dysfunction, rather than the promotion of 
atherosclerosis.
The inverse relationship found between PAI activity and severity of disease was surprising. 
Elevated PAI activity has been consistently demonstrated in peripheral arterial disease (Smith 
et al 1993; Cortellaro et al 1994) and is also predictive of thrombotic cardiovascular events in 
claudicants (Cortellaro et al 1994). In the present study, PAI activity decreased with disease 
severity in men, whereas women showed a positive correlation. Since there was no difference 
in severity of disease between the sexes, this conflicting relationship may have been due to the 
significantly higher packyears in the men.
Higher thrombin levels in men resulting from a greater degree of endothelial damage may be 
responsible for the inverse association obseived between PAI activity and disease. When 
fibrin is present, the release of t-PA (which converts plasminogen to plasmin) and PAI (the 
specific inhibitor of t-PA) are triggered from the endothelium (Wojta et al 1993), or from 
platelets (Sprengers and Kluft 1987). A high (possibly threshold) level of thrombin may 
stimulate an additional release of t-PA which complexes rapidly with PAI, thus effectively 
depleting systemic PAI activity.
Alternatively, PAI activity may be directly inactivated by thrombin through proteolysis or 
indirectly through thrombin-mediated protein C inhibition (Van Hinsbergh et al 1987). 
Although the degree of endothelial damage may be greater, a relative increase would result in 
men, such that the severity of disease would not be appreciably different between the sexes. 
It is also possible, however, that there may be sex differences in the relationship between PAI
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and peripheral arterial disease which are unrelated to smoking, but due to associations with 
other risk factors, for example, semm triglycerides, obesity and insulin levels (Juhan-Vague 
and Alessi 1993).
63  Prognostic Study of Intermittent Claudication: Methods
In a prospective cohort study, there may often be several sources of bias. These may include 
selection bias and losses to follow-up leading to a non-representative study sample, and 
problems in the assessment of the prognostic variables due to measurement variability and 
changes in exposure during the period of follow-up. In this study, the measurement of 
outcome was not considered to be a major problem because of the detailed verification from 
the case records and other sources.
63.1 Representativeness of study sample
The patients were similar to those who composed the study sample in the Sites of Atheroma 
Study, in that they had all been consecutive referrals to the Royal Infirmary of Edinburgh 
which provides the only vascular service within the Lothian Health Board area. These subjects 
could be considered representative of the defined population with respect to moderate to severe 
inteimittent claudication, but not sufficiently severe to warrant vascular inteivention. Since 
many of those with minor symptoms of claudication are unlikely to attend a vascular clinic, 
the study results would not be generalisable to all claudicants in the general population.
There is some evidence that responders participating in epidemiological studies may differ
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from non-responders in ways related to health and risk factor status (Hennekens and Buring 
1987). In a cohort study, if non-response is related to risk factors or prognostic factors 
associated with outcome, then it is possible that bias is introduced. In this study, 742 subjects 
were initially identified as eligible to participate and 49 of these refused to take part. 
However, since the non-responders were not followed up to determine either incidence of 
disease or their prognostic factor status, some degree of bias in the association between 
prognostic factors and outcome cannot be excluded.
Out of the total of 647 eligible study participants, 30 (4.6%) were not included in the final 
analysis because their medical records, although available at the inception of the cohort at 
baseline were not available at the time of follow-up. In most of these cases, the medical 
records had been destroyed because the patient had not attended the particular hospital within 
a designated period of time for treatment. The reasons for non-attendance were unknown. It 
could be that these losses to follow-up developed less disease than those who participated, or 
became too ill to attend, or had migrated out of the study area. Tire proportion lost to follow- 
up was so low, however, that any bias would have had a minimal effect on the results of the 
study.
63.2 Measurement of prognostic factors
Another source of potential bias is error in the classification of subjects by prognostic factor 
and disease status, either at baseline or during the follow-up period. For example, as 
previously discussed, self-reported cigarette smoking by questionnaire may have under­
estimated the true levels of smoking in the study sample, particularly as biochemical markers
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for smoking (semm cotinine and thiocyanate) were not measured in the present study to verify 
current smoking status. By using multiple sources to obtain information on disease during 
follow-up, however, the possibility of misclassification of disease status during follow-up was 
minimised.
The extent to which cardiovascular risk factors change during follow-up and influence the 
relationship with peripheral arterial disease has recently been assessed in one prospective 
cohort study of males aged 55 years (Ogren et al 1996). Twenty seven per cent of men had 
stopped smoking; 40% of men developed hypertension; and more than 50% had higher 
cholesterol levels when re-examined at 68 years of age. Furthermore, increased mortality, and 
hence loss to follow-up in those at high risk, was thought to bias the associations between the 
risk factors and peripheral arterial disease at follow-up. In respect to the present study, the 
change in exposure to smoking was assessed by examining the questionnaires of surviving 
patients returned during 1996. Out of a total of 225 questionnaires, 30 (13%) of patients had 
stopped smoking, whereas 16 (7%) patients had restarted smoking during the six years since 
baseline. However, since only about 50% of the 1996 questionnaires were returned, it was not 
possible to determine the true extent to which smoking behaviour had changed in the study 
sample after six years. Furthermore, since only one classification of exposure was made for 
each subject at baseline, the analysis could not take into account the total length of exposure 
and changes in exposure which may have occurred.
6 3 3  Variability in haemostatic factors
Another difficulty in the measurement of prognostic factors is the variability in haemostatic
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factors, as previously discussed, Bashir et al (1997) examined the effects of correcting for 
measurement error in several haemostatic factors (t-PA, PAI, vWF and factor VII) on the risk 
of transient ischaemic attack and minor stroke. This was based on one preliminary 
measurement and a second measurement was then taken one year later for each factor. Errors 
related to laboratory measurement were found to be relatively low, ranging between 4% and 
7%. However, the temporal variation in the factor levels over one year was substantial, 
particularly for PAI (41%) and vWF (30%). Similarly, inter-individual variation was very 
high. When the risk estimates were corrected for misclassification due to the differences in 
factor levels changing over one year, the odds of stroke for a standard deviation or one unit 
change in vWF increased from 1.88 to 3.56 and a slight increase occurred in the odds ratios 
of the other three factors. One large cohort study, the ARIC Study, has also demonstrated 
increased relative risks for coronary heart disease when haemostatic factor levels were 
corrected for measurement error (Folsom et al 1997).
The above findings indicate that some degree of misclassification will probably occur in any 
study relating one estimation of haemostatic factor levels to disease. The associations found 
in the previous study are unlikely to be erroneous, but since the effect of variability is to mask 
associations between haemostatic factors and disease, it is possible that there may be real 
associations which are not revealed. Furthermore, the long term predictive power of these 
factors may become weaker because regression dilution bias, which tends to underestimate the 
magnitude of the tme association, will be greater over a longer period of time.
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6.4 Prognostic Study of Intermittent Claudication; Results
6.4.1 Incidence of cardiovascular and cerebrovascular events in claudicants
Patients with intermittent claudication have a high risk of death, not from deterioration of limb 
ischaemia, but from premature ischaemic heart disease and stroke (Reunanen et al 1982; 
Dormandy et al 1989; Criqui et al 1992). In previous studies, the cumulative five year 
mortality rate in men with intermittent claudication has been estimated at approximately 15% 
(Reunanen et al 1982), and claudicants at the time of presentation are three times more likely 
to die than the general population after ten years (Kallero 1981). Between 50%-60% of deaths 
of those with symptomatic peripheral arterial disease have been reported to be due to 
ischaemic heart disease, whereas the proportion of cases dying of cerebrovascular disease is 
approximately 10%-15%. Ten per cent of patients will die from causes related to visceral 
ischaemia or rupture of an abdominal aortic aneurysm (Dormandy et al 1989). The remainder 
die from non cardiovascular causes, primarily smoking-related cancer and respiratory disease. 
Identification of risk factors which can predict subsequent events in this high risk group of 
patients is therefore potentially important from the perspective of clinical intervention.
In the present study, the overall mortality was 34.6% after six years of follow-up. This finding 
is in keeping with the majority of studies of hospital patients with claudication with a similar 
period of follow-up, regardless of differences in patient selection in respect to age, severity of 
disease and stage of presentation (Dormandy et al 1989). Cause of mortality, primarily from 
ischaemic heart disease and stroke, was also in agreement with other studies of hospital 
claudicants where comparisons were made with non-claudicant controls (Kallero 1981;
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Dormandy et al 1989). Analysis of cause of death showed that 30.5% of the claudicants died 
from a myocardial infarction in the present study, which is comparable to results from the 
recent Prevention of Atherosclerotic Complications by Ketanserin (PACK) study, in which 
36% died from a myocardial infarction (Dormandy and Murray 1991). However, this latter 
study reported twice as many deaths due to stroke than the present study (28% compared to 
13.8% respectively).
The all cause mortality rate was significantly higher in males than in females in the present 
study. More specifically, the death rate from ischaemic heart disease, especially myocardial 
infarction, was greater in males compared to females, but there was relatively little difference 
in the incidence of fatal stroke by gender. It is conceivable that the sex differential in mortality 
rates for vascular disease may reflect differences in baseline severity of co-existing coronary 
and cerebrovascular disease between men and women. Alternatively, an increased 
susceptibility to, or higher risk factor prevalence in men, in factors such as cigarette smoking, 
hypertension and hyperlipidaemia may partly contribute to the sex differential in coronary 
mortality (Price and Fowkes 1997).
The high mortality from ischaemic heart disease and stroke in claudicants may be due 
primarily to concomitant disease in the coronary, carotid and cerebral arteries. While between 
30% and 50% of hospital claudicants have ischaemic heart disease diagnosed by ECG, or by 
clinical history, as many as 90% of patients have evidence of heart disease if examined by 
coronary angiography. The percentage of claudicants with a history of cerebrovascular disease 
appears to be lower overall, with a prevalence of between 0.5-52%, but angiography or duplex 
scanning is rarely performed to assess the presence of asymptomatic disease. Thus, the true
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extent of concomitant coronary and cerebrovascular disease in patients with claudication may 
be an underestimation and may account for some of the conflicting results regarding mortality 
when adjustments are made for co-existing vascular disease.
There is comparatively little data on the incidence of non-fatal ischaemic heart disease and 
stroke events in patients with intermittent claudication. Most information is derived from 
population studies in which there are relatively few subjects with claudication. In the 
Northwick Park Study, which followed up 400 claudicants for over five years, 14% of the 
subjects had a non-fatal coronary event (Gilliland et al 1986). The Basle study, based on a 
sample of workers in the pharmaceutical industry, found that 17% of the surviving cases with 
peripheral arterial disease developed angina pectoris, 15.0%, a non-fatal myocardial infarction 
and 12.4%, a cerebrovascular event during 11 years of follow-up (Widmer and Da Silva 1991). 
These results are comparable to the present study, in which 15.3% of subjects suffered a non- 
fatal myocardial infarction, and 10% developed a stroke but the incidence of angina was 
considerably less than the Basle study at 9.2%. These differences may be because of survival 
bias effects in the Basle study or may be related to differences in severity of vascular disease 
and risk factor prevalence at baseline.
In the present study, a male predominance in the incidence of non-fatal myocardial infarction 
was not so apparent, as was the case in fatal infarction. Also, a similar proportion of males and 
females developed angina pectoris, transient ischaemic attack and non-fatal stroke. Since 
males were more prone to a fatal coronary thrombosis than females, those at higher coronary 
risk may have died at an earlier stage of follow-up. Hence selective survival may have led to 
a apparent narrowing of the incidence rate in non-fatal myocardial infarction between the
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sexes.
6,4.2 Fibrinogen and prediction of cardiovascular and cerebrovascular events
Increased mortality is only partly explained by the co-existent ischaemic heart disease 
associated with claudication and adjusting for conventional cardiovascular risk factors has only 
a small effect on risk estimates (Davey Smith et al 1990; Criqui et al 1992; Bainton et al 
1994). This suggests that lifestyle changes and therapeutic interventions to reduce risk factor 
levels will not eliminate the increased risk and that other therapeutic measures are required. 
An oveiYiew of randomised controlled trials has shown that anti-platelet therapy can reduce 
the incidence of cardiovascular events in patients with intermittent claudication (Antiplatelet 
Trialists' Collaboration 1994). This suggests that thrombotic risk factors may be important in 
determining cardiovascular outcome in the later stages of established peripheral arterial 
disease.
Several studies have reported that levels of plasma fibrinogen, t-PA antigen and vWF were 
independent predictors of mortality from ischaemic heart disease in men and women who have 
had a myocardial infarction or who have angina pectoris (Haines et al 1983; Cooper et al 1991; 
Jansson et al 1991; Thompson et al 1995; Benderly et al 1996). However, few have 
investigated the role of fibrinogen and other haemostatic factors in the prediction of ischaemic 
heart disease and stroke in subjects with peripheral arterial disease.
Results from this prospective cohort of men and women showed that levels of fibrinogen, t-PA 
antigen, vWF and fibrin D-dimer were higher in claudicants who subsequently developed an
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ischaemic heart disease or stroke event. Only t-PA antigen levels were significantly higher 
in those who subsequently had a stroke. After adjusting for age and sex, t-PA antigen 
remained significantly associated with increased risk of a future stroke, whereas elevated fibrin 
D-dimer and fibrinogen levels were more strongly associated with a future ischaemic heart 
disease event. All of these relationships became weaker and were no longer statistically 
significant after adjusting for the combined effects of smoking, glucose, systolic blood 
pressure and baseline evidence of ischaemic heart disease.
These results suggest that the associations between the haemostatic factors and adverse 
outcome in symptomatic peripheral arterial disease are partly due to inter-relationships with 
confounding risk factors. However, since the claudicants who experienced ischaemic heart 
disease and stroke events had higher levels of haemostatic factors at baseline than claudicants 
who had no events, the elevations in these factors, regardless of their origin, are likely to be 
of pathological importance and may have contributed to the development of these thrombotic 
events.
In an interim analysis of this study, which was conducted after one year, plasma fibrinogen 
was an independent predictor of death from coronary disease (Fowkes et al 1993). The 
magnitude of this relationship was weaker in the longer teim. Possible explanations for this 
discrepancy could be related to the fact that the early analysis was based on small numbers of 
events (15 fatal and 21 non-fatal coronary events). In addition, in the one year multivariate 
analysis, there was no adjustment for baseline ischaemic heart disease, which may have raised 
the mean level of, for example, fibrinogen among those claudicants who subsequently 
developed a vascular event.
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Only two other studies have so far investigated the relationship between haemostatic function 
and clinical outcome in claudicants. Baneijee et al (1992) studied the association between 
mortality rate and fibrinogen levels in stable claudicants. The authors reported that there was 
a two-fold increase in the odds of dying which was highly significant and associated with an 
increase in fibrinogen of Ig/L, In the present study, fibrinogen was also significantly 
associated with all-cause mortality, but the relative risk was substantially lower, based on a 
standard deviation increase of only 0.21g/L in fibrinogen (data not shown). In contrast, in the 
A.D.E.P. Study, which was a multi-centre trial of patients with claudication assessing the 
effects of an anti-platelet drug (picotamide), the follow-up period was only 18 months, and no 
association was found between fibrinogen and mortality. However, a statistically significant 
relationship was noted between fibrinogen and the risk of cerebrovascular disease (Violi et al 
1994).
Elevated plasma fibrinogen levels have also been shown to be related to incident vascular 
events in those with established heart disease. Several studies have reported that raised levels 
of plasma fibrinogen are an independent predictor of mortality from ischaemic heart disease 
in men and women who have suiwived a myocardial infarction or have prevalent angina 
pectoris (Cooper and Douglas 1991; Thompson et al 1995; Benderly et al 1996), One large 
angiographie study has also provided evidence that fibrinogen may have a stronger association 
with occlusion than with atherogenic changes in the coronary arteries, which implies that high 
fibrinogen levels may contribute to a tendency to thrombogenesis in patients with established 
vascular disease (ECAT Angina Pectoris Study Group 1993).
Chronic inflammation may play an important role in both the initiation and progression of
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atherosclerosis (Ross 1993). An important question is whether raised levels of haemostatic 
factors are due to an inflammatory response to the extent of arterial disease, or are causally 
related to thrombogenesis. In the ECAT study, the correlation obsei-ved between C-reactive 
protein (an acute phase reactant and marker for systemic inflammation), and increasing risk 
of myocardial infarction or sudden death, suggests that inflammation may be involved in the 
clinical outcome of atherosclerosis (Thompson et al 1995). Moreover, as fibrinogen levels 
were also positively associated with C-reactive protein in that study, it is conceivable that 
fibrinogen levels may rise, at least in part, because of inflammatory activity within advanced 
arterial lesions.
All the major prospective studies to date have identified fibrinogen as an independent predictor 
of future ischaemic heart disease or stroke in initially healthy subjects in the general 
population (Wilhelmsen et al 1984; Stone and Thorp 1985; Meade et al 1986; Kannel et al 
1987; Heinrich et al 1994; Sweetnam et al 1996; Folsom et al 1997; Smith et al 1997; 
Woodward et al 1998). Three of these prospective studies have follow-up periods of ten years 
or more, which strengthens the evidence that any reported association between fibrinogen and 
ischaemic heart disease could be causal. In a recent meta-analysis of six of these studies which 
compared the highest tertile of fibrinogen to the lowest tertile, the odds ratio for ischaemic 
heart disease was estimated at 2.3 (95% Cl 1.9-2.8) (Ernst and Resch 1993). The relationship 
between fibrinogen and the risk of ischaemic heart disease appeared to be stronger in younger 
men (Meade et al 1986) and slightly higher in men compared to women (Folsom et al 1997). 
The magnitude of fibrinogen-mediated risk of heart disease also seems to diminish with age 
in women (Kannel et al 1987). However, differences in defining ischaemic heart disease 
events, race, the age and sex structures of the populations and the numbers of subjects may
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account for the varying strength of associations obsei*ved between fibrinogen and heart disease 
in these prospective studies.
In the Gothenborg Study and the Edinburgh Artery Study, both of which recruited 
comparatively older participants, baseline fibrinogen levels were more strongly associated with 
the risk of stroke than with myocardial infarction (Wilhelmsen et al 1984; Smith et al 1997). 
It is possible that these findings may indicate suiwival bias effects. The results are also based 
on relatively few stroke events (37 and 45 respectively) compared to the number of ischaemic 
heart disease events. Data from the Framingham Study have shown that the risk of stroke rises 
progressively in men with fibrinogen levels between 1.3-7.0 g/L. This effect was only 
apparent in men aged between 55-79 years, however and did not occur in either younger men 
or in women of any age (Kannel et al 1987).
Although it is agreed that high fibrinogen levels probably increase the risk of ischaemic stroke, 
its role in haemorrhagic stroke is unclear, but is generally thought not to be implicated in the 
pathophysiology. There are clear difficulties in distinguishing between cases of ischaemic and 
haemorrhagic stroke based on clinical signs, and the use of computed tomography scanning 
is not uniformly performed. Although ischaemic stroke accounts for approximately 80% of 
all strokes (Warlow 1987), the true strength of the association between fibrinogen and 
ischaemic stroke may be greater than obseived in these studies, given that cases of 
haemorrhagic origin may not have been reliably excluded from the stroke categories.
Fibrinogen has also been found to be an independent risk factor for transient ischaemic attack 
and minor ischaemic stroke (Qizilbash et al 1991). In secondary risk prediction, fibrinogen
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predicted a second cardiovascular event within two years in those who survived an ischaemic 
stroke (Resch et al 1992). The observation that fibrinogen levels were elevated in a small 
sample of patients who suffered a transient ischaemic attack and did not subsequently rise 
suggests that fibrinogen may have a causal role in promoting cerebrovascular events (Ernst et 
al 1988). However, these findings have yet to be confirmed.
6.43 Fibrin D-dimer and prediction of cardiovascular and cerebrovascular events
There are few previous reports about the relationship between fibrin D-dimer and prediction 
of vascular events in claudicants (Cortellaro et al 1992; Fowkes 1993) or the incidence of these 
events in the general population (Ridker et al 1994a; Lowe et al 1998). Although in the one 
year interim analysis conducted in the present study, fibrin D-dimer was independently 
associated with the risk of combined fatal and non-fatal coronary events, this was not 
maintained over the longer follow-up period of six years. The Edinburgh Artery Study 
recently demonstrated that fibrin D-dimer was related to the risk of stroke, independently of 
cigarette smoking, systolic blood pressure, LDL cholesterol and baseline ischaemic heart 
disease (Smith et al 1997). In one cross-sectional survey, D-dimer was linked to the extent of 
atherosclerosis within the cerebral arteries (Heinrich et al 1995). Takano et ai (1992) further- 
showed that fibrin D-dimer levels were strongly associated with re-embolisation following 
acute ischaemic stroke. This implies that high fibrin turnover may contribute to a 
prothrombotic state which may be critical for progression of disease within the cerebral 
arteries.
Data has recently been published describing the relationship between fibrin D-dimer and future
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ischaemic heart disease. In the Physicians' Health Study, there was an increased risk of a first 
myocardial infarction across quartiles of fibrin D-dimer, the relative risk being two times 
higher in the top quartile compared to that of men in the bottom quartile (Ridker et al 1994a). 
Similarly, Lowe et al (1998) observed a substantially greater risk of ischaemic heart disease 
in middle-aged men with high fibrin D-dimer levels, which was unrelated to the correlation 
with fibrinogen levels. These results were in contrast to another high-risk population sample, 
the Edinburgh Artery Study, which found that multi-adjustment for cardiovascular risk factors 
and baseline ischaemic heart disease reduced the association between fibrin D-dimer and risk 
of myocardial infarction (but not stroke) to non-significance (Smith et al 1997). This may be 
a reflection of stronger interactions between fibrin D-dimer, pre-existing disease and the 
conventional risk factors in subjects who developed a myocardial infarction than for subjects 
with stroke.
6,4.4 Other haemostatic factors and events and prediction of cardiovascular and 
cerebrovascular events
Tissue plasminogen activator
To date, only one other prospective study has examined possible associations between t-PA 
antigen and the risk of stroke, although the study population was limited to a selected group 
of male physicians (Ridker et al 1994b). In that study, exclusion of haemorrhagic events from 
the multivariate analysis had no substantial effect on the magnitude of relative risk. Increases 
in t-PA antigen levels in both the acute and chronic phases of ischaemic stroke have been 
reported (Lindgren et al 1996) and t-PA antigen has also been found to be a strong
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discriminator of subjects with and without a history of cerebrovascular events (Margaglione 
1994). These findings suggest that abnormal fibrinolytic activity may identify those at risk 
of cerebrovascular events.
A strong long-term association between high levels of t-PA and incidence of ischaemic heart 
disease has been reported in several studies of patients with prevalent coronary disease 
(Jansson et al 1993; Thompson et al 1995). However, Ridker et al (1993) suggested that high 
t-PA may represent a secondary response to the progression of atherosclerosis, because 
adjusting for atherosclerotic risk factors reduced the association of t-PA and myocardial 
infarction (but not stroke) to non-significance. This finding was also confirmed in the most 
recent prospective survey of incident ischaemic heart disease (Lowe et al 1998). The stronger 
relationship obseived between t-PA and stroke than between t-PA and myocardial infarction 
may reflect differences in risk factor associations between the two disease groups. A recent 
case-control study has also provided evidence of an association between t-PA and the risk of 
myocardial infarction, which was markedly reduced by inclusion of cardiovascular risk factors 
in the multivariate analysis. However, a genetic polymorphism of the t-PA was found to be 
independently associated with increased risk of non-fatal myocardial infarction in this study 
(van der Bom 1997).
It is not known which component of the fibrinolytic system is the more important in predicting 
vascular risk. t-PA antigen levels reflect inactive t-PA/PAI complexes rather than free active 
t-PA (Nicoloson et al 1988; Nilsson 1989), and thus raised levels may indicate elevated PAI 
activity and impaired fibrinolytic activity, rather than a dysfunctional endothelium. 
Furthermore, because these two factors are strongly correlated with each other and also with
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lipid and metabolic factors, it is difficult to detenuine their separate effects in epidemiological 
studies.
von Willebrand Factor
The evidence relating vWF to the development of cardiovascular disease is conflicting at 
present. The Edinburgh Artery Study found no relationship between vWF and the risk of 
myocardial infarction or stroke (Smith et al 1997), in contrast to two studies which observed 
that vWF was independently related to the incidence of ischaemic heart disease (Meade et al 
1994; Lowe et al 1998). One large prospective survey, the ARIC Study, reported a strong 
univariate association between vWF and combined myocardial infarction and ischaemic heart 
disease mortality, especially in blacks (Folsom et al 1997). This relationship, however, did 
not persist on multivariate analysis.
Data from clinical studies suggest that there may be a stronger relationship between vWF and 
poor prognosis among patients with established vascular disease than among initially healthy 
individuals. For example, vWF has consistently predicted a secondary acute coronary event 
in patients with either prevalent angina pectoris (Thompson et al 1995) or in those who have 
already experienced a myocardial infarction (Jansson et al 1991). In the Progetto Lombardo 
Atero-Trombosi (PLAT) Study, elevated vWF levels also predicted further clinical events in 
patients with angina pectoris (Cortellaro et al 1992).
Whether the relationship between vWF and co-existing vascular disease represents part of an 
acute phase reaction to injury to the endothelium or is causally related to progression of arterial
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disease is uncertain. vWF is considered to be a marker of endothelial damage and is raised in 
conditions associated with risk factors for atherosclerosis, such as hypertension, 
hypercholesterolaemia, cigarette smoking, obesity and diabetes mellitus. It is also an essential 
co-factor for the development of occlusive thrombi through interactions with platelets at sites 
of vascular injury and at arterial stenoses. As elevated levels of vWF have been associated 
with the development of new vascular events in small cohorts of patients with hyperlipidaemia 
(Blarm et al 1997) and with hypertension (Blann and Waite 1996), damage to the endothelium 
(and resulting thrombus fonnation) may be mechanisms by which high blood pressure and 
lipoprotein levels influence haemostatic function and contribute to atherogenesis or 
thrombogenesis.
In general, the statistical 'independence' observed in population studies, but not found in high 
risk studies, such as this present study, may be due to the choice of covariates included in 
multivariate analysis. On the other hand, there may be stronger interactions between the 
haemostatic factors and cardiovascular risk factors in subjects with peripheral arterial disease 
than in apparently healthy subjects. In addition, what is termed 'disease-based spectrum bias' 
may attenuate the risk estimates in high risk studies, such as in the present study (Miller 1994). 
In contrast to population-based surveys, where the comparison group consists of healthy 
individuals, the comparison group in this study consisted of claudicants who have substantially 
more atherosclerosis than the general population. Thus, the absolute severity of disease 
between the claudicants who develop events and those who do not may be narrower than 
equivalent groups in population surveys. It follows therefore, that the levels of haemostatic 
factors in the claudicants who do not develop subsequent events will probably be higher than 
they would be in an apparently healthy comparison group, and this could effectively lower the
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risk estimates.
6.4.5 Clinical progression of peripheral arterial disease
Studies of intermittent claudication have shown that about 25% of patients referred to a 
peripheral vascular clinic will deteriorate significantly (Dormandy et al 1989). Some will be 
treated by angioplasty; up to 74% of angioplasties performed in vascular units are conducted 
on claudicants (Belli et al 1990). Some patients will progress to rest pain, ulceration and 
gangrene, and of these, more than 90% will undergo major amputation, arterial reconstruction 
or angioplasty, procedures which involve a high risk to the patient and major cost to hospital 
services (Wolfe 1986).
Although factors such as cigarette smoking (Jonason and Bergstrom 1987), diabetes mellitus 
(Bowers et al 1993), systolic blood pressure (Smith et al 1996), hypertriglyceridaemia (Smith 
et al 1996) and low ABPI (Cronenwett et al 1984) have been independently associated with 
deterioration of limb ischaemia, the role of haemostatic factors in the clinical progression of 
peripheral arterial disease is not clear.
In this prospective cohort of claudicants, a total of 109 (18%) patients developed clinical 
deterioration of limb ischaemia over six years of follow-up. The six year incidence of severe 
chronic leg ischaemia was approximately 10.5%, which is comparable to some studies 
(Cronenwett et al 1984; Jelnes et al 1986), but less than reported in earlier studies, in which 
early intervention techniques, such as angioplasty were not readily available (Imparato et al 
1975; Hughson et al 1978b; Kozol et al 1984; Naschitz et al 1988). The high mortality rate
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associated with severe chronic leg ischaemia reported in these studies was also confimied in 
the present study; 50% of the patients subsequently died, primarily from ischaemic heart 
disease and stroke.
6.4.6 Fibrinogen, fibrin D-dimer and clinical progression
The results from this study indicated that baseline levels of fibrinogen were significantly 
associated with the risk of vascular investigations when life-time smoking consumption was 
taken into account, but not with symptoms of severe chronic leg ischaemia. One possible 
explanation for these findings is that vascular intervention could have been peif oi*med on those 
who actually had more advanced disease. However, the baseline ABPI was not significantly 
different in the patients who subsequently underwent vascular intervention compared to those 
who had no evidence of peripheral arterial disease progression, although the former group had 
reported more severe symptoms of intermittent claudication at baseline. Another interesting 
result from this study was that fibrinogen and total cholesterol levels were slightly lower in 
those who subsequently developed severe chronic leg ischaemia. The reasons for this are not 
known, but this may reflect an on-going negative acute-phase haematological reaction in 
response to the underlying severity of disease, which was significantly higher at baseline (as 
indicated by the lowest ABPI of 0.48) in those with severe chronic leg ischaemia. Fibrinogen 
levels, measured prior to angioplasty, have also been found to be significantly lower in patients 
who developed restenosis following angioplasty of the iliac and femoro-popliteal arteries for 
intermittent claudication or rest pain (Price et al 1997).
The mechanisms whereby fibrinogen may influence the apparent worsening of disease is
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uncertain. An elevation in fibrinogen may have important effects on reduction of blood flow 
which could contribute to atherogenesis and to the progression of disease. Fibrinogen is a 
major determinant of blood and plasma viscosity and a strong association has recently been 
reported between fibrinogen and plasma viscosity with incident ischaemic heart disease events 
in the general population (Sweetnam et al 1996). In a previous case-control analysis based on 
these claudicants, plasma viscosity was associated with the risk of claudication, independently 
of age, sex and packyears, but not after adjusting for the ABPI (Lee et al 1996). It is 
increasingly thought that increases in viscosity could be the most important pathway by which 
fibrinogen promotes vascular disease. The findings in the present study are consistent with 
the hypothesis that fibrinogen may directly promote symptomatic and progressive worsening 
of leg muscle ischaemia during exercise due to reductions of microcirculatory blood flow, 
distal to arterial stenoses, regardless of the extent of peripheral arterial disease (Lowe et al 
1993).
To date, only two other studies have examined the prognostic significance of haemostatic 
factors in the progression of intermittent claudication (Dormandy et al 1973b; Violi et al 
1996). The first was based on a series of 62 patients, of which only eight demonstrated 
definite signs of clinical deterioration. The results were in accordance with the present study 
in that fibrinogen was significantly correlated with deterioration of peripheral arterial disease, 
assessed by changes in walking distance and flow patterns recorded by plethysmography 
(Dormandy et al 1973b). In contrast, the A.D.E.P. Study which was a multi-centre clinical 
trial of patients with claudication who were followed up for 18 months, found no association 
between fibrinogen and peripheral arterial deterioration (Violi et al 1996).
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The risk of severe chronic leg ischaemia associated with elevated fibrin D-dimer, although 
marginally non-significant at the 5% level was substantially raised. Adjustment for life-time 
smoking had little effect on the relative risk, suggesting that any relationship between this 
factor and progression of peripheral arterial disease in claudicants is not explained by cigarette 
smoking. There have been no previous studies which have investigated the relationship 
between fibrin D-dimer and clinical progression of peripheral arterial disease. However, in 
the interim analysis conducted after one year, fibrin D-dimer was independently associated 
with a reduction of ABPI (Fowkes et al 1993). This association with deterioration of 
peripheral arterial disease was weaker after the longer follow-up period, but may have been 
related to the small numbers in each disease category. The results from the six year follow-up 
are also not directly comparable to those of the one year follow-up. In the current analysis, 
since a change in ABPI could not be assessed, deterioration of disease was mainly based on 
symptoms indicative of clinical progress, assessment of which are subjective and known to 
lack reliability. In contrast, the ABPI measure used in the preliminary analysis is a more 
objective measure of underlying atherosclerotic disease and is also a continuous variable 
allowing more power to detect associations with progression of underlying lower limb 
atherosclerosis.
6.4.7 Other haemostatic factors and clinical progression
Tissue plasminogen activator
The role of tissue plasminogen activator in the progression of peripheral arterial disease in 
claudicants has not previously been investigated. A though t-PA antigen levels are elevated
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in subjects with prevalent peripheral arterial disease (Smith et al 1995), the concentration of 
this factor, measured at baseline in the present study was not associated with either the risk of 
vascular intervention or risk of severe chronic leg ischaemia in claudicants. This suggests that 
altered fibrinolysis is not involved in the aetiology of deterioration of symptomatic peripheral 
arterial disease.
von Willebrand Factor
The results from the present study showed that von Willebrand Factor was predictive of the 
future development of severe chronic leg ischaemia. Adjustment for life-time smoking history 
increased the relative risk only slightly, although the level of statistical significance was raised 
to the 5% level. This suggests that the effect of vWF on the progression of peripheral arterial 
disease was mostly independent of smoking history.
The role of vWF in the outcome of peripheral arterial disease has not been widely investigated. 
In a clinical study, vWF was predictive of graft occlusion in patients who had undergone infra- 
inguinal revascularisation (Woodbum et al 1996). The mechanisms by which vWF may 
promote thrombosis are not certain. vWF is thought to mediate platelet adhesion to damaged 
subendothelium (Baumgartner 1973), and is a co-factor for platelet aggregation at high shear 
rates (Sixma 1987). Furthermore, vWF is raised in subjects with peripheral arterial disease 
(Blann and McCollum 1992, Smith et al 1993), and in smokers compared to non-smokers 
(Blann and McCollum 1993); it has also been suggested that smoking may be responsible for 
a major part of endothelial dysfunction in peripheral arterial disease (Smith et al 1993). In the 
present study, elevated vWF was associated with the development of severe chronic leg
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ischaemia, an asssociation which persisted after adjusting for age, sex and smoking habit. This 
may partly have reflected greater smoking-induced endothelial injury in those who 
subsequently developed severe chronic leg ischaemia, since their baseline packyear levels 
tended to be higher, A tem atively, it also could reflect the microcirculatory endothelial 
disturbance associated with ischaemia, as this is a major source of raised vWF levels (Blann 
and McCollum 1994). However, it is more likely that the elevated vWF levels contributed to 
occlusive platelet-fibrin thrombi formation in the severely stenosed arteries of these patients 
and hence may have promoted the development of severe chronic leg ischaemia.
It should be noted that the categorisation of these patients by symptoms, rather than by an 
objective assessment of worsening severity of disease may have biased the results of this 
study. It is not known whether the vascular intervention group had deteriorated over the six 
year follow-up, or whether they were merely considered more suitable for early intervention, 
given that they were younger and reported more severe symptoms at baseline. The occurrence 
of vascular intervention may also have reflected the particular inteivention practice of the 
treating surgeon. It is also plausible that this group represented a pathologically different 
group with a slower rate of progression of peripheral arterial disease compared to the severe 
chronic leg ischaemia patients. This hypothesis is supported by the finding that over half of 
those who had vascular intervention underwent angiography only, and none progressed to 
severe chronic leg ischaemia.
6.5 Measurement in Clinical Practice
6.5.1 Fibrinogen in clinical practice
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At present, measurement of plasma fibrinogen is not routinely included in clinical practice for 
use in either the primary or secondary prevention of vascular disease. Although current data 
indicate a clear role for elevated fibrinogen in the prediction of future events, further research 
in a number of areas is required before this factor would be considered relevant to practising 
physicians in evaluating patients at risk.
Firstly, an optimal assay must be agreed upon. A variety of assay techniques are used in 
epidemiological studies at present, based on clotting, precipitation and immunological 
methods, partly because there is disagreement about which form of fibrinogen should be 
measured. Whereas the Clauss method which measures only clotting fibrinogen has been 
widely adopted in many surveys, total circulating fibrinogen (e,g. as measured by heat 
precipitation) may in fact be a better predictor of thrombotic risk (Sweetnam et al 1998). A so , 
measurement of fibrinogen has been poorly standardised which has made it difficult to 
establish normal reference ranges for the distribution of fibrinogen levels in the population. 
An international standard has now been developed, but this has been based only on the Clauss 
assay and further work on standardisation using other assays, such as the heat precipitation 
method is required. Ideally, the routine measurement of fibrinogen should be simple, rapid 
and inexpensive and be resistant to the variation in sampling and storage occurring in different 
laboratories and therefore protocols regarding these problems should be established. Another 
problem is related to the high inter- and intra-individual variability in fibrinogen levels in 
réponse to many lifestyle and other factors and therefore a single reading may not accurately 
define the 'normal' level in an individual. The number of fibrinogen measurements and 
optimal timing of repeat measurements has yet to be defined.
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Another area which requires further work is in establishing the predictive value of a fibrinogen 
level for a single individual, rather than for groups within a population, in relation to 
cardiovascular events. This will depend on establishing the exact relationship and interaction 
between fibrinogen, environmental and other cardiovascular risk factors. The extent to which 
genetic variation detennines an individual's response to these factors should also be further 
elucidated, since there is increasing evidence that fibrinogen genotype is related to inter­
individual differences in levels in the general population. However, measurement of 
fibrinogen in clinical practice will probably only be included if it provides additional 
information on the degree of risk which factors, such as smoking, cholesterol and blood 
pressure show at present.
From a clinical perspective, incorporation of fibrinogen into risk models will only be 
considered worthwhile if reduction of fibrinogen levels lowers the risk of arterial events. Life­
style changes, such as exercise, weight loss and particularly smoking cessation may be initially 
be advised as these changes appear to have some effect in reducing fibrinogen levels. Several 
oral drugs are now available which have been shown to lower fibrinogen. Among these drugs, 
fibiic acid derivatives, such as bezafibrate and the platelet inhibitor, ticlopidine are proving 
the most effective, but it is not clear exactly how these dmgs lower fibrinogen and the 
mechanism may not be specific to fibrinogen. At present, there are a number of randomised 
controlled trials assessing bezafibrate in progress which are investigating the effect of possible 
fibrinogen lowering on vascular outcome in patients with myocardial infarction and 
claudication. If this does occur, it would confiim the hypothesis that fibrinogen is causally 
linked to the development of atherosclerotic disease (at least following initial clinical 
diagnosis) and would indicate the importance of lowering fibrinogen in clinical practice.
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However, further analysis of data derived from prospective studies is required to confirm the 
role of fibrinogen reduction in prevention of atherothrombotic disease.
6.5.2 Measurement of fibrin D-dimer in clinical practice
Although there is increasing evidence that fibrin D-dimer has prognostic significance in the 
incidence of atherothrombotic events, further large-scale prospective studies are necessary 
before it can be confirmed as a clinical marker of intravascular thrombi formation. This is 
partly because raised fibrin D-dimer levels may also be indicative of extravascular fibrin 
turnover, such as occurs in a variety of disorders including infection or injury, renal and liver 
dysfunction and cardiac failure. Thus, the specificity of fibrin D-dimer in prediction of 
vascular disorders is uncertain.
Currently, fibrin D-dimer assays are commercially available only for the diagnosis of 
disseminated intravascular coagulation and venous thromboembolism in clinical practice. 
However, there are resei-vations about the usefulness of these tests. For example, a normal 
level of fibrin D-dimer is considered indicative that a venous thromboembolism has not 
occurred, but the test has a low positive predictive value if levels are raised. Elevated fibrin 
D-dimer has also been reported in conditions associated with thromboembolic risk, such as 
chronic atrial fibrillation and ventricular aneurysms and this factor may be of future use in 
assessing the response to anti-coagulant treatment (Lip and Lowe 1995).
In most recent epidemiological studies of arterial risk, the enzyme linked immunosorbent 
assay (ELISA) has been almost universally adopted for estimation of fibrin D-dimer.
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However, the antibodies used in commercial kits tend to vary and reference ranges differ 
between individual manufacturers. Interpretation of the results regarding D-dimer from 
different surveys is therefore difficult at present, and it is also unlikely that an international 
standard will be developed in the near future to facilitate comparison of fibrin D-dimer levels.
Furthermore, in comparison to fibrinogen, few studies have examined the influence of 
environmental factors in deteimining levels of fibrin D-dimer in the general population. 
Knowledge of these correlates would be of value in determining the role of fibrin D-dimer as 
an independent marker of vascular risk, which has generally been inconsistent 
epidemiologically.
The studies reported in this thesis indicate that both plasma fibrinogen and fibrin D-dimer (and 
also other haemostatic markers) are related to the presence and progression of peripheral 
atherosclerotic disease. These associations indicate a possible role in causation, but this has 
not been confirmed in randomised controlled trials as yet. Furthermore, the measurement of 
these factors is not sufficiently developed, and the associations with disease not sufficiently 




In this brief chapter, the principal conclusions from each study and the recommendations for
further research are listed.
7.1 Sites of Atheroma Study; Conclusions
1. Subjects referred for angiography were categorised by site (aorto-iliac, femoro- 
popliteal or dual-site) and severity of peripheral atherosclerosis using the Bollinger 
scoring system. This demonstrated the diffuse distribution of disease in symptomatic 
peripheral arterial disease, although many patients could be categorised as having 
disease predominantly in the aorto-iliac or femoro-popliteal segments.
2. Levels of the three main cardiovascular risk factors (blood pressure, serum cholesterol 
and cigarette smoking) varied in patients depending on the main site of peripheral 
atherosclerosis. The differences were not statistically significant, but this may have 
been due to the small numbers of subjects in each site category. It is therefore 
conceivable that single risk factors or interactions between the risk factors may 
influence the initiation or progression of peripheral atherosclerosis in different leg 
arteries.
3. There were no significant differences in the mean levels of plasma fibrinogen and
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fibrin D-dimer, or other haemostatic factors between patients with disease affecting 
different sites (femoro-popliteal, aorto-iliac or dual-site). However, levels of the 
factors (with the exception of fibrin D-dimer) tended to be higher in those with more 
diffuse disease. This suggests that coagulation and fibrinolytic activity in symptomatic 
peripheral arterial disease may be associated with differing patterns of disease within 
the lower limb arteries.
4. Plasma fibrinogen (measured by nephelometry), fibrin D-dimer and von Willebrand 
Factor were more strongly correlated with the severity of disease (additive score) in 
the femoro-popliteal arteries than in the aorto-iliac arteries, after adjusting for age and 
sex. The implication of these results is that a greater degree of endothelial dysfunction, 
fibrin formation and breakdown may occur in relation to disease in the femoro- 
popliteal arteries.
5. After inclusion of all haemostatic factors and time of venepuncture into a multiple 
regression model, independent relationships between nephelometric fibrinogen, fibrin 
D-dimer and disease severity was found only in the femoro-popliteal arteries. In 
contrast, the association between von Willebrand Factor and severity of disease 
became non-significant. This suggests that greater coagulation and fibrin turnover may 
contribute to the extent of atherosclerotic disease within these arteries. Atematively, 
these findings may reflect an inflammatory response to the presence of atheroma.
6. Further adjustment for life-time smoking consumption, or for current smoking had 
little effect on the association between nephelometric fibrinogen and disease. By
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comparison, life-time smoking reduced the relationship between fibrin D-dimer to non­
significance. This may indicate a stronger influence of chronic smoking on increased 
fibrin turnover than fibrinogen in symptomatic peripheral arterial disease.
7.2 Prognostic Study of Intermittent Claudication: Conclusions
1. A high incidence of both fatal and non-fatal vascular events occurred during the six 
year follow-up period. This is consistent with the majority of studies of hospital 
patients with inteimittent claudication and may be partly due to co-existing disease in 
the coronary and cerebral arteries. The all cause mortality rate was significantly higher 
in males than in females.
2. The high mortality rate associated with progression to severe chronic leg ischaemia 
was confirmed. Myocardial infarction and stroke accounted for most deaths and only 
a minority of patients died from causes directly related to peripheral atherosclerosis.
3. Correlations were found between all the haemostatic factors and increasing severity 
of disease (ABPI) at baseline. The strongest associations occurred with the factors 
associated with fibrin breakdown (fibrin D-dimer and tissue plasminogen activator). 
This implies that increasing severity of lower limb atherosclerosis is associated with 
deposition of fibrin and increased fibrinolytic activity.
4. Baseline median levels of plasma fibrinogen, fibrin D-dimer and von Willebrand 
Factor were significantly higher in subjects who subsequently died from ischaemic
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heart disease compared to those who had no vascular events during follow-up. This 
suggests that increased coagulation and fibrinolytic activity may have contributed to 
thrombosis or progression of atherosclerosis in the coronary arteries.
5. In relation to the development of stroke, only tissue plasminogen activator antigen 
levels showed a significant elevation at baseline. These findings suggest that abnormal 
fibrinolytic activity may identify those at risk of cerebrovascular events in claudicants.
6. In multivariate analysis adjusting for age and sex, smoking, blood glucose, systolic 
blood pressure and baseline evidence of ischaemic heart disease, all the relationships 
between haemostatic factors and vascular events became weaker and were no longer 
statistically significant. These results indicate that the associations between the 
haemostatic factors and adverse outcome in symptomatic peripheral arterial disease are 
partly due to inter-relationships with confounding risk factors. However, haemostatic 
variables may still be mechanisms through which such risk factors may promote 
events.
7. There were no significant differences in baseline levels of any of the haemostatic 
factors between subjects who had deterioration of limb ischaemia and who underwent 
vascular investigations, in comparison to the group who experienced no deterioration 
of limb ischaemia. Only von Willebrand Factor levels were significantly raised in 
patients who developed severe chronic leg ischaemia (rest pain, ulceration and 
gangrene). This may indicate a higher degree of endothelial disturbance in these 
patients.
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8. In multivariate analyses adjusting for life-time smoking, the relationships between 
fibrinogen, fibrin D-dimer, other haemostatic factors and the progression of peripheral 
arterial disease remained similar indicating that any slight effect that these factors 
might have had in the progression of disease was mostly independent of cigarette 
smoking.
7.3 Recommendations
1. The Bollinger scoring system was used to quantify the site and severity of peripheral 
atherosclerosis in this study, but the method has limitations. Research is required in 
the use of more advanced techniques such as computer-generated densitometry to 
improve measurement precision and reduce variability in the interpretation of 
angiographic images.
2. In view of the inconclusive relationship found between cardiovascular risk factors and 
also haemostatic factors and site of peripheral arterial disease, further research is 
required in larger studies to delineate the importance and independent effect of these 
factors on the site of atherosclerosis. Epidemiological suiveys using newer non- 
invasive imaging techniques are also required to confirm whether relationships 
between risk factors and site of peripheral arterial disease occur in the general 
population.
3. The reasons why cigarette smoking appears to be more strongly associated with aorto- 
iliac disease in women than in men are unknown. Further work is needed to examine
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the inter-relationships between smoking, anatomical differences and haemodynamic 
effects in separate samples of men and women in relation to peripheral arterial disease.
4. There is also evidence that certain haemostatic factors, such as fibrinogen may be 
relatively more important in determining the degree of risk of peripheral arterial 
disease in men than in women. Sex differences in susceptibility to haemostatic factors 
for the development of peripheral arterial disease should be investigated further.
5. Further studies are required to determine whether the relationships between fibrinogen, 
fibrin D-dimer or other haemostatic factors and the development and progression of 
atherothrombotic disease are likely to be causal. Randomised controlled trials (e.g. the 
LEADER Study) are currently in progress to test this hypothesis by assessing the 
effects of fibrinogen lowering agents on the prognosis and incidence of cardiovascular 
events in claudicants and those with established ischaemic heart disease. These will 
provide direct evidence on whether thrombotic risk can be modified in individuals at 
high risk.
6. Given that routine measurement of fibrinogen and fibrin D-dimer is not feasible at 
present, attention in clinical practice should be given to the use of modifying 
cardiovascular risk factors associated with peripheral arterial disease, such as smoking, 
lipids and blood pressure on the incidence of vascular events in claudicants, and the 
use of simple intervention agents, such as aspirin.
7. The results from the Prognostic Study suggest that fibrinogen and fibrin D-dimer may
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be relatively weak prognostic factors in the development of ischaemic heart disease 
and stroke events in claudicants. The value of other markers in risk prediction should 
therefore be investigated. In particular, the relationship between inflammatory 
markers, such as C-reactive protein, semm amyloid A and cytokines, haemostatic 
function and clinical outcome in claudicants requires clarification.
8. Impaired fibrinolytic activity may enable identification of those claudicants who are 
more likely to suffer a stroke. However, it is not clear whether t-PA or P A  activity 
is the more important fibrinolytic marker in determining thrombotic risk. Therefore, 
the relationship between these two factors in terms of fibrinolytic potential should be 
studied. The extent to which plasma levels of t-PA and P A  are genetically and 
environmentally determined in claudicants should also be examined.
9. Elevated levels of the haemostatic factors, fibrinogen and von Willebrand Factor were 
significantly associated with deterioration of peripheral arterial disease in the 
Prognostic Study. Research is required to evaluate the effects of these factors in 
predicting other outcomes of treatment for symptomatic peripheral arterial disease, 
such as graft occlusion and angioplasty.
10. Given the developments in genetic techniques and analysis in recent years, research 
is required into the investigation of the particular genotypes influencing the formation 
and metabolism of haemostatic factors which have been shown in these and other 
studies to be related to the development and progression of atherothrombotic disease.
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APPENDIX 1
Hospital Record N o ..............................................  Subject No
SITES OF ATHEROMA STUDY 
CONSENT FORM
Purpose of the Study
The purpose of this study is to obtain further information as to why narrowing of the arteries tends to occur in 
certain areas of the leg, with a view to improving prevention and treatment of the disease.
Research Examination
A blood sample will be taken and your blood pressure will be measured on both arms and ankles after five 
minutes rest. You will then be asked some questions about your health and smoking habits.
Consent Agreement
I understand the purpose of this research which has been fully explained to me by a member of the research team. 
The study has been given ethical approval by a Medical Ethics Sub-Committee of the Lothian Health Board.
I give my consent to the research team carrying out a medical examination on me as described, although I can 





SIGNATURE OF RESEARCH TEAM MEMBER
APPENDIX II
SITES OF ATHEROMA STUDY
VENEPUNCTURE RECORDING FORM




Has patient had jaundice in last 12 months?







Was venepuncture difficult/slow? 
Was venepuncture not possible?
COMMENTS
APPENDIX III
Record No .. Study No
Subject Name
SITES OF ATHEROMA STUDY 
BLOOD PRESSURE RECORDING FORM
...................................... D a te .................


























SITES OF ATHEROMA STUDY
OUESTIONNAIRE
THE INFORMATION GATHERED IN THIS QUESTIONNAIRE IS STRICTLY CONFIDENTIAL AND 
WILL ONLY BE USED BY THE RESEARCH TEAM IN THIS STUDY. THE RESULTS WILL APPEAR 
ONLY AS GENERAL STATISTICS WITH NO MEANS OF INDIVIDUAL IDENTIFICATION.




DATE OF BIRTH 
DATE
IF YOU NEED ANY HELP COMPLETING THIS QUESTIONNAIRE THE RESEARCH TEAM WILL BE 
PLEASED TO ASSIST.
THANK YOU VERY MUCH FOR THIS INFORMATION. WE ARE GRATEFUL FOR YOUR CO­
OPERATION IN THIS STUDY.
MEDICAL HISTORY
WE SHOULD LIKE TO ASK YOU SOME QUESTIONS ABOUT ILLNESSES YOU MAY 
HAVE HAD IN THE PAST OR YOU HAVE AT PRESENT. HAVE YOU EVER BEEN TOLD 
BY YOUR DOCTOR THAT YOU HAVE OR HAVE HAD ANY OF THESE ILLNESSES? 
PLEASE TICK ONE BOX.
Yes No Unsur
i) ANGINA □ □ □
ii) MYOCARDIAL INFARCTION/CORONARY □ □ □
THROMBOSIS/HEART ATTACK
iii) HIGH BLOOD PRESSURE □ □ □
iv) STROKE □ □ □
v) DIABETES □ □ □
vi) BLOOD CLOT IN LEG OR LUNG □ □ □
vii) OTHER SERIOUS ILLNESSES
II MEDICATIONS
ARE YOU AT PRESENT RECEIVING ANY REGULAR MEDICATIONS FROM YOUR 
DOCTOR? PLEASE ANSWER YES OR NO AS APPROPRIATE TO ALL THE FOLLOWING 
QUESTIONS. PLEASE GIVE NAMES OR DRUGS IF POSSIBLE.
Yes No
i) DRUGS TO IMPROVE CIRCULATION C H  [ U
Name ...........................................................................
ii) DRUGS TO LOWER BLOOD PRESSURE CH CH
Name ...........................................................................




v) DIABETIC TABLETS CH CH
Name ...........................................................................
vi) ASPIRIN TABLETS CH CH
HAVE YOU TAICEN ANY ASPIRIN TABLETS IN THE LAST 10 DAYS? 
IF YES, HOW MANY?
DO YOU TAICE ANY OTHER MEDICINES?




III OTHER MEMBERS OF YOUR FAMILY







i) HEART ATTACK □ □ □ □
ii) ANGINA □ □ □ □
iii) HARDENING OF THE 
ARTERIES IN THE LEG/
□ □ □ □
CLAUDICATION
DO YOU HAVE ANY BROTHERS AND SISTERS?






DO YOU SMOKE AT PRESENT?
IF NO, PROCEED TO QUESTION 5




Yes No □ □
Yes No □ □□ □□ □
2. HOW MANY DO YOU USUALLY SMOKE NOW?
CIGARETTES/ROLLED TOBACCO PER DAY ............................ cigarettes/oz
PIPE TOBACCO PER WEEK......................................... ............................  oz
CIGARS PER WEEK........................................................ ............................  cigars
3. HOW MANY YEARS DURING YOUR LIFE HAVE
YOU SMOKED CIGARETTES? ............................  years
4. HOW MANY CIGARETTES HAVE YOU SMOKED ON
AVERAGE PER DAY DURING THE PERIOD YOU
HAVE SMOKED? ............................  cigarettes
PROCEED TO SECTION V OVER PAGE
IF YOU DO NOT SMOKE NOW, HAVE YOU EVER 
SMOKED REGULARLY?
IF NO, PROCEED TO SECTION V OVER PAGE
Yes No □ □




Yes No □ □□ □□ □
HOW MUCH DID YOU SMOKE ON AVERAGE WHILE 
YOU WERE A SMOKER?
CIGARETTES/ROLLED TOBACCO PER DAY





FOR HOW MANY YEARS DID YOU SMOKE 
CIGARETTES? years
IF YOU SMOKED CIGARETTES, HOW LONG 
IS IT SINCE YOU FINALLY GAVE UP? years  months
V LEG PAIN/CLAUDICATION
Yes
1. DO YOU GET A PAIN OR DISCOMFORT IN YOUR 
LEG(S) WHEN YOU WALK?
IF YOU ANSWERED "YES" TO QUESTION 1, PLEASE 
ANSWER THE FOLLOWING QUESTIONS. OTHERWISE 
PROCEED TO QUESTION 8 OVER THE PAGE.
2. DOES THIS PAIN EVER BEGIN WHEN YOU ARE 
STANDING STILL OR SITTING?
3. DO YOU GET IT IF YOU WALK UPHILL OR HURRY?
DO YOU GET IT WHEN YOU WALK AT AN ORDINARY 





I Am Unable 




WFIAT HAPPENS TO IT IF YOU STAND STILL?
USUALLY CONTINUES MORE THAN 10 MINUTES
USUALLY DISAPPEARS IN 10 MINUTES OR LESS
□□
6. WHERE DO YOU GET THIS PAIN OR DISCOMFORT?
MARK THE PLACES(S) WITH AN "X" ON THE DIAGRAM BELOW
HOW LONG DID YOU EXPERIENCE THIS PAIN BEFORE ATTENDING 
THE HOSPITAL CLINIC?
UNDER 6 MONTHS
MORE THAN 6 MONTHS
□ □
years  months
HAVE YOU EVER HAD SURGERY ON THE 
ARTERIES OF YOUR LEGS IN THE PAST?
IF YES, WAS THE SURGERY




(WHERE PIECES OF THE VEINS IN YOUR 
LEGS ARE REMOVED TO REPLACE DISEASED 
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DOB/XR No : 
Date of Angio :
A B D O M IN A L A O R T IC  S E G M E N T
O cc lu s iv e  P a tte rn
g  1/ §  I  w  I A dd itive  S c o re  : 
L oca tion  :
13 4 2 1 S in g le
5 3 2 M ultiple £ H
15 6 4 3 M ultiple > H
: V ecto ria l S c o re
C O M M O N  ILIAC S E G M E N T
O cc lu s iv e  P a t te rn
A dd itive  S c o r e  :
L oca tion  :
S in g le
M ultiple s  H
M ultiple > H
: V ecto ria l S c o r e
L E FT  L E G  
CO M M O N  ILIAC S E G M E N T
O c c lu s iv e  P a t te rn
8  w  / K? A dditive S c o re
L oca tion
13 4 2 1 S in g le
5 3 2 M u ltip le s  H
IE 6 4 3 M ultiple > H
: V ecto ria l S c o re
EX T E R N A L  ILIAC S E G M E N T
O cc lu s iv e  P a tte rn
A dditive S c o re  :
L o ca tio n  :
S in g le
M u ltip le s  H
M ultiple > H
: V ecto ria l S c o re
EX T E R N A L  ILIAC S E G M E N T
O cc lu s iv e  P a t te rn
Loca tion  :
S in g le
M ultiple H
M ultipia > H
: V ecto ria l S c o re
R IG H T  LEG 
IN T ER N A L ILIAC S E G M E N T
O c c lu s iv e  P a lte rn
A dditive S c o r e  ; 
L oca tion  :
13 4 S 1 S in g le
5 3 2 M ultiple £  H
t 5 6 4 3 M ultiple > H
: V ec to ria l S c o re
IN T ER N A L ILIAC SE G M E N T
O cc lu s iv e  P a tte rn
A dd itive S c o re  :
L o ca tio n  :
S in g le
M uillpie a  H
M ultipie > H
; V ec to ria l S c o re
P R O F U N D A  F E M O R IS  S E G M E N T
O c c lu s iv e  P a t te rn
Xj I A dditive S c o r e  : 
L oca tion  :
13 4 2 1 S in g le
5 3 2 M ultiple £ H
15 6 4 3 M ultiple > H
: V ecto ria l S c o re
P R O F U N D A  F E M O R IS  S E G M E N T
O cc lu s iv e  P a tte rn
A dditive S c o re  :
L o ca tio n  :
S in g le
M u ltip le s  H
M ultiple > H
: V ecto ria l S c o re
S U P E R F IC IA L  FE M O R A L  S E G M E N T  
O cc lu s iv e  P a tte rn
A dditive S c o re  ; 
L oca tion  ;
13 4 2 1 S in g le
6 3 2 M ultiple £  H
15 6 4 3 M ultiple > H
: V ec to ria l S c o re
S U P E R F IC IA L  F E M O R A L  S E G M E N T
O cc lu s iv e  P a tte rn
A dd itive S c o re  : 
L oca tion  :
13 4 2 1 S in g le
5 3 2 M ultiple £ H
15 6 4 3 M ultiple > H
: V ecto ria l S c o re
R IG H T LEG  
P O P L IT E A L  SE G M E N T
O c c lu s iv e  P a t te rn
A dditive S c o r e  : 
L oca tion  :
13 4 2 1 S in g le
5 3 2 M ultiple s  H
15 6 4 3 M ultiple > H
: V ecto ria l S c o re
L E F T  L E G  
P O P L IT E A L  S E G M E N T
O cc lu s iv e  P a t te rn
A dditive S c o re  : 
L o ca tio n  :
13 4 2 1 S in g le
5 3 2 M u ltip le s  H
15 6 4 3 M ultiple > H
; V ecto ria l S c o re
A P P E N D I X  V I I
PERIPHERAL VASCLIDJÎ CLINIC 
R a y a i I n f ir m a r y  o f  E d in b u r g h  
L au rist-.on  P la c e  
EDlNBlfRGH EH3 9AV
Da t e  
D e a r
I am w r i t i n g  t o  you  a s  a  p a t i e n t  who h a s  b e e n  s e e n  r e c e n t l y  a t  t h e  P e r ip h e r a l  
V a s c u la r  C l i n i c  in  t h e  R o y a l I n f i r m a r y  t o  i n v i t e  you  t o  h a \ e a  f u r t h iw  
e x a m in a t i o n . T h is  w i l l  b e  p a r t  o f  a  M e d ic a l R e s e a r c h  C o u n c i l  s t u d y  w h ic h  w i l l  
b e  \ ' i  t a l l y  im p o r ta n t  in  h e l p i n g  u s  t o  u n d e r s t a n d  a r t e r y  d i s e a s e  and  t o  im p r o \ c  
t r e a t j n e n t .  The in fo n n a t . io n  w i l l  a l s o  p r o v e  h e l p f u l  in  y o u r  c a s e .
T s h o u ld  l i k e  you  t o  a t t e n d  t h e  P e r i p h e r a l  V a s c u la r  C l i n i c  f o r  an  e x a m in a t io n  
t o  b e  c a r r i e d  o u t  b y  a  m ember o f  o u r  s p e c i a l l y  t r a i n e d  r e s e a r c h  te a m . Y ou r:  
b l o o d  p r e s s u r e  w i l l  b e  m e a su r e d  on  b o t h  arm s a n d  on  b o th  a r d î l e s .  A l s o  s m a l I ,  
s a m p le s  o f  u r i n e  and  b lo o d  w i l l  b e  c o l l e c t e d .  Y ou . w i l l  th e n  b e  g i \ e n  a  s h o r t  
q u e s t i o n n a i r e  on y o u r  h e a l t h ,  a f t e r  w h ic h  t e a  o r  c o f f e e  w i l l  b e  s e r v e d .
Y o u r  a p p o in t m e n t  i s  a s  f o l l o w s  : 
D a te  Day T im e P la c e
P e r i p h e r a l  V a s c u la r  C l i n i c  
R o y a l I n f ir m a r y  o f  E d in b u r g h
I f  y o u  h a \ e  a n y  q u e r i e s  p l e a s e  t e l e p h o n e  M rs Anna R a t t r a y  a t :  0 3 1 - 5 6 '  
E x t .  2 4 8 9 ,  9am -2pm  d a i l y  M o n d a y -F r id a y .
1 0 1 1 ,:
We \ e  r y  much lo o k  fo n ^ a r d  t o  s e e i n g  y o u  a t  t h e  c l i n i c ,  a t  w h ic h  t im e  we s h a l l v  
m al(e e \ c r y  e f f o r t  t o  m ake j'ou  f e e l  w e lc o m e  a n d  a n s w e r  a n y  q u e r i e s .
W ith  b e s t  w i s h e s .
Y o u r s  s i n c e r e l y .
Dr E H o u s le y  
C o n s u l t .a n t  P h y s i c i a n
P l e a s e  t e ; i r  o f f  an d  r e t u r n  in  p r e - p a i d  e n v e lo p e
Name ...........................................................................................  T e l  S o ..............
A d d r e s s  ...........................................................................................  H o s p i t a l  N o.
R e c .  N o .
DEIET’E AS APITOPRlATEt :
t  A p p o in tm e n t  i s  s u i t a b l e  
o r
* A p p o in tm e n t  i s  n o t  s u i t ^ a b le ,  I w i l l  t e l e p h o n e  Mx's R a t t r a y  0 3 1 - 6 6 7  1011  
e x t .  2 5 8 9 .
o r
i  A p p o in tm e n t  i s  n o t  s u i t a b l e , p l e a s e  s e n d  me a n o t h e r  a p p o in t m e n t
A P P E N D I X  VIII
FR0Œ4O8TIC STUDY OF IM T ia ilT rE N T  CLAUDICATICSJ
U E S T I O N N A I R E
THE INPCBMATIŒ GATHERED IN  THIS QUESTIONNAIRE I S  STRICTLY CONFIDENTIAL 
T he Q u e s t i o n n a i r e  c o n t a i n s  in f o r m a t io n  w h ic h  w i l l  o n l y  b e  u s e d  b y  t h e  
r e s e a r c h  te a m  i n  t h i s  s t u d y .  T he r e s u l t s  o b t a i n e d  w i l l  a p p e a r  o n l y  a s  
g e n e r a l  s t a t i s t i c s  w i t h  n o  m ean s o f  i n d i v i d u a l  i d e n t i f i c a t i o n  p o s s i b l e
P l e a s e  c o m p le t e  t h e  f o l l o w i n g  i n  b l o c k  c a p i t a l s :  
TITLE: M r /M r s /M iss  ............................................
SURNAME: ............................................
MAIDEN/PREVIOUS NAMES: ......................... ..................
FORENAMES: ............................................
DATE;
N .H .S .  NO. ( i f  tm ow n)
G .P . & ADDRESS
PLEASE COMPLETE THE REMAINDER OF THE QUESTIONNAIRE WITH THE HELP OF THE 
RESEARCH TEAM
THANK YOU VERY B#1CH PCS THIS INFORMATION. WE ARE (MATEIUL FOR YOUR 
CO-OPERATION IN THE STUDY.
S u b j e c t  N o.
PERSONAL HISTCW
1 . ( a )  P l e a s e  t i c k  o n e  b o x  
(b )  M a r i t a l  S t a t u s S i n g l e
M a r r ie d
D iv o r c e d
O th e r
Day
2 . E n t e r  y o u r  d a t e  o f  b i r t h
M ale  F e m a le
□  □
□□
M onth Y e a r
M EDICATimS
3 . A re y o u  a t  p r e s e n t  r e c e i v i n g  a n y  r e g u l a r  m e d i c a t i o n s  from  v o u r  d o c t o r .  
P l e a s e  a n s w e r  Y e s  o r  N o , a s  a p p r o p r i a t e ,  t o  a l l  t h e  f o l l o w i n g  q u e s t i o n s
D ru g s t o  im p r o v e  c i r c u l a t i o n
D ru gs t o  lo w e r  b lo o d  p r e s s u r e
D i u r e t i c s / w a t e r  t a b l e t s
I n s u l i n  i n j e c t i o n s




O th e r  t a b l e t s  -  p l e a s e  g i v e  n am es o f  m e d ic in e s  i f  p o s s i b l e  j |  j_ _ I
MEDICAL HISTCÜY
4 . The q u e s t i o n s  b e lo w  c o n c e r n  i l l n e s s e s  y o u  may h a v e  h a d  i n  t h e  p a s t  o r  
i l l n e s s e s  y o u  h a v e  a t  p r e s e n t .  P l e a s e  a n sw e r  Y e s  o r  N o, a s  a p p r o p r i a t e ,  
t o  a l l  o f  t h e  f o l l o w i n g  q u e s t i o n s .
H ave y o u  e v e r  b e e n  t o l d  b y  y o u r  d o c t o r  t h a t  y o u  h a v e  h ad  o r  h a v e  a n y  o f  
t h e  c o n d i t i o n s  l i s t e d  b e lo w ?
Y es No
i . A n g in a □  □
i i .  M y o c a r d ia l  i n f a r c t i o n / c o r o n a r y  j
t h r o m b o s i s / h e a r t  a t t a c k
i i i .  H ig h  b lo o d  p r e s s u r e  
i v .  S t r o k e  
V .  D i a b e t e s
v i .  D e e p  V en o u s t h r o m b o s is  o r  p u lm o n a r y  e m b o lis m
□  □  
□  □




i .  Do y o u  g e t  a  p a in  i n  e i t h e r  l e g  on w a lk in g ?  j j  [ |
i i .  Do y o u  g e t  t h i s  p a in  in  y o u r  r i g h t  c a l f ?  | [ | j
i i i .  Do y o u  g e t  t h i s  p a in  i n  y o u r  l e f t  c a l f ?  j j [ |
i v .  D o es  t h i s  p a i n  e v e r  b e g in  w hen y o u  a r e   . _^__ _
s t a n d i n g  s t i l l  o r  s i t t i n g ?  j j |___[
V .  Do yo u  g e t  i t  w hen y o u  w a lk  u p h i l l  o r  h u r r y ?  j j j |
v i . Do y o u  g e t  i t  w hen  y o u  w a lk  a t  an  o r d in a r y  , , i---- ,
p a c e  o n  t h e  l e v e l ?  j j j___j
v i i .  D o e s  t h e  p a in  e v e r  d i s a p p e a r  w h i l e  y o u  a r e  t— - ,  ,---- r
s t i l l  w a lk in g ?  I | |___|
v i i i .  (Vhat d o  y o u  d o  i f  y o u  g e t  i t  w hen y o u  a r e  
w a lk in g ?
S to p
S lo w  down
C o n t in u e  a t  sam e p a c e
i x .  W hat h a p p e n s  t o  i t  i f  y o u  s t a n d  s t i l l ?
U s u a l l y  c o n t i n u e s  f o r  m ore t h a n  10 m in u t e s
U s u a l l y  d i s a p p e a r s  i n  10 m in u t e s  o r  l e s s
X .  How lo n g  d i d  y o u  e x p e r i e n c e  t h i s  p a in  b e f o r e  
a t t e n d i n g  t h e  P e r i p h e r a l  V a s c u la r  C l i n i c ?
U n d er  6 m o n th s
6 m o n th s o r  o v e r  a n d  u n d e r  1 y e a r  
1 y e a r  o r  o v e r  a n d  u n d e r  18 m o n th s  









6 . H ave y o u  e v e r  h a d  s u r g e r y  o n  t h e  a r t e r i e s  o f  y o u r  Y es  No
l e g s ,  s u r g e r y  t o  re m o v e  a n y  p a r t  o f  t h e  l e g  o r  ____ ___
f o o t  o r  a n g i o p l a s t y  ( B a l l o o n  d i l a t a t i o n )  t o  y o u r  l e g ?  j |
FOR OFFICE USE ONLY GEÎADE '
OUEST PAIN Yes Mo
7 .  i .  Do y o u  e v e r  g e t  p a in  o r  d i s c o m f o r t  i n  y o u r  
c h e s t ?  IF  NO, PROCEED TO QUESTION 8 □
i i .  Do y o u  g e t  t h i s  p a in  o r  d i s c o m f o r t  w hen y o u  
w a lk  u p h i l l  o r  h u r r y ?
IF  NO, PROCEED TO QUESTIW  8 ( v i i ) □
i i i .  Do y o u  g e t  i t  w hen y o u  w a lk  a t  a n  o r d in a r y  
p a c e  o n  t h e  l e v e l ? r - - - - - !
i v .  When y o u  g e t  a n y  p a in  o r  d i s c o m f o r t  i n  y o u r  
c h e s t  w h a t d o  y o u  d o ?
S t o p
S lo w  down




V .  D o e s  i t  g o  aw ay  w hen y o u  s t a n d  s t i l l  
o r  s i t  dow n? □  □
v i . How so o n ?
10 m in u t e s  o r  l e s s  
m ore th a n  10  m in u t e s
□
□
v i i .  W here d o  y o u  g e t  t h i s  p a in  o r  d i s c o m f o r t ?  
Mark t h e  p l a c e ( s ) w i t h  ’X* o n  t h e  d ia g r a m .
RIGHT LEFT
i . H ave y o u  e v e r  h a d  a  s e v e r e  p a i n  a c r o s s  t h e  f r o n t  
o f  y o u r  c h e s t  l a s t i n g  f o r  h a l f  a n  h o u r  o r  m ore?
Y e s
□
i i  . W hat WEIS t h e  c a u s e ?  . . . 
FOR OFFICE USE ONLY A: GRADE MI:
SMOKING
9 . S m o k in g  h a s  b e e n  l i n l t e d  w i t h  many h e a l t h  p r o b le m s . I t  i s  im p o r ta n t  t h a t  
y o u  a n s w e r  t h e  f o l l o w i n g  s e c t i o n  a s  a c c u r a t e l y  a s  p o s s i b l e .  P l e a s e  t i c k  
a p p r o p r i a t e  b o x e s
Y es No
Do y o u  sm ok e a t  p r e s e n t ?  j j j
IF  NO, PROCEED TO W E S T im  11  1 '----
1 0 . i . W hat d o  y o u  u s u a l l y  sm oke now?
: Ic i g a r e t t e s _________________________________________________,___ I
p i p e _________________________________________________________ , _ _ j
c i g a r s  ; |
i i .  How many d o  y o u  u s u a l l y  sm oke now?
c i g a r e t t e s / r o l l e d  t o b b a c o  p e r  d a y    c i g a r e t t e s / o z
p ip e  t o b a c c o  p e r  w eek  ..............o z
c i g a r s  -  p e r  w eek  .............  c i g a r s
i i i .  F o r  how  m any y e a r s  d u r in g  y o u r  l i f e
h a v e  y o u  sm o k ed  c i g a r e t t e s ?  .............. y e a r s
i v .  How many c i g a r e t t e s  h a v e  y o u  sm ok ed  on  a v e r a g e
p e r  d a y  d u r in g  t h e  p e r i o d  y o u  h a v e  sm ok ed ?  .............. c i g a r e t t e s
PROCEED TO QUESTION 13
Y es No
1 1 . I f  y o u  d o  NOT sm ok e n ow , h a v e  y o u  e v e r  sm ok ed  1 j ( j
r e g u l a r l y ?  IF  t O , PROCEED TO QUESTIŒ1 13-----------------------------1------ ! i-----i
1 2 . i .  W hat d i d  y o u  u s u a l l y  sm oke?
c i g a r e t t e s  I I
□
c i g a r s  □
i i .  How much d i d  y o u  sm oke o n  a v e r a g e  w h i l e  yo u  
w e r e  a  sm o k er?
c i g a r e t t e s / r o l l e d  t o b b a c o  p e r  d a y    c i g a r e t t e s / o z
o z .  p i p e  t o b a c c o  p e r  w eek  ..............  o z .
c i g a r s  p e r  w eek    c i g a r s
i i i .  F o r  how m any y e a r s  d i d  y o u  sm oke c i g a r e t t e s ?  .............. y e a r s
i v .  I f  y o u  sm o k ed  c i g a r e t t e s ,  how lo n g
i s  i t  s i n c e  y o u  f i n a l l y  g a v e  up?    . y e a r s   ..............  m o n th s
□  □1 3 . I s  a n y  o t h e r  m em ber o f  y o u r  h o u s e h o ld  a  sm o k er?  Y es No 





Your patient has been followed up for the last six years as part of a research investigation to deteitnine 
whether haemorheological factors influence the prognosis of arterial disease. We would be very grateful if 
you could provide us with any information concerning any cardiovascular events, hospital admissions and 
medication that have occurred in the past six years. Please complete the enclosed form and return it to us in 
the envelope provided. However, if this is not convenient, a member of the research staff would be available 
to visit your practice to obtain this information.
If you have any queries, please telephone Ms Felicity Smith on 0131-650-3245.
Thank you very much for your help.
Yours sincerely
Dr Gillian Leng Ms Felicity Smith
Clinical Research Fellow Research Associate
A P P E N D I X  X
STUDY NO,
P R O G N O ST IC  ST U D Y  OF IN T E R M IT T E N T  C L A U D IC A T IO N
P a t i e n t  n a m e :  
A d d r e s s  :
D a t e  o f  B i r t h :
Y e s  No
D o e s  t h i s  p a t i e n t  s t i l l  a t t e n d  □  □
y o u r  p r a c t i c e ?
C h a n g e  o f  a d d r e s s  ( i f  k n o w n )
P l e a s e  t i c k  i f  y o u r  p a t i e n t  h a s  b e e n  n e w l y  d i a g n o s e d  w i t h  a n y  o f  
t h e  f o l l o w i n g  c o n d i t i o n s  i n  t h e  l a s t  6 y e a r s ,  a n d  p r o v i d e  d e t a i l s  
a s  a p p r o p r i a t e :
D a t e  H o s p i t a l
M y o c a r d i a l  I n f a r c t i o n  □
A n g i n a  P e c t o r i s  □
S t r o k e  □
T r a n s i e n t  I s c h a e m i c  A t t a c k  □
C r i t i c a l  L im b  □
I s c h a e r a i a  ( p l e a s e  s p e c i f y )
A o r t i c  A n e u r y s m  □
O t h e r  C a r d i o v a s c u l a r  □
E v e n t  ( p l e a s e  s p e c i f y )
H a s  e x p e r i e n c e d  n o n e  o f  t h e  
a b o v e
MANY THANKS FOR YOUR H E L P . P L E A S E  RETURN IN  P R E -P A I D  ENV ELO PE
APPENDIX XI
Study No
PROGNOSTIC STUDY OF INTERMITTENT CLAUDICATION 
1996 QUESTIONNAIRE
THE INFORMATION GATHERED IN THIS QUESTIONNAIRE IS STRICTLY CONFIDENTIAL. This 
information will only be used by the research team in this study. The results obtained will appear only as general 
statistics with no means of individual identification possible.





GP NAME & ADDRESS
THANK YOU VERY MUCH FOR THIS INFORMATION. 
WE ARE GRATEFUL FOR YOUR CO-OPERATION IN THE STUDY,
A MEDICAL HISTORY
HAVE YOU HAD ANY OF THE FOLLOWING ILLNESSES OR CONDITIONS IN THE LAST 
6 YEARS ;
Please tick boxes as appropriate.
Yes No
1. Angina □  □
2. Heart Attack □  □
(Myocardial Infarction
Coronary Thrombosis)
3. Stroke □  □
4. Diabetes □  □
5. Blood clot in leg veins or lungs □  □
6. Aortic aneurysm □  □
7. High blood pressure □  □
If yes to any of the above conditions, please provide details of any hospital attendances that were required, 
either at a clinic or as an inpatient.
Condition Hospital Date of Attendance
B MEDICATION
PLEASE LIST ANY REGULAR MEDICATIONS THAT YOU ARE TAIGNG AT PRESENT.
Name of Medication Duration of Treatment Condition Prescribed For
C LEG PAIN
Yes No
1. Do you still get a pain in either leg on walking? □  □
IF YES, PLEASE COMPLETE THE FOLLOWING QUESTIONS, OTHERWISE PROCEED 
TO SECTION D OVER THE PAGE.
2. Does the pain ever begin when you are standing still or sitting? □ □
3. Do you get this pain in your calf (or calves)? □ □
4. Do you get it when you walk uphill or hurry? □ □
5. Do you get it when you walk at an ordinary pace on the level? □ □
6. Does the pain ever disappear while you are still walking? □ □
7. What do you do if you get it when you are walking?
□  Stop
□  Slow down
□  Continue at same pace
8. What happens to it if you stand still?
□  Usually continues more than 10 minutes
□  Usually disappears in 10 minutes or less
Where do you get this pain or discomfort?
Mark the place(s) with an X on the diagrams below
D LEG PAIN TREATM ENT
HAVE YOU HAD ANY O F TH E FOLLOW ING TREATM ENTS FO R  YOUR LEG PAIN IN 
TH E LAST 6 YEARS ?
Yes No
1. Angioplasty (balloon dilatation) □  □
2. Surgery, eg bypass, amputation □  □
3. Treatment for ulcer or gangrene □  □
4. Other □  □
I f  yes to any of the above, please give details:
Treatment Hospital Date
E CHEST PAIN





IF  YES, PLEASE CO M PLETE TH E FOLLOW ING QUESTIONS, OTHERW ISE PROCEED 
TO SECTION F.
2. Has this pain or discomfort developed in the past 6 years? □
3. Do you get it when you walk uphill or hurry? □
4. Do you get it when you walk at an ordinary pace on the level? □
5. When you get the pain or discomfort in your chest, what do you do?
□  Stop
□  Slow down
□  Continue at same pace
6. Does it go away when you stand still or sit down? □
7. How soon does it go away?
□  10 minutes or less
□  more than 10 minutes
8. Where do you get this pain or discomfort?





9. Have you ever had a severe pain across the front of your chest
lasting for more than half an hour in the last 6 years?
10. What was the cause? .........................................................................
□ □
F SM OKING
1. Do you smoke?
IF  YES:
2. How much do you smoke on average?
cigarettes/rolled tobacco ..........  cigs/oz per day
pipe tobacco ..........  oz per week
cigars ..........  cigars per week
□ □
IF  NO ;
3. I have never smoked




A P P E N D I X  X I I
R EC O R D IN G  FORM FOR STU D Y  P A T IE N T  DEATHS






A D D L N l
A D D L N 2
A D D L N 3
GP
A D D L N l
A D D L N 2
B IN FO R M A T IO N  SOURCE DEATH C E R T IF IC A T E  INFORM ATION
DATE N O T IF IE D
NHSCR
R E L A T IV E











H O S P IT A L  
OTHER 
1 , 2  OR 3
D P R O V IS IO N A L  D IA G N O S IS
MYOCARDIAL IN F A R C T IO N  ___ 1
STROKE „  2
SUDDEN DEATH   3
T H R O M B O SIS/E M B O L ISM  4
PVD
OTHER CV RELATED  
UNKNOWN
E F IN A L  D IA G N O S IS  OF C A R D IO V A SC U LA R  EVENT
MYOCARDIAL IN F A R C T IO N
D E F IN IT E
P O S S IB L E
SUDDEN DEATH
STROKE -  D E F IN IT E
P O S S IB L E
T H R O M B O SIS/E M B O L ISM  
PVD RELATED  
CV RELATED  











F C O N FIR M A T IO N  C R IT E R IA  
P O ST  MORTEM 
DEATH C E R T IF IC A T E  
H I CONFIRM ED < 4 WEEKS 
STROKE CONFIRM ED < 6 WEEKS 
OTHER
G CV DEATH CONFIRM ATIO N  
STUDY C R IT E R IA  
C L IN IC A L  IM P R E S S IO N
H CONFIRM ATORY IN FO R M A T IO N  FROM
DEATH C E R T IF IC A T E  
H O S P IT A L  PM 
PROC F IS C A L  PH 
H O S P IT A L  RECORDS















□□ Date / /
1. Information Source 4. Final Diaenosis
Patient/Relative □  1 Myocardial Infarction Definite □  1
GP □  2 Myocardial Infarction Possible □  2
PVC □  3 Primary Cardiac Arrest □  3
CSA □  4 Stroke Definite □  4
Other □  5 Stroke Possible □  5
Unknown □  6 Angina □  6
Transient Ischaemic Attack □  7
2. Provisional Diagnosis Intermittent Claudication □  8
Rest Pain/Ulcer/Gangrene □  9
Myocardial Infarction □  1 Thrombosis/Embolism □  10
Stroke □  2 Vascular Surgery (not amp) □  11
Angina □  3 Amputation □  12
Transient Ischaemic Attack □  4 Other CV □  13
Intermittent Claudication □  5 Other Non CV □  14
Thrombosis/Embolism □  6 Unknown □  15
Amputation □  7 Angioplasty □  16
Other CV □  8 CAB G □  17
Other Non CV □  9
Unknown □  10 5. Confirmatory Criteria for Ml
3. Confirmation Source Pain □  1
ECG □  2
Patient/Relative □  1 Enzymes □  3
GP Record □  2 Equivocal ECG □  4
Hospital Record □  3 Equivocal Enzymes □  5
Other □  4
Unknown □  5 6. Confinnatorv Criteria for Stroke
Clinical Criteria □  1
CTScan □  2
Discharge Diagnosis □  3
7. Final Diagnosis Confirmation
Study Criteria □  1
Clinical Impression □  2
